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Abstract 
 Nitric oxide (NO) is one the most important and multifaceted messengers of the mammalian organism. To a 
large part it is synthesized by different isoforms of the NO-synthase (NOS). Under normoxia the enzyme 
metabolizes L-arginine to citrulline and NO with the assistance of oxygen (O2). The produced NO acts as 
messenger mediating neurological signals and supporting a host defense. In the cardiovascular system, NO has 
a great impact on vasodilation and vascular homeostasis e. g. by inhibiting platelet activation. Under hypoxia 
and ischemia this sensitive system is impaired, as the needed cofactor O2 is deficient. A back-up system partly 
compensates the emerging lack of endogenous NO, by way of NO synthesis. Gaseous NO has a short half-life 
and is fast oxidized to nitrite (NO2-) and further to nitrate (NO3-). These circulating metabolites could be 
reduced back to NO by e. g. myoglobin, hemoglobin, and cytoglobin whereby, on the whole NO3- is reduced to 
NO2- by commensal oral bacteria. Without O2, these enzymes switch from e. g. NO-scavengers to NO producing 
molecules absorbing reduced endogenous NO synthesis. However, NO2- and NO3- are not only endogenously 
produced. Both are ingredients of several foods. These ingested inorganic NO2- and NO3- also fill up the pool of 
reducible NO metabolites. Hence, recent works could show that an increase in dietary NO3- (and NO2-) not only 
increases the endogenous NO3- (NO2-) pool, but could also improve regeneration after ischemia. These works, 
in combination with novel considerations referring the toxicity of NO2- and NO3- resulted in a new perception of 
these nutritional ingredients with relativization of hazardous effects and more emphasis on its beneficial 
potential. 
The current study hypothesized that supplementation with dietary NO3- improves regeneration in the 
murine hind limb model, an animal model of peripheral ischemia. It is supposed that regeneration is supported 
by revascularization, increased mobilization of Endothelial-regenerating cells and increased muscle tissue 
protection. Finally, it is proposed that the decrease in NO production and the subsequent decreased 
endothelial-regenerating cell level is associated with a severe cardiovascular disease, such as the myocardial 
infarction.   
Accordingly, present work demonstrates that the increase of bioavailable NO by dietary NO3- increases 
perfusion of affected tissue elucidating its regenerative potential.  It could be shown that mobilization and 
migration of Endothelial-regenerating cells is significantly improved. Moreover, it shows that not only 
revascularization but also tissue protection is improved. It is proposed that this cytoprotection is mediated by 
Endothelial-regenerating cells with the Fas/FasL pathway, as candidate for paracrine reactions. Indeed, the 
work in hand shows that Endothelial-regenerating cells express FasL modulated by NO3- intake. Presented 
clinical studies corroborate the hypothesis of decreased NO bioavailability in myocardial infarction with 
associative relation to its severity.  
In conclusion, it could be demonstrated that dietary NO3- acts cytoprotective in the ischemic hind limb 
model, mediating mobilization and migration of endothelial-regenerating cells. Description of decreased NO 
bioavailability in myocardial infarction underscores the importance of increasing NO level in (cardio)vascular 
disease. The relevance of the beneficial potential of the NO3--NO2--NO pathway is supported, highlighting the 
impact of dietary NO3- in ischemia. 
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Zusammenfassung 
Stickstoffmonoxid (NO) ist einer der wichtigsten, vielseitigsten Botenstoffe des Säugerorganismus. Größtenteils 
wird es durch verschiedene Isoformen der NO-Synthase (NOS) synthetisiert. Unter Normoxie metabolisiert das 
Enzym unter Zuhilfenahme von Sauerstoff (O2) L-Arginin zu Citrullin und NO. Das produzierte NO agiert als 
neurologischer und immun-protektiver Botenstoff. Im kardiovaskulären System spielt NO eine wichtige Rolle 
bei der Vasodilatation und vaskulären Homeostase, bspw. durch die Hemmung der Plättchen-Aktivierung. Bei 
Hypoxie und Ischämie ist dieses System geschwächt, weil der  benötigte Kofaktor O2 fehlt. Ein Back-Up System 
kompensiert teilweise den Mangel endogenen NOs durch einen alternativen Weg der NO Synthese. 
Gasförmiges NO hat eine kurze Halbwertszeit und wird zügig zu Nitrit (NO2-) und weiter zu Nitrat (NO3-) 
oxidiert. Diese Metabolite können wiederum zu NO reduziert werden z. B. durch Myoglobin, Hämoglobin und 
Cytoglobin, wobei NO3- größtenteils durch kommensale, orale Bakterien zu NO2- reduziert wird. Ohne O2 
werden diese NO-Fänger (z. B.) zu NO produzierenden Enzymen, die den Abfall der endogenen NO Synthese 
auffangen. NO2- und NO3- werden jedoch nicht nur endogen produziert. Beide sind Bestandteil zahlreicher 
Nahrungsmittel. Das so aufgenommene inorganische NO2- und NO3- füllt zusätzlich den Pool reduzierbarer 
Metabolite. Daraus folgend, konnten neuere Arbeiten zeigen, dass ein Anstieg dietätischen NO3- (und NO2-) den 
endogenen NO3- (NO2-) Pool erweitert und so die Regeneration nach einer Ischämie verbessert. Diese Arbeiten, 
kombiniert mit einer aktualisierten Einschätzung der Toxizität von NO2- und NO3-, resultierten in einer neuen 
Wahrnehmung dieser Nahrungsbestandteile, mit Relativierung ihres Gefährdungspotentials und größerer 
Betonung ihres Nutzens. 
Die vorliegende Studie hat hypothetisiert, dass eine Ergänzung der Nahrung mit NO3- die Regeneration in 
dem murinen „hind limb model“, einem Ischämie-Modell, verbessert. Es wurde vorgeschlagen, dass die 
Regeneration durch Revaskularisation, gesteigerte Mobilisierung Endothel-regenerierender Zellen und 
gesteigerten Schutz des Muskelgewebes unterstützt wird. Schließlich wurde untersucht, ob die Reduktion der 
NO Produktion assoziiert ist mit schweren kardiovaskulären Erkrankungen wie dem Myokardinfarkt. 
Die Ergebnisse der präsentierten Arbeit zeigen, dass der Anstieg bioverfügbaren NOs durch dietätisches NO3- 
die Durchblutung in dem betroffenen Gewebes verbessert und verdeutlicht so sein regeneratives Potential. 
Weiterhin sind die Mobilisierung und die Migration Endothel-regenerierender Zellen signifikant verbessert. 
Mehr noch, auch die Geweberegeneration ist angestiegen. Es wird vorgeschlagen, dass die Zytoprotektion 
parakrin durch Endothel-regenerierende Zellen vermittelt wird, möglicherweise über den Fas/FasL Signalweg. 
Tatsächlich exprimieren Endothel-regenerierende Zellen FasL NO3- Aufnahme-abhängig. Die präsentierten 
klinischen Studien schließlich unterstützen die Hypothese einer gesunkenen NO Bioverfügbarkeit beim 
Myokardinfarkt. 
Zusammenfassend konnte demonstriert werden, dass dietätisches NO3- im ischämischen „hind limb model“ 
zytoprotektiv wirkt und Endothel-regenerierende Zellen mobilisierend. Die Beschreibung einer gesunkenen NO 
Bioverfügbarkeit im Myokardinfarkt unterstreicht die Bedeutung zu steigernder NO Spiegel in 
(kardio)vaskulären Erkrankungen. Die Relevanz des nützlichen Potentials des NO3--NO2--NO Signalweges wird 
mit Betonung auf die Rolle dietätischen NO3- in der Ischämie unterstützt. 
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Introduction 
1. Nitric Oxide 
1.1 Nitric Oxide 
In 1980 Furchgott et al. discovered the EDRF (endothelium dependent relaxation factor) and seven years 
later it was proved that EDRF was synonymous to NO1. Indeed, no one could believe that a pollutant 
could have such beneficial effects delaying evaluation2. Now we know that NO is one of the most 
important transmitters of the cardiovascular system. It is responsible for vasodilation and the 
maintaining of the vascular homeostasis by inhibiting platelet activation (e. g.)2. Furthermore, it has a 
great impact on immune responses to microorganisms and inflammation. In neurology it plays a role as 
a neurotransmitter and mediates neuronal plasticity2. 
In principle two different NO sources exist. It can be taken in either exogenously or generated 
endogenously. Exogenously it is inhaled or ingested with food and water, in most cases comprised in 
metabolites like nitrite (NO2-) or nitrate (NO3-). Endogenously it is produced via the “classical way” by NO 
synthases (NOS) or it is “recycled” from its metabolites NO2- and NO3- via an alternative way. Pivotal 
elements of the “classical way” of NO synthesis under normoxia are the NOS. The chemical reaction 
mediated by the enzymes is presented in figure 1, explaining the complexity of the reaction with needed 
O2 and multiple cofactors. Four different NOS are responsible for NO generation: neuronal NOS (nNOS), 
inducible NOS (iNOS), erythrocyte NOS (which is possibly an eNOS isoform. This issue is a matter of 
debate), and endothelial NOS (eNOS)2–6. nNOS produced NO as neurotransmitter in the cerebellum, 
especially3. iNOS is not constitutive expressed, but induced in inflammatory processes4. Erythrocyte NOS 
was discovered in 2006, but is actually suggested to be an isoform of the eNOS, with important 
regulatory functions for erythrocytes5. Thus, concerning the cardiovascular system the constitutive 
expressed eNOS, located in the vascular wall is the most important NOS. Furthermore, eNOS derived NO 
mediated vessel relaxation was the first to be discovered. 
From the producing endothelial cell (EC) the molecule diffuses into neighboring smooth muscle cells 
(SMC). Once it has arrived there, it activates the soluble guanylyl cyclase (sGC), which subsequently 
produces cGMP. In turn cGMP activates the signalling pathways that mediate the NO functions2. 
However, not every synthesized NO molecule reaches its target. NO is a reactive gaseous molecule with 
a very short half-life of 1-2 ms and thus, a great part of the endogenously produced NO is autooxidized 
to NO2-. This NO2- is only a little more stable (half life of 1-5 min) and further oxidized to NO3- with an 
EC50 of 5-8 h7. Additionally, NO could react with free thiol groups of proteins. Theses nitrosothiols are 
also suggested to mediate important signals in physiology and pathology, e. g. inflammation or 
apoptosis8. Suggested reactions are presented in figure 2.  
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Figure 1. Formation and metabolization of NO3-. 
Ingested dietary NO3- is first reduced to NO2- by bacterial reduction in the oral cavity (1). After passing 
oesophagus NO2- enters the stomach and is acidified to NO (2). Additionally, NO2- in circulation and 
tissue and is reduced to NO (3). At the same time, NO is enzymatically synthesized (4) and fast oxidized 
to NO2- (5). NO2- could be further oxidized to NO3- by hemoglobin (6)2,9. 
Figure 2. Generation of nitrosothiols 
The reaction of NO with the O2• generates 
ONOO- which could further react to NO2+ and 
NO2•. 
 
 
Figure 3. Peroxynitrite production and 
decomposition to nitrogen dioxide and 
hydroxyl radicals. 
With oxygen, NO could react to NO2 and further 
to N2O3. This peroxynitrite seems to be involved 
in RSNO generation. Besides NO binds directly 
to protein building RSNO. 
  
 
Finally, NO could react with reactive oxygen generating peroxynitrite. The protonated form of 
peroxynitrite could further react to extremely reactive, destructive radicals (figure 3).  
However, amongst these reactions the autooxidation to NO2- and NO3- is probably the most common 
one. Moreover, it is possibly the most important one, as recent work revealed that NO3- presents an 
endogenous NO store and thus an important third NO source especially in hypoxia10. Thus, 
2NO + O2  2NO2 
2NO2+2NO2  2N2O3 
2N2O3+2protein-SH  2protein-S-NO +2H+ + 2NO2 
 
or: NO + RS•  RSNO 
NO + O2•  ONOO- + H+  ONOO 
ONOOH  OH- + NO2+ 
ONOOH  OH• + NO2•  
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autooxidation of NO does not produce almost inert waste products (as thought for a long time), but 
stores NO in a stable form until it is needed.  
 As diffusion is a non-directed process, endogenous NO also reaches blood stream and the above 
mentioned oxidative reactions produce circulating NO3-, which is mixed with dietary NO3- entering 
together the entero-salivary circulation by active uptake of salivary glands. This entero-salivary 
circulation currently provides alternatively produced NO and extends from the salivary glands (and oral 
cavity) to the stomach (and gut) ending in re-entering the cycle or excretion.  
Experiments with dietary NO3- could evaluate that 25 % of ingested NO3- is detectable in saliva within 
30-60 min11. After overnight fasting basal NO3- concentrations in saliva were 200 µM12 representing 
highest level in human bodies except in urine. After ingestion of 10 mg/kg /100 ml NO3- levels increase 
to 800 µM. At the same time, NO2- concentration raises, indicating a profound NO3- reduction in the oral 
cavity. A first account of a relationship between NO3- content and NO2- concentration was done in 1976 
(redox equation is shown in figure 1)11,13. By testing NO3- reduction, after antiseptic mouthwash 
treatment a strong correlation between NO3- reduction and composition of oral microflora was 
proposed13. Different mammalian species have different compositions and numbers of commensals, but 
the principles are comparable, thus studies with rodents specified bacterial NO3- reduction to NO2- in 
mammals. From 1275 different identified strains of bacteria on rat tongues, 147 were able to reduce 
NO3-. The four main reducing strains were Staphylococcus, Pasteurella, Streptococcus, and Listonella14. 
In addition, bacteria were differentially distributed on the tongue. Towards the posterior end of the 
tongue, the general number of bacteria, and the specific number of NO3-  reducing bacteria increased14. 
Acidification of NO2- could complete the two-step NO bioactivation from NO3-. Acidic milieu is supplied 
by (sub-)gingival microflora around the teeth and periodontal tissue and is proposed to protect against 
periodontal disease (written down in figure 1)15.  
Two groups also independently analyzed acidic gastric NO2- reduction (shown in figure 1) after oral 
NO3- reduction and proposed an important function of NO for host defense against swallowed 
pathogens, regulation of mucosal blood flow, mucus formation, and gastric motility16,17. As the lower 
gastrointestinal tract is also densely populated by bacteria, a similar function of acidic reduced NO2- was 
proposed for intestinal mucosa and microflora18. NO3-, which is not reduced to NO2-, arrives the gut. In 
the gut this No3- is absorbed from the epithelium of the gut. In the next step the absorbed NO3- arrives 
the capillaries and the circulation. 19  
In summary, it could be estimated that 40-45 % of ingested NO3- was metabolized (in contrast 55 to 
60 % excreted). Half of metabolized NO3- is processed by bacterial mechanisms and half by mammalian 
reactions (discussed below), as shown by Tannenbaum and Coworkers20. The last sentence illustrates 
that, despite manifold mechanisms for the utilization of NO3- and NO2-, the majority is excreted as 
urinary NO3-. However, this urinary NO3- status enables an assumption about infection status, and daily 
ingestion21,22.  
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Parallel to the described bacterial and acidic reduction, and the ability to reduce NO3- to NO2- and 
NO2- to NO, mammals evolved similar mechanisms. NO3- (and NO2-) crossing blood stream and tissues by 
diffusion and absorption could be “recycled” to NO by a variety of enzymes. In many cases these 
enzymes have different functions under normoxia changing to NO2- (or NO3-) reducing enzymes under 
hypoxia. A recent work suggested a mammalian NO3- reductase in tissue23. In the study bacterial 
reduction was excluded by showing an effective NO3- reduction in germ-free mice. Instead of this, NO3- 
reduction was inhibited by treating tissue with the xanthine-oxidoreductase (XOR) inhibitor Allopurinol 
(AP), proposing a NO3- reductive function in the multipotent and ubiquitous expressed enzyme XOR23. 
However, mammalian reactions metabolizing NO2- to NO are better known. Over the last decades 
several molecules were identified, which are able to reduce NO2- to NO, under hypoxic conditions24–27, . 
First NO2- reductive to be identified was hemoglobin (equation is shown in figure 1). Even in 1937, 
Brooks described the oxygen sensitivity of hemoglobin and a NO2- reductase activity, but did not discuss 
physiological consequences28. The next groundbreaking work was done by Doyle and co-workers, who 
analyzed kinetics of NO2- reduction by deoxyhemoglobin, but were focused on the second effect of the 
reaction, the oxygenation of deoxyhemoglobin29. Indeed, until 2003 it was thought that (concerning NO 
metabolism) hemoglobin physiologically only scavenges NO, lowering its bioavailability. In contrast, 
Cosby and colleagues identified NO2--reducing deoxyhemoglobin as a physiologically important 
vasodilator24. Efficiency increases along the vascular tree from artery to capillary, with decreasing 
oxygen concentration reaching its maximum at the midpoint of hemoglobin dissociation curve (oxygen 
saturation: 50 %). This is due to the fact that, the deoxygenated T-state of hemoglobin is necessary to 
bind NO2-, but oxygenated R-state heme is essential to increase intrinsic reactivity of the enzyme24. After 
discovery of hemoglobin reductase activity, similar processes in myoglobin seemed natural. Indeed, our 
laboratory and an US group described NO2- reduction in the deoxymyoglobin molecule25,30, written 
down in figure 1. Moreover, because of the lower heme reduction potential of myoglobin NO2- 
reduction occurs 32 times faster than in hemoglobin25. These first studies postulated a regulatory 
function of NO2- reductase activity of deoxymyoglobin in mitochondrial respiration and cardiac 
energetics25,30, which could be expanded to a modulating role in oxygen consumption while exercising31 
and a protective function in I/R injury32. However, not only heme-molecules developed the ability to use 
NO2- as an electron acceptor by reducing it to NO. Several complexes of the mitochondrial electron 
transport chain 33, Cytochrom P45026, and even NOS34 shifted from molecular oxygen to NO2- as electron 
acceptor with decreasing oxygen tension. Finally, XOR provide an alternative path for NO synthesis. 
Under normoxic conditions, XOR reduces molecular oxygen to superoxide (O2-)35, but with decreasing 
oxygen concentration catalytic domain at the molybdenium side of the enzyme (independent from the 
second enzymatic active FAD domain of the protein36) ,changes from oxygen to NO2- reduction37 
(illustrated in figure 1). In the following, several studies supported the impact of non-enzymatic NO 
production via the NO3--NO2--NO-pathway under physiological and pathophysiological hypoxia9,38,39. 
Bryan et al. even proposed a signalling function for NO2- itself40. Consequently, endogenous NOx levels 
(summarized in table 1) could be considered as marker for NO homeostasis, but also as a constant 
supported NO-store by dietary of NO3- (NO2-). 
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Combined, processes have evolved to ensure NO delivery for the whole range of oxygen tension, 
clearly illustrated in a review from 2008 as ying (normoxic enzymatic NO synthesis) and yang (hypoxic 
non-enzymatic NO synthesis) of NO metabolism9. Subsequently, the question arose as to whether an 
increase of NO3- ingestion would have a real benefit in human disease or whether risks would prevail. 
Table 1. Levels of NO metabolites in health. 
Listed values summarize concentrations of NO3-, NO2- and NO in biological fluids involved in the circuit of 
dietary NO3- metabolization7,12,22. 
1.2 Nitrate (NO3-) 
Nitrogen is an essential molecule in prokaryotic and eukaryotic organisms for production of nucleic 
acids, amino acids, and proteins. Additionally, NO2- and NO3- are used as an energy source for various 
bacteria41. In ecosystems this demand is covered by the nitrogen cycle, composed of nitrification and 
denitrfication processes. The mentioned above NO synthesis together with the entero-salivary 
circulation, presents a similar mammalian cycle of “nitrification” and “denitrification”. However, it is not 
nitrogen but NO which is the essential molecule needed. It was presented that NO is fast oxidized to 
NO2- and NO3-, due to its short half live42,43 and that NO2- and NO3- are also ingested by food and water 
9,19. This mixture of endo- and exogenous NO3- circulates throughout the body and is thus present in high 
concentrations in the mammalian organism.  
Previously it was thought that this NO3- was an almost inert reaction product of NO, although its 
“recycling” in nitrogen-cycle was known9,44. It was thought that the chain (NO  NO2-  NO3-) is a one-
way street, and NO3- is excreted unused. Indeed, it could be shown, that the reaction cascade is not a 
chain but a circuit. Since 1976 it has been known that circulating NO3- is concentrated in saliva and 
reduced back to NO2- by commensals in the oral cavity11. In the 1990’s, it was shown that this NO2- 
reenters circulation and is “recycled” to NO16,17. Despite this physiological generation, both NO2- and 
NO3- were demonized to be toxic and carcinogen45,46. 
This attitude of hazardous NO3- (and NO2-) is somewhat astonishing considering the known 
importance of NO3- for ecosystems. Most nitrogen is stored in the atmosphere in gaseous form (N2), but 
inaccessible for most plants, because there are only able to take up nitrogen as ammonium (NH4+) or 
NO3-. Similar counts exist for many bacteria and animals that cover their requirement by consumption of 
organic material47. Other bacteria, fungi, and actinomycetes decompose dead organic material providing 
it for the nitrogen cycle47. Autotrophic bacteria assimilate nitrogen by oxidization of NH4+ to NO2-. A 
second group oxidizes NO2- to NO3-, completing the process of nitrification48. Subsequently, this NO3- is 
available to plants for assimilation and heterotrophic bacteria as energy source. This enzymatic 
respiratory reaction of denitrification closes the cycle. Obviously, NO3- is a key factor for life, used by a 
plethora of organisms and currently transformed in the nitrogen cycle. On the other hand, the first iahes 
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or words that spring to mind when one hears of  NO3- are pollution, fertilization, or toxic precipitation. 
Increased livestock ranching and sewage waste produce large amounts of ammonia (NH3) reaching soil 
and groundwater, increasing their NH3, NO2-, and NO3- concentrations47. In fact, the nitrogen cycle is 
massively influenced by industrialization, but nevertheless it is also one of the most important nutrient 
cycles in terrestrial ecosystems, with NO3- as a key player in this biogeochemical cycle47,48.  
The last paragraph clarified that the dissent existing for NO3- (and NO2-), concerning mammalian 
physiology and health is also evident for NO3- in ecology. Regarding human healthcare NO3- and NO2- 
levels in food and water are restricted by administration to avoid risks of health (see also chapter 
1.3)49,50. Otherwise, NO3- was newly discovered as a stable but utilizable storage form of NO with a 
possible benefit to healthcare12. Indeed, dietary NO derivates were shown to have beneficial effects on 
cardiovascular disease, gastric ulcers, or host defence e. g. (detailed in chapter 1.5). Discovery of this 
non-enzymatic NO synthesis and its great potential for health care begin to change the image of NO3- 52. 
Obviously, the issue is complex and one does not do justice to NO3- by describing it either as demon or 
as savior. However, in recent years there has been more and more focus on dietary NO3- (and NO2-) as a 
beneficial supplement. 
1.3 Dietary NO3- 
As every organism needs nitrogen, but cannot assimilate and incorporate it in its molecular form, NO3- is 
a ubiquitous molecule in food and water19. Over the last decades, increased industrialization (fossil fuel), 
agriculture (fertilization), and livestock ranching (sewage) has meant that NO3- content was further 
amplified47. In vegetables NO3- concentration is dependent on temperature, lighting conditions, and 
NO3- content in soil. High NO3- content in soil, in combination with lower temperature and light 
quantities leads to the highest NO3- amounts. Thus, NO3- content fluctuates and is higher in northern 
Europe than in southern Europe53. Additionally, NO3- concentration in groundwater and accordingly in 
soda could be high by leaching and fertilization47,53. Highest levels are found in leafy vegetables, such as 
spinach and root vegetables like beet root19,53, summarized in table 2. Finally, NO3- / NO2- are used as a 
preservative for meat, fish, and cheese productions, as it inhibits late blowing53. 
Estimations are that the average daily intake of NO3- in Europe lie at between 31 - 185 mg/d and 40 -
 100 mg/d NO3- in the US (NO2- ingestion varies between 0 - 20 mg/d)19. At the same time, the vegetable 
and fruit rich DASH diet has been recognized to lower blood pressure54,55. Hord and co-workers 
hypothesized that this beneficial effect refers to the NO3- content in the diet and calculates daily 
ingestion for two variations of DASH diet, a NO3- rich one and a NO3- low one. The NO3- content varies 
between 174 to 1,222 mg per day, exceeding WHO recommendations by 550 % (for a 60 kg adult), but 
with health benefits12,19,49. Apart from the question raised as to whether the WHO recommendation is in 
fact up-to-date (concerning daily NO3- uptake) the study impressively illustrates the huge range and 
suggestibility of dietary NO3- intake. 
Nevertheless, only a part of this dietary NO3- arrives via circulation and is available for NO 
metabolism. Every step in the reaction cascade, results in a 3-log loss19. Only 20 % of ingested NO3- is 
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reduced to NO2-, which corresponds to 5-8 % of the ingested amount 19. Instead of this, almost all 
residual NO3- arriving via the small intestine is absorbed19. This exogenously ingested NO3- is mixed with 
endogenously produced NO3-. In a healthy adult about 1 mg/kg NO3- is produced endogenously (e. g. 
80 mg in an 80 kg adult). If both are taken into account, about two thirds of produced NO is eNOS 
derived and one third is delivered by diet19. This ratio elucidated that endogenous synthesis is the more 
important NO source for mammals and diet could only support this function. This classical way of 
endogenous NO synthesis via NOS is well-investigated and understood. Recent work shows that this 
mechanism of NO production only functions under normoxia and that under hypoxia alternative enzyme 
independent machinery takes over the role of NO provision, which could be well supported by diet.  
Table 2. Chosen NO3- concentrations in food. 
NO3- content varies from season to season and is dependent from the area of cultivation. Thus, not 
absolute numbers but ranges or means are listed. Additionally, indices specify the source. *Hord et al., 
2009; §Weiß et al., 200819,53. 
1.4 Toxicity and Carcinogen Potential  
In the 1940s a health risk was discovered, associated with the consumption of NO3- (and NO2-). In the 
following decades these reports about methemoglobenia resulted in recommendations regulating NO2- 
and NO3- consumption. Additionally, not only methemoglobenia but some forms of cancer were 
associated with excessive NO3- (and NO2-) intake. However, none of these studies could provide a real 
correlation and some of it showed methodical faults after retrospective analysis.  Thus, reinterpretation 
of the results supported the actual discussion of revaluation of dietary NO3- (and NO2-).  
One of the first alerting studies, published in 1948, described methemoglobenia in infants,46 leading 
to guidelines restricting NO3- and NO2- content in water. Since then, new cases have been published, but 
at the same time retrospective studies have also appeared impaired alerting assumptions. In 
methemoglobenia NO2- is bound to hemoglobin suppressing oxygen binding. This alternative binding can 
lead to cyanosis and asphyxia, in the worst case56. However, only after exceeding 50 % methemoglobin 
in blood, which corresponds to 1 - 2 g NO2- or 15 g NO3-53, could acute life-threatening poisoning occur. 
Physiologically, methemoglobin-reductase bind NO2- until the amount of methemoglobin exceeds its 
capacity53. Although given the fact that 1 - 3 % of methemoglobin is within the physiological range56, the 
likelihood of poisoning in children and adults is extremely low, with the exception of a hereditary deficit 
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in methemoglobin-reductase, of course. Single case studies refer to special conditions, for example in 
New York in 2002, when a whole family suffered from methemoglobenia, caused by eating bad food56. 
The only subpopulation, in which incidence to methemoglobenia is increased are infants below three 
months of age. The three most important factors facilitating the sickening in infants are denoted 
below57. They have a higher gastric pH, possibly supporting NO3- reducing microflora. Additionally, foetal 
hemoglobin is more readily oxidized by NO2- than adult hemoglobin, and finally methemoglobin-
reductase is not as active in infants as in adults53,58. Nevertheless, only infants, which are not breastfed, 
are vulnerable. NO3- ingestion of the mother does not influence NO3- content of breast milk and 
lactobacillus as the dominant commensal in the stomach and gut of breastfed children is not able to 
reduce NO3-58. Although the higher incidence of infants is uncontroversial, more recent studies place 
doubt on the fact that NO3- alone could be sufficient to induce methemoglobenia59,60. No NO3- or NO2- 
exposure study could cause the “blue baby syndrome” and bacterial contaminations of water or pre-
existing gastroenteritis were suspicious to trigger methemoglobenia in reported cases. Such infections 
would increase iNOS expression, possibly increasing endogenously produced NO2- in an acute toxic 
manner59,60. To this end, it is not infants but adults or even elderly persons who form the demographic 
group thought to profit from NO3- supplementation. Another problem could be the blocking of the 
sodium-iodine symporter by NO3-, inhibiting uptake of iodine in the thyroid. However, epidemiological 
studies weakened this hypothesis by negating a correlation between goiter and NO3- ingestion61. At last, 
a carcinogen potential of NO2- formed from NO3- is discussed. NO2- could react with secondary amines or 
amides forming N-nitroso compounds (NOCs)11, which were found to act as mutagen in animal 
models62,63. Therefore, many studies analyzed the potential relation between NO3- and NO2- ingestion 
and risk of cancer (gastric, enteric cancer, and glioma, peculiar)64–66. Nonetheless, no careful 
interpretation and prospective or retrospective analysis could reveal a correlation in human beings44,57. 
For example, Michaud and colleagues combined three prospective cohort studies to analyze dietary 
habits of 121,700 females from the Nurses´ Health Study I (NHS I), 116,686 females from the NHS II, and 
51,529 males from the Health Professionals Follow-Up Study (HPFS)67–69 all of whom were more than 24 
years old. They screened questionnaires for meat intake, NO3-, NO2-, and even nitrosamine levels in 
nutrition and glioma, but did not find any relation70.  
Altogether, alerting studies led to guidelines referring maximal values in water and processed food 
and recommendations for daily ingestion of NO3- and NO2-49,50. However, opposing studies negated a 
strong relation between dietary NO3-, NO2-, and disease, in contrast they proposed a beneficial effect 
and suggested an actualization of guidelines9,60. 
1.5 NO and Metabolites as Beneficial Concomitant Therapy 
Dietary NO3- as Beneficial Supplement 
Nutrients represent an important regulating factor for good health.  As malnutrition could lead to 
sickness (e. g. fat or sugar) the right dietary supplements could maintain good health71. Over the last 
decades many nutrients and ingredients were lauded as valuable with great benefit to healthcare. 
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Recently, polyphenols have been intensively analyzed for their protective potential, e. g.72–74. These 
secondary plant products show high anti-oxidant, -inflammatory, and -carcinogen effects75. Among 
others, they are the ingredients of red wine, green tea, and cocoa and several studies analyzed 
correlations between health and ingestion in populations with particular high intake of these 
products76,77. However, consumption of red wine is only one of the elements of a Mediterranean diet 
and the separate benefits diminish and harmful components have a greater impact. In this case, the 
alcohol content has to be considered. NO3- as an ingredient of a mass of nourishments (described in 
paragraph 1.3 Dietary NO3-) and a storage pool of NO (explained in passage 1.) with only minor risks 
(discussed in chapter 1.4 Toxicity and Carcinogen Potential), also becomes the focus of attention as a 
beneficial supplement. This is also the case for the cardiology dysregulation of NO metabolism, which is 
one of the key features leading to atherosclerosis78. Therefore, it should be a goal to maintain and 
restore NO homeostasis. Moreover, recent work demonstrated NO mediated regenerative effects, 
beyond its known physiological functions in cardiology79,80. It could be shown that controlled 
administration of NO2- increases revascularisation and regeneration in the animal model of hind limb 
ischemia. Testing different doses of chronic NO2- therapy, the lowest dose was the most effective. Even 
after three days of therapy, hind limb perfusion was significantly increased, which illustrates the 
potency and the efficiacy of NO2- as a beneficial agent81. As NO3- is reduced to NO2- it could be also be a 
promising health supplement, even more so as its’ potential for healthcare seems extensive and has still 
not been fully exploited.  
However, in the beginning diets as a whole were analyzed without considering daily NO3- ingestion (or 
other special ingredients). The American Heart Association developed the DASH diet and described 
antihypertensive effects after consumption82, and an Italian group analyzed improved cardiovascular 
risk profile and oxidative stress status in Italians following a Mediterranean diet76. After revaluation of 
the health risks of NO3- the hypothesis raised the issue that seen positive effects in diets as DASH or 
Mediterranean diet, refer to their NO3- content. Suggested benefits mediated by dietary NO3- or NO2- 
concentrated on three major issues. NO operating as antibacterial agent supporting host defense83, 
acting regenerative in ischemic diseases 84, and comprising anti-atherosclerotic and cardioprotective 
functions85.  
During the first developed studies, NO2- or NO3- was administered as a drug (inhaled or injected) and 
later on as a diet supplement. A second round of studies correlated daily NO3- ingestion with disease. In 
1999 and 2004 two studies discovered a relation between high salivary NO3- concentrations and 
decreased caries 86,87. A key role in entero-gastric host defense and mucus homeostasis for non-
enzymatic derived NO could be shown manifold16,83,88–90. Gastric NO has an impact on protection against 
gastric ulcer and mucosal lesions 88–90 and promotes mucosal flow and generation83. In the whole gastro-
intestinal tract NO strengthens host defense by killing gastric and intestinal pathogens88,91. Additionally, 
it could be illustrated that in mechanically ventilated patients NO-mediated gastric host defense is 
impaired. These patients who are not able to swallow saliva are fed non-orally, which represses 
bacterial NO3- reduction in oral cavity92. Furthermore, not only did NO2- and NO levels rise after NO3- 
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ingestion, but gastric RSNO levels also increased and inhibited platelet function after supplementation 
with KNO393. A benefit of the antibacterial potential of NO was also proven on human skin and in urinary 
infections. NO is produced by dermal commensals from sweat controlling bacterial growth and 
inhibiting fungal proliferation94. In urine, in combination with ascorbic acid, NO2- reduces the pH of 
urine, acting bacteriostatic and dietary NO3- supplementation was suggested as new treatment strategy 
in urinary infections95. 
At the same time, much research was done evaluating the impact of non-enzymatic derived NO in 
cardiology, underscoring the potential of dietary supplementation24,93,96–98. Additionally, in the 
respiratory tract non-enzymatic NO unveiled its whole capability. With the discovery of inorganic NO2- 
mediated pulmonary vasodilation, new therapies for pulmonary thromboembolism and newborn 
pulmonary hypertension evolved99,100. Consequently, the discovery of vasodilative capacity led to the 
broadened use of inorganic NO2- and NO3- in ischemic diseases in the cardiovascular system and other 
vital organs. Promising results could be gained by influencing regeneration in peripheral artery disease 
(PAD) and hind limb ischemia, respectively, which will be the animal model in the presented work, by 
increasing NO levels. Several studies could enhance outcome after hind limb ischemia by administration 
of NO-releasing drugs101 or medication, which mediates augmentation of NO synthesis79. In 2008 the 
first try was done with the direct administration of intraperitoneally administered NO2- by Kumar and 
colleagues81. They could evaluate improved regeneration with concomitant increased angiogenesis in a 
model of murine hind limb ischemia. Accordingly, several animal studies quantified a reduced infarct 
size in myocardial I/R-injury27,85. Parallel, experiments were expanded from heart to liver determining 
improved outcome in liver I/R-injury after NO2- supplementation84,102. Subsequently, intravenous NO2- 
protects the kidney against I/R-injury103 and reduces neurological damage after stroke104. In addition, 
treatment with infused NO2- or inhaled NO show neuro-protective effects avoiding cerebral vasospasm 
in a primate model of subarachnoid hemorrhage105 and reduces brain injury in premature newborns 
with respiratory failure106.  
Another series of work focused on the mechanism by which NO could mediate its cytoprotection. 
Clementi et al. could show that S-nitrosated proteins are able to inhibit mitochondrial complex I 
depressing mitochondrial respiration107. In the following, molecular evidence for the proposed inhibition 
was supplied and a protective role of it in I/R-injury proposed108. Mitochondrial experiments and in vivo 
models were combined enabling determination of the protective function of inhibition of mitochondrial 
respiration in hepatic and cardiac I/R-injury. A decrease in ROS production and prevention of 
mitochondrial permeability transition pore opening after reperfusion could be determined109. 
Preceding paragraphs summarize treatment and therapy by increasing NO bioavailability, in general, 
independently from source. Manifold examples emphasize the huge range of beneficial functions of NO 
in health care. Nevertheless, more and more studies focus on the potential of dietary supplementation 
able to gain sufficient results for all analyzed organ systems and syndromes presented. Already the 
study done by Benjamin et al. showed profound salivary NO2- and gastric NO formation after NO3- 
ingestion, in the following manifold confirmed16,83,87,90,93. Animal models and observational studies 
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evaluated the vasodilative and blood pressure lowering potential of dietary NO2- and NO3-19,98 and 
expanded analyses to I/R-injury85. Shiva et al. transferred in vitro results concerning inhibition of 
mitochondrial respiration by NO to dietary NO2- 5.  
What are the reasons for dietary approaches becoming more important during the last few years? 
Firstly, nothing is easier to influence than diet. Nutrients are easy to obtain and to deliver with no or less 
risks and side effects. Moreover, the dosage of nutrients can also be easily controlled.  In addition, risks 
of anesthesia, surgery, or inflammation can be avoided. Costs are minimized and the problem of 
compliance is circumvented; although large effects could be evaluated. In the case of nitrate 
supplementation, it brings another advanatage. By treating myocardial infarction first measure often is 
administration of organic nitrates like nitroglycerin (GTN) for vasodilation. However during the 
metabolization process to NO, organic components of such nitrates need enzymatic metabolization by 
mitochondrial aldehyde dehydrogenase (e. g.) inducing tolerance9. During the chronic administration, 
these enzymes are partly irreversibly modified at their active sites, lowering the efficiency of 
treatment110. This phenomenon does not occur with inorganic NO3-, because the critical enzymatic step 
is redundant. Thus, augmented daily intake of NO3- is assumed to significantly improve the state of 
health of (cardio-)vascular diseased patients. 
2. Cardiovascular Ischemia 
 Oxygen, water and nutrition belong to the three essentials needed for life. Water is essential for organic 
life as it is known and every cell consists to 70-90 % of water. For example, it is a universal solvent 
ensuring distribution of minerals and proteins, e. g., in cells and transport within the body111. Nutrition 
delivers the bricks of life. Minerals, amino acids, fats, carbohydrates, and many more are all essential to 
build up cells and organs and to ensure formation, proliferation, and adaptation. However, none of 
these key elements function without energy, which is supplied by oxygen and subsequent synthesized 
ATP. Consequently, deficits in oxygen delivery cause severe disease. Hypoxia is defined by a single deficit 
of oxygen, but in ischemia blood flow is diminished causing a deficit in oxygen and nutrients. Thus, the 
narrowing and occlusion of arteries lead to ischemia. One of the most prominent diseases caused by 
ischemia is the endothelial dysfunction, leading to atherosclerosis, peripheral artery disease, and 
myocardial infarction.  
Severe acute ischemic events like myocardial infarction or stroke do not occur spontaneously in 50 % of 
cases. A long history of chronic ischemia proceeds, for which there are not neceesarily any evident 
symptoms. The first step in the progression of disease is endothelial dysfunction provoking 
atherosclerosis112–114. Apart from age and hereditary risk factors like a family history of atherosclerosis, 
the increased prevalence of African Americans and an eNOS gene polymorphism, it is mainly life-style 
which is responsible for the disease115. Risk factors are adipositas, hyperlipidemia, smoking, and 
hypertension. However, diabetes mellitus type 2, chronic kidney disease, hypercoagulability (elevated 
levels of d-dimer, homocystein and lipoprotein A), and increased concentrations of inflammatory 
markers (CRP, fibrinogen, leukocytes, IL-6) are also hazard factors116. 
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Atherogenic lipids (oxLDL) induce monocyte adhesion and promote procoagulant properties of the 
vessel wall. Subsequently, leukocytes, smooth muscle cells (SMC) and platelets intake lipids and 
differentiate into foam cells forming the fatty streak. They adhere to the activated EC, incorporate into 
the intima of the artery and an inflammatory lesion develops (see figure 4), presenting the beginning of 
atherosclerosis117,118. NO bioavailability is decreased, because eNOS substrate (L-arginine) is reduced 
and arginase II is activated (which destroys L-arginine). Moreover, eNOS is uncoupled unable to produce 
NO. However, it is a matter of debate whether decreased NO bioavailability is the cause or result of 
endothelial dysfunction. Altered enzymatic activities lead to increased synthesis of reactive oxygen 
species, damaging cells119,120.  
Next, the lesion expands representing an advanced lesion or atheroma (plaque). This vigorous cellular 
structure consists of EC, SMC, leukocytes, and cartilage and is covered by a fibrous cap. These 
atheromas accelerate in size, so that arteries are forced to compensate lowered lumen by remodeling. 
This includes an expansion of the media by SMC. However, atherosclerosis progresses until remodeling 
would be insufficient and perfusion is limited. Stenosis (narrowing of a vessel) and chronic ischemia are 
the consequences. Additionally, arteries loose their flexibility and become rigid. Finally, a complete 
occlusion elicits an acute event. Either the plaque closes up the lumen entirely or the stable plaque 
becomes unstable and breaks up. In the latter case the fibrous cap bursts and circulates as 
prothrombus. While circulating, a thrombus evolves until it obstructs an artery, e. g. in the coronary or 
the cerebral circulation. Indeed, aggravating atherosclerosis over decades could precede such an 
event116,118. 
Figure 4. Atherosclerosis 
Progression. 
The left arterial section shows 
a healthy artery with vast 
lumen. From the second to 
the last section, lumen is 
increasingly narrowed until 
total occlusion. 
 
 
Chronic ischemia developing by progressing atherosclerosis, belongs to the group of cardiovascular 
diseases (CVD), could lead to CAD and PAD, dependent from the affected tissues and arteries. If a 
coronary circuit is involved, the patient develops a coronary artery disease (CAD), but if peripheral 
arteries are mainly narrowed the patient suffers from a peripheral artery disease (PAD). CVD is the most 
common cause of death and a third of all deaths (17.5 million) refer to it, as estimated by the WHO in 
2005. In Europe even every second death is attributable to CVD121. Although neither CAD nor PAD 
directly cause mortality, the progress of disease leads to life-threatening acute events like myocardial 
infarction or stroke116. CAD includes patients affected with a stable angina (SA) caused by flow-limiting 
stenoses. In contrast to that, in unstable angina (UA) plaques disrupt and occlude arteries transiently122. 
PAD also leads to clinical symptoms by stenoses and occlusions, but is concentrated mainly on lower 
extremities. The animal model of hind limb ischemia (explained in detail in Methods and Materials, 
chapter 2.3) does not imitate these conditions, but could be observed as an artificial, general approach 
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enabling its analysis. In the beginning many patients are symptom-free, but in advanced stages they 
even experience pain while resting and they have limited mobility. The first approach for treatment of 
PAD is a change in life-style to reduce risk factors. Additionally, statins should lower cholesterol level 
and improve endothelial function. Besides, moderate exercise training had been proven to attain good 
results. With the progression of disease ulcerations (non-healing wounds), necrosis could emerge. At 
this stage interventional therapy has to be preferred to avoid amputations123. 
If the fibrous cap of a stable plaque of a CVD patient disrupts and a prothrombus evolves, it becomes 
an acute event. Subsequently, the structure circulates until it gets stuck in a small or narrowed artery 
which occludes it. Relative to the affected vascular network, the patient suffered a liver or a kidney 
infarction, a stroke, or a heart attack. Differential diagnostics describe an instable angina pectoris, a 
NSTEMI (non-ST-elevation myocardial infarction), and a STEMI (ST-elevation myocardial infarction). The 
most severe infarction, the STEMI, is diagnosed by a characterizing electrocardiogram, elevated CK 
(creatin-kinase), and CK-MB (creatin kinase-muscle brain) values, elucidating tissue damage. The first 
emergency measurements are treatment with organic nitrates. On arrival at the hospital, an early 
balloon catheter-assisted revascularization (PCI) would be advised, which would decrease the risk of 
death and increase sufficient reperfusions124. The occluded artery would then be reopened by inflating 
the balloon and kept open by implanting a bare metal or drug eluting stent. Although early 
revascularization could be life-saving it also initiates processes that further damage the myocardium. In 
proportion, without reperfusion infarct size accounts for 70 % of myocardium, this is reduced to 30 % by 
reperfusion. Nevertheless, remaining 30 % refer to the ischemia-reperfusion injury (I/R injury) initiated 
by necessary revascularization125. In order to reduce I/R injury, Encouraging results to reduce I/R injury 
could, up until now, only be accomplished in animal models, decreasing infarct size after reperfusion 
significantly126–128. Indeed, to date none of the approaches could be sufficiently translated to the clinical 
setting129. On the other hand, understanding of the paradox phenomenom of I/R injury has become 
much clearer in recent years125,130. 
During the so called oxygen paradox, cells come under oxidative stress attributable to reactive oxygen 
species (ROS) after sudden re-energization of the cells with O2. Destructive ROS are mainly produced by 
the electron transport chain in mitochondria, the endothelial XOR, and the neutrophilic NADPH oxidase. 
In the following, ROS induces dysfunction of the sarcoplasmatic reticulum, injures the cell membrane by 
lipid peroxidation, acts as chemoattractant for additional neutrophiles, and is involved in the opening of 
the mitochondrial permeability transition pore (PTP). Additionally, ROS reduces NO bioavailability, 
repressing its cardioprotective effects125,128,131. Ar the same time, damaged sarcolemmal membrane and 
dysfunctional sarcoplasmatic reticulum lead to a rapid Ca2+ overload of the cardiac cell. The process is 
supported by the reversed Na+Ca2+ exchanger. In summary, the overload causes a hypercontracture and 
promotes opening of the mitochondrial PTP leading to cell death125,130. Similarly, fast pH correction 
causes a paradox damaging effect. Whereas reperfusion lactic acid is washed out and supported by the 
Na+-H+ exchanger and the Na+-HCO3 symporter pH increases to physiological values. Nonetheless, this 
process further facilitates hypercontracture of the cell and mitochondrial PTP opening damns the cell to 
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death125,132. Previously, ischemic myocardial cell death induced inflammatory processes, which are 
further strengthened by ROS for I/R injury. A complement system is activated, and neutrophiles 
areattracted to the cardiac tissue. Inflammatory cytokines and increased expression of adhesion 
molecules trapping leukocytes additionally enhance inflammation125,133. Combined, all processes 
contribute to the opening of the mitochondrial PTP. Open pore uncouples oxidative phosphorylation 
and perforates mitochondrial membrane leading to mitochondrial swelling, ATP depletion and cell 
death125,134. In conclusion, despite enhanced therapy of myocardial ischemia to date, damage induced 
by I/R injury still counts for 10 % of deaths125,135. Thus, protection of affected tissue is still a priority goal, 
including myocardium and skeletal muscle tissue, as well as increased revascularization. 
3. Endothelial-Regenerating Cells  
On the one hand, the presented potential benefit of increased NO bioavailability by dietary NO3- is 
impressive.  It was assumed that NO3- is reduced to NO and NO decelerate the progress of disease. On 
the other hand, the described mechanism of action in the cardiovascular system, namely vasodilation 
can only be sufficient to widen blood flow of stiffed, narrowed arteries in the initial stages of    
atherosclerosis. In the progressed stages of disease, occlusion reaches a level which can not be 
compensated by vasodilation and remodeling118. Accordingly, additional beneficial pathways have to be 
activated by NO. A first hint was given from our laboratory.  A positive regulation of endothelial 
progenitor cells (EPC) proliferation and migration by NO was determined in vitro136,137. Moreover, in 
2010 the chemokinetic impact of NO on CAC in contrast to the chemotactic impact of chemokines and 
its orchestrated collaboration could be evaluated80. Both, EPC and CAC (in the current work renamed to 
Endothelial-regenerating cells) are cells pertaining to the group of BM-derived progenitor cells with 
endothelial regenerating and angiogenic potential.    
3.1 Definition 
EPC are progenitor cells, which were first isolated and characterized in 1997 by Asahara and colleagues. 
They isolated a CD34+KDR+ subpopulation of hematopoietic precursor cells able to differentiate into 
CD31+ endothelial cells (EC)138. The markers CD34 and KDR (kinase insert domain receptor) were chosen 
as they are stem cell (CD34) and endothelial (KDR) markers defining the special phenotype. Subsequent 
work supported the assumption that EPC are mobilized from BM, differentiated into EC and are involved 
in neovasculogenesis138–140. Neovasculogenesis, the formation of blood vessels independently from 
preexisting capillaries, was thought to be exclusively limited to embryonic vascularization141. In the adult 
organism only angiogenesis could be evidenced142, which is characterized by the sprouting of preexisting 
vessels by mature EC build up new capillaries143. The identification of EPC derails this paradigm, 
revealing neovasculogenesis in adults138,143. In the following, EPC were intensively analyzed, concerning 
mobilizing factors, migration behavior, functionality in vascularization, and identity. It became apparent 
that the isolated population of angiogenic precursor cells, circulating in peripheral blood is 
heterogeneous144,145. Nevertheless, some principles are valid and accepted for the whole group. EPC 
reside immaturely in the BM and held there by kitL and a positive chemotactic gradient146. Trigger 
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factors, mainly hypoxia, initiating signal cascades at which end cytokines were produced and which 
loosen extracellular matrix (ECM) by matrix-metalloproteinases (e. g. MMP-9)147 cleave kitL to soluble 
kitL (skitL)148 and reverse the chemotactic gradient. Now, chemokines attract EPC from BM into 
circulation, directing them to the sites of demand. The most important attracting factors were the 
granulocyte macrophage colony-stimulating factor (GM-CSF), the granulocyte colony-stimulating factor 
(G-CSF), the vascular endothelial growth factor (VEGF), and the stromal cell-derived factor-1α (SDF-
1α)149,150. Furthermore, nicotine, estradiol, α4-integrin, and β2-integrin were discovered as molecules 
promoting mobilization and migration of EPC151–154. However, the “right” definition and the exact 
function of BM-derived progenitor cells are still under debate. 
Determination of the “right” definition of BM-derived progenitor cells and comparison of different 
studies was difficult in the last decade, because of the mass of publications which all had slightly 
different isolation, culture, and staining methods. Hence, it is a methodological problem and a problem 
of heterogeneous cell population. Based on reviews and original works, the most important trends are 
presented leading to the definition used in the current work80,144,145,155–163. Asahara et al. and Hill and 
coworkers isolated so called EPC from peripheral blood by selection against CD34 or KDR. Non-adherent 
cells were cultured for five days and the intake of acetylated low-density lipoprotein (acLDL) was 
confirmed. Cells were spindle-shaped forming clusters138,160. Due to colonization, the cells were also 
called colony-forming unit-EC (CFU-EC). Another method described the culture of adherent cells for up 
to seven days158,159 ,defined after one week by the binding of Ulex Europeus Agglutinin-1 (UEA-1) and 
intake of acLDL. Based on surface marker expression and in vitro function, these cells appear similar to 
CFU-EC isolated from Asahara and Hill and were often grouped together as EPC. However, culturing is 
slightly different, and no clustering is observed. Promotion of neovasculogenesis was reported equally, 
because the cells were termed circulating angiogenic cells (CAC). These cells are suggested to promote 
neovasculogenesis mainly by secreting angiogenic factors156. Thirdly, culturing of CEC (circulating 
endothelial cells) was extended to about 10 – 21 d161. These cells exhibit cobblestone morphology and 
are phenotypical similar to EC. Thus, this subpopulation was addressed as endothelial colony-forming 
cells (ECFC) supporting neovasculogenesis by differentiation into EC. In contrast to EPC, secretion of 
angiogenic factors is reduced156. Referring to this varying paracrine potential and duration of culture, 
EPC were subdivided in “early outgrowth EPC” and “late outgrowth EPC” (similar to ECFC). Finally, 
characterization by flowcytometry (FACS) has to be linked with definition after culture. This method 
enables quantification and direct characterization, reflecting in vivo status. On the other hand, 
characterization by culture is more sensible, because morphology and growth behavior could be taken 
into account. Modern instruments lend the opportunity to multicolor FACS, compensating for that 
disadvantage partially by detailed surface marker characterization, but every additional marker 
decreases an already low number of gated cells, limiting the validity of experiment. With this limitation 
in mind some authors termed CD34+KDR+ (in mice: CD34+Flk-1+) cells determined by FACS “putative 
EPC”157. A variety of markers is circulating in literature164, but coming back to the roots to define a 
progenitor cell with endothelial characteristics, a combination of the mostly used markers CD34 and 
KDR should describe an “immature cell with endothelial priming”, enabling concurrent count of a valid 
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amount of cells157. This method is confirmed by studies, which detected these cells as similar decreased 
in cardiovascular ill patients as shown for EPC165,166 and was also able to promote 
neovasculogenesis167,168. As CD34+KDR+ cells were similarly detected to act as angiogen, circulating in 
peripheral blood, and acts as endothelial-regenerating, the term Endothelial-regenerating cells seems 
useful. Furthermore, it has to be considered that all subpopulations derived from the same origin and 
that, in in vivo all subpopulations have, possibly, parallel angiogenic eligibilities and functions. Thus, to 
determine the angiogenic potential of progenitor cells in ischemia, and capture the entirety of 
“endothelial-regenerating cells” seems favorable. It could be assumed that, in vivo the early outgrowth 
cell (CAC) secretes angiogenic factors while migrating to its target side, supporting vascularization from 
the time leaving BM niche until reaching ischemic tissue. Once arrived at the place of demand, the cell 
continuously changed from the early to the late type (late outgrowth cell or ECFC), decreasing secretion 
and maturing into an EC.  
In conclusion, in the current work the term Endothelial-regenerating cell describes BM derived cells 
with angiogenic potential, circulating in peripheral blood and migrating into ischemic tissue. Recent 
literature confirmed an angiogenic potential for BM derived cells, but even today after 15 years of 
research, a consistent definition of involved subpopulations is lacking162.  
3.2 Function 
Mentioned above, Endothelial-regenerating cells were also defined and differentiated by their function. 
However, even this “parameter” could not deliver unambiguously defined populations, because it is also 
a matter of debate. Asahara and coworkers have already tried to reveal EPC function139. In an extended 
in vitro series they observed a progressing EC-like phenotype, with duration of culture and the ability to 
form tube-like structures. Following, in vivo experiments were done and i. v. injected EPC were found 
exclusively in newly-built capillaries. They concluded that, EPC are BM-derived progenitor cells with the 
potential to differentiate into EC and to form new capillaries by vasculogenesis, a mechanism which was 
thought to be limited to embryogenesis. Further work confirmed incorporation into capillaries formed 
by vasculogenesis and the paradigm of embryonic vasculogenesis was replaced160,169–172. Subsequently, 
mechanisms responsible for EPC mobilization were investigated148,149,172–174 and quantification in 
physiology and pathology followed175. Quantification elucidates that Endothelial-regenerating cells are 
detectable in healthy volunteers but impressively increased under certain conditions, or radically 
repressed under distinct pathological circumstances (3.3 Endothelial-Regenerating Cells in Pathology). 
However, in general, the number of Endothelial-regenerating cells in peripheral blood deemed to be 
extremely low144. Low number of cells in contrast to copious new-formed vascular networks and 
heterogeneous subpopulation cast the first doubt on the hypothesis drafted by Asahara et al. and 
others. Purhonen and coworkers contested the impact of Endothelial-regenerating cells in 
vasculogenesis and angiogenesisl176. Through detailed immunofluorescent analyses, they stated that BM 
derived cells are detectable perivascular to the endothelium, but not incorporated. However, total 
negation of an impact by Purhonen and others were focused on vascularization in tumor growth176 in 
contrast to cardiovascular models158,159. Possibly, trigger factors and mechanisms initiating 
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vascularization are different in these unequal models. Nevertheless, such studies brought attention to a 
discrepancy in the hypothesis (high number of new vessels and low number of progenitors). Moreover, 
advanced characterization of cells determined subpopulations unable to form tube-like structures144. 
The in vivo series and clinical studies described large benefits of Endothelial-regenerating cells 
treatment and strong correlations between pathology and Endothelial-regenerating cells number and/or 
function, confirming the vast impact of Endothelial-regenerating cells177,178.  
It was assumed that Endothelial-regenerating cells support vascularisation by another process than 
incorporation into vessel wall. The group of Kalka focused on angiogenic chemokines and growth factors 
and analyzed Endothelial-regenerating cells concerning their paracrine potential179. It became obvious 
that Endothelial-regenerating cells secrete angiogenic factors (VEGF, HGF, or Tie-2, e. g.) promoting 
vascularization, but also interleukins with anti-inflammatory functions (IL-8, IL-1Ra, or IL-10, e. g.). 
Moreover, conditioned medium stem-cell mobilizing factors were found in Endothelial-regenerating 
cells, suggesting a positive mobilizing feedback-loop (MMP-9, GM-CSF, or SCF, e. g.) together with 
several factors acting immunomodulatory protecting the cell or strengthen inflammatory response (MIF 
or NAP-2 ,e. g.)180,181. Indeed, studies comparing the beneficial effects of Endothelial-regenerating cells 
conditioned medium to cell-based therapy found similar effects171,182. Additionally, it could be 
determined that the different Endothelial-regenerating cells subpopulations show different secretion 
patterns. The more the cell equals an EC the less of factors are secreted144. Thus, recent knowledge 
leads to different camps referring Endothelial-regenerating cells function. The first group is still 
persuaded of vasculogenetic function of Endothelial-regenerating cells by incorporation into the vessel 
wall183. The second faction now believes in the great impact in cytoprotection and vascularisation by 
secretion of paracrine mediators145. A third group regards Endothelial-regenerating cells as an artificial, 
not really existing cell population, whose functions are indeed fulfilled by hematopoietic and myeloid 
stem cells184. It could be assumed that such sharp borders do not exist. Probably, other hematopoietic 
and myeloid stem cells are additionally mobilized from BM niche175, mixed with Endothelial-
regenerating cells. Evidence for paracrine effector mechanisms could be considered as proven179, but 
endothelial priming also suggests differentiation144. In conclusion, mammalian organism evolved a 
strong angiogenic system maintained by Endothelial-regenerating cells, but supported by additional cell 
groups, initiating vascularization by two functional pillars (paracrine action and build-up capillaries)185. 
3.3 Endothelial-Regenerating Cells in Pathology 
Because hypoxia is the main trigger for Endothelial-regenerating cells mobilization, two clinical fields are 
mostly interested in the function and regulation of Endothelial-regenerating cells. In oncology, tumor 
vascularization seems to be partly mediated by similar processes as physiological vascularization and 
understanding these mechanisms could help to treat cancer by inhibiting vascularization, starving the 
tumor186,187. In contrast, in cardiology, in which a multitude of diseases are caused, ischemia promotion 
of vascularization is desirable188. Beside these mainstream fields, the impact of Endothelial-regenerating 
cells in rheumatid arthritis189, burn injury190, renal failure191, and many others was investigated. The 
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following chapter will concentrate on the impact and potential of Endothelial-regenerating cells in 
cardiovascular disease. 
A review from 2008 stated that Endothelial-regenerating cells could be used as surrogate marker for 
vascular homeostasis and endothelial regenerative capacity146. Indeed, Hill and coworkers could 
correlate decreased Endothelial-regenerating cells level with increased Framingham risk score (an 
artificial score describing vulnerability to atherosclerosis by risk factors)160, which could be confirmed for 
hypercholesterolemia192 and hyperlipidemia193, in detail. The same applies to overweight men194 and 
passive smokers195. All risk factors are associated with decreased Endothelial-regenerating cells 
concentration and function. Despite these clinical findings, animal studies illustrated an increased 
plaque size after Endothelial-regenerating cells transplantation196. Progressed atherosclerosis gives rise 
to coronary artery disease (CAD or stable angina) and inverse correlation between Endothelial-
regenerating cells level and function and CAD could be rewritten197,198. In contrast, levels of unstable 
angina in patients seemed to increase199,200. Furthermore, Leone and coworkers correlated Endothelial-
regenerating cells mobilizing factors with Endothelial-regenerating cells concentrations in healthy 
volunteers, CAD and acute myocardial infarction (AMI) patients. A slight correlation between G-CSF and 
SCF (stem cell factor) and Endothelial-regenerating cells in AMI could be shown201. Subsequently, it was 
hypothesized that Endothelial-regenerating cells number predict progression of atherosclerosis, 
prevalence of cardiovascular events and death from cardiovascular causes202,203. Following, two studies 
could illustrate therapeutic approaches to compensate for the deficit in Endothelial-regenerating cells 
with flavanols80 and moderate exercise188. Parallel, the relation between Endothelial-regenerating cells 
and peripheral artery disease (PAD) was analyzed, determining similar decreased levels. This low 
concentration increased following revascularization204, but decreased further after vascular injury 
(endarterectomy)205. Yoon and coworkers examined the regulation of Endothelial-regenerating cells 
migration in the murine model of PAD (hind limb model), elucidating an impact of intracellular adhesion 
molecule (ICAM)206. Additionally, measurements in patients suffering from arterial hypertension (AH) 
substantiated relation between endothelial dysfunction and Endothelial-regenerating cells. In contrast 
to controlled AH Endothelial-regenerating cells, levels were decreased in resistant, incurable AH 
patients, which is supposed to be associated with chronic inflammation and progressed endothelial 
dysfunction207,208. In chronic heart failure (CHF) a difference between the different stages of disease 
became apparent. From asymptomatic CHF (NYHA class I) to complaints in rest (NYHA class IV),initial 
elevated Endothelial-regenerating cells concentrations decrease beneath control levels209. This deficit 
could be partly improved by one acute exercise unit (increase of migratory capability of Endothelial-
regenerating cells), but increase of absolute number of Endothelial-regenerating cells needed 
continuous training210,211. Mechanistically, it could be evaluated that in diabetes, decreased Endothelial-
regenerating cells number refer to dysfunctional mobilization150,212,213. 
In 2012, a review critically revaluated EPC phenotypes from the perspective that EPC are proposed as 
biomarkers for chronic ischemic disease (pAD) and acute cardiovascular events (e. g. acute myocardial 
infarction (AMI))162. This review is supported by an actual study examining the metabolic activity and 
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composition of BM derived cells after AMI, confirming an increase of EPC163. Shintani and colleagues 
could show this effect first214, but levels were not further elevated after percutaneous coronary 
intervention (PCI) excluding an impact of vascular injury on Endothelial-regenerating cells mobilization 
215,216. Numaguchi and coworkers expanded the results by demonstration of a positive relation of 
capability of Endothelial-regenerating cells to differentiate with an improved outcome after AMI217. At 
the same time, the enlargement of G-CSF and SDF-1α levels in relation to increased Endothelial-
regenerating cells concentrations were detected201,218. Moreover, G-CSF treatment showed similar 
beneficial effects219 as transplantation of BM progenitor cells do220.  
Accordingly, the therapeutic potential of Endothelial-regenerating cells in cardiovascular disease was 
analyzed. In particular, approaches were done using the rodent hind limb model with great therapeutic 
potential149,159. Moreover, Madeddu and coworkers could show the advantage of CD34+KDR+ 
Endothelial-regenerating cells by improving vascularisation, in contrast to CD34+KDR- hematopoietic 
stem cells221. As SDF-1α was known as potent mobilizing factor, Walter and coworkers could show that 
CXCR-4 signaling (SDF-1α receptor) is impaired in CAD patients contributing to the decreased 
Endothelial-regenerating cells mobilization. Consequently, injection of Endothelial-regenerating cells, 
pre-treated with a CXCR-4 antibody in murine hind limbs, depressed outcome222. Other studies could 
improve therapeutic benefit of transplanted Endothelial-regenerating cells by pre-treatment with an 
Ang-1/VEGF coding vector or activation of the EphB4 system223,224. Additionally, sufficient clinical trials 
with nutritional supplementation were performed, administrating e. g red wine.225. 
Regarding the therapeutic and diagnostic potential of EPC in coronary and peripheral artery disease, 
rewieved by Fadini and Dimmeler in 2012162, and the correlation between cardiovascular disease and 
NO, the assumption of a functional association between NO and EPC comes to the foreground. Thus, a 
group of studies focused on NO metabolism in ischemia and vascularization in relation to EPC. As early 
as 1998, Murohara et al. could show that eNOS-/- mice have impaired angiogenesis226.  One year later, 
Lee and colleagues proved that angiogenesis is a NOS-dependent process227. In 2003, Aicher et al. 
confirmed that impaired angiogenesesis in eNOS-/- mice is due to decreased Endothelial-regenerating 
cells mobilization177. This knowledge could be expanded by the discovery that eNOS is inhibited by 
oxLDL, leading to Endothelial-regenerating cells dysfunction228. It could be analyzed, simultaneously, 
that Endothelial-regenerating cells number and function are depressed in diabetes mellitus in a NO 
dependent manner229. Statins were used for a long time in AMI and recent results could elucidate an 
underlying mechanism. Thus, the drugs mediated their beneficial effect by increasing NO bioavailability, 
followed by amplification of Endothelial-regenerating cells number230,231. Moreover, Heiss et al. could 
show a direct increase in Endothelial-regenerating cells after NO3- intake232. In summary, studies 
clarified that decreased NO bioavailability is jointly responsible for diminished Endothelial-regenerating 
cells number and function and ensuing impaired angiogenesis in endothelial dysfunction and 
subsequent diseases. Subsequently, studies were planned, which tried to amplify neovascularization by 
supporting the Endothelial-regenerating cells -NO axis. Irradiation with infrared light improved outcome 
after hind limb ischemia, as well as medication with organic nitrates and Benfotiamine (vitamin B3 
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derivate)79,233,234. Thus, comprising the previous chapter (1.5 NO and Metabolites as Beneficial 
Concomitant Therapy), the increase of NO bioavailability to augment Endothelial-regenerating cells 
number and regenerative capacity seems to be a promising approach in positively influencing 
regeneration in cardiovascular disease. However, to construct hypothesis and make a decision which 
would affect chronic CAD and PAD or to intervene during an acute event like AMI, pathophysiology has 
to be taken into consideration. 
4. Tissue Injury and regeneration  
Every tissue has special features including composition, origin, resilience, and reparative mechanisms. 
For this reason, therapeutic approaches should be adopted to the affected organ, although a key 
element in treating ischemia remains restoring O2 delivery. 
In chronic ischemia, compensatory mechanisms are of paramount importance. Besides the 
remodeling of existing arteries, new vessels are formed from pre-existing arterioles or de novo 
capillaries were formed. After an acute event, regenerative processes obtain priority. Irreversible 
damaged cells have to be removed and the gap has to be filled. For example, skeletal muscle fibers 
could be renewed to a certain degree, but cardiomyocytes do not have this ability. In the heart necrotic, 
tissue is replaced by fibrous scar tissue. 
4.1 Vascularization 
Skeletal muscle of human legs is traversed by a ramified vessel network originated from three main 
arteries being descendent from the iliac arteries. At the groin A. iliaca externa changed into A. femoralis 
communis, which is subdivided into A. poplitea and A. saphena at the knee, serving the calf. Starting 
from these vessels, arteries ramified into surrounding tissue. These arteries changed into collaterals and 
arterioles, which finally end in capillaries. In this way, every station has characteristic possibilities for 
growth and reaction to ischemia (shown in figure 4). Conductive arteries are competent to perfom 
remodeling. Media gradually dilates, widening lumen. However, this process is limited and only capable 
of compensating for lumen narrowing plaques and not for stenoses and occlusions235. On the other 
hand, stenoses occurring in conductive arteries were threatening and thus it was necessary to treat 
them. In these cases a bypass surgery could be preferred236. To a certain degree, arterioles could grow 
out to arteries forming natural bypasses. This process is termed arteriogenesis143. 
Initial mechanical trigger of ateriogenesis is increased to shear stress caused by elevated blood flow. 
In principle, two signal cascades are started. The first pathway is responsible for recruitment of BM-
derived cells, supporting arteriogenesis, and the second one enables EC and SMC to re-enter the cell-
cycle. Involved are MAP kinases, Rho mediated pathways, and NO dependent signaling. Nonetheless, 
impact of NO remains enigmatic. There are studies demonstrating impaired arteriogenesis in eNOS-/- 
mice, which is activated by shear stress177, but conflicting results were equally presented237. The 
peripheral nervous system is only regulatory when involved in arteriogenetic processes. As re-entry in 
the cell-cycle and mitosis are key features of arteriogenesis, several mitogens and growth factors were 
Introduction  
 21 
thought to have important functions in the mechanism. However, to date none of the most abundant 
factors (VEGF, FGF, and PDGF) could be identified as “master factor”. Every one of them is capable of 
augmenting collateralization, but none reaches levels obtained by shear stress. To support local 
alterations, BM-derived cells are mobilized and migrated to the proliferative sites of the vessel. It is 
mainly angiogenic monocytes, which promote arteriogenesis by secreting paracrine factors and 
accumulate, but T-cells, NK cells, and BM-derived stem cells are also present238. The impact of 
lymphocytes becomes obvious when comparing regeneration after ischemia in different mouse strains. 
C57Bl/J6 mice show higher lymphocyte levels than BalbC mice, which is reflected in better regeneration 
(additionally, different vessel anatomy support regeneration in C57Bl/J6 mice, presented in discussion 
chapter 3.1). The impact of stem cells is still a matter of debate, but directs into no direct incorporation 
of new-formed vessels, but facilitation by paracrine mechanisms239. 
Triggered by mentioned factors and pathways, all cell layers of the artery are activated, intima 
(consisting of EC), and media (composed of SMC), as well as adventitia (mainly fibroblasts). Activated 
fibroblasts in adventitia undergo inflammatory changes and attract macrophages. Fibrous and 
collagenous structures were dispersed by increased expressed proteolytic factors (e. g. MMPs) enabling 
the outgrowth of the vessel and EC activation includes proliferation and morphological changes.  The 
cells appear swollen and surrender their orientation towards blood flow. Following, orientation seems 
randomized. As a consequence, in addition to a change in open-probability of Ca2+-dependent Cl-
channels and –inhibitors and the proliferative status of the cells, permeability of the endothelium is 
elevated, facilitating both migration and outgrowth. Finally, the SMC undergoes drastic changes and 
accomplishes most work in arteriogenesis. Their phenotype changed from contractile to synthetic, 
visible by abolishment of characteristic contractile actins (mainly desmin). Yet, two zones of collateral 
growth could be distinguished. The inner neointima consisting of highly active, synthetic SMC and the 
outer media composed of less active SMC. Nevertheless, increase of tissue mass is impressive. Murine 
tissue could be amplified to the 3-fold and human tissue to even more than the 20-fold240. 
Instead of the myocardium, in which arteriogenic and angiogenic processes are initiated in parallel, 
periphery arteriogenesis dominates only the thigh of a leg. In the calf, angiogenic mechanisms prevail. 
These capillary-forming mechanisms are distinguished in angiogenesis and neovasculogenesis. These 
processes differ in the construction of new vessels, but are initiated and realized by equal factors and 
pathways. Indeed, angiogenesis EC sprouts from pre-existing vessels, expanding present capillary-
networks. Otherwise, neovasculogenesis capillaries are generated de-novo without an adjacent vascular 
tree. As described, in detail, in chapter 3.2 Function” progenitor cells, stem cells, and circulating EC 
migrate into ischemic tissue. Furthermore, the cells form blood islands, differentiate into early EC, and 
generate a primary plexus. This primary plexus matures into a secondary plexus, presenting the new 
capillary network (see in figure 5)143,241. 
The impetus of both mechanisms is a lack of oxygen triggering expression and DNA binding of the 
transcription factor hypoxia inducible factor (HIF). HIF activates a multitude of pro-angiogenic genes. 
Expression of VEGF, the most important angiogenic mitogen, is a 30-fold increase within minutes. 
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Subsequently, EC derived proteolytic enzymes (MMPs, e. g.) degrade ECM and EC solve its intercellular 
junctions. Mediated by VEGF, capillaries are dilated and permeability is increased. Furthermore, leaked 
plasma proteins form a scaffold for EC migration. EC change into the activated phenotype and migrate 
towards a chemotactic gradient mediated by PECAM-1, VE-Cadherin and Src-kinase into tissue. Next, 
maturation completes the process. In a highly orchestrated manner EC fusion create anastomoses and 
form the lumen. The Notch-pathway mediates arterial differentiation by depressing venous signaling. At 
the boundaries the Eph-Ephrin system marks arterial and venous capillaries (Eph-B2 = arterial; Eph-
B4 = venous). The whole process is supported by monocytes and macrophages. Finally, newly-formed 
vessels are stabilized by VEGF-recruited pericytes and ECM is rebuilt. In general, angiogenesis occurs 
more often than neovasculogenesis, but both mechanisms complement each other241,242. 
Figure 5. Arteriogenesis, angiogenesis, and neovasculogenesis in comparison. 
A In arteriogenesis small collaterals grow out to arteries in response to increased shear stress. B 
Angiogenesis is triggered by hypoxia describing EC sprouting from a pre-existing network. C 
Neovasculogenesis, is able to build new capillaries de-novo without conjunction to pre-existing vessels. 
4.2 Myocardium  
Previously described vascular network serves myocardium and skeletal muscle tissue. Both organ 
systems belong to the striated muscle, but myocardium has evolved unique characteristics to 
accomplish its special function. 
Cardiomyocytes develop from special cardiac myoblasts. This cell population does not fuse to 
polynuclear fibers, but remains mononuclear with intensive connections to adjacent cells. Thus, narrow 
connection enables fast transmission of the myogene produced potentials, inducing contraction of the 
muscle. Different from skeletal muscle, which is innervated by motoaxons, cardiomyocytes produce 
myogene potentials itself and peripheral nervous system has only modulating functions. There are three 
different subtypes of cardiomyocytes. First, cardiomyocytes of the sinus and atrioventricular nodes are 
small and only slightly contractile. They are auto-rhythmic and generate the myogene potential. 
Secondly, cardiomyocytes of the inner endocard are the largest and specialized to fast transmission of 
the myogene potential. Thirdly, the majority of cardiomyocytes is of medium size and responsible for 
contraction. They form the outer epicard, which is enclosed by the membranous pericard243. In contrast, 
myoblasts of the skeletal muscle fuse to polynuclear fibers within maturation encompassed by 
connective tissue, the endomysium. After differentiation nuclei are postponed to the edge of the fiber, 
which reach a length of many centimeters as they range from one bone or tendon to another. Next, 10 
to 100 fibers are summarized to a bundle (fascicle), surrounded by the perimysium and another 
connective tissue layer. The epimysium forms the outer sheath of connective tissue enclosing the entire 
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muscle and with connection to bone and tendon. This type of striated muscle is innervated by 
motoaxons and is counted among the voluntary muscles243. 
Under ischemic conditions, cells primarily become necrotic. Additionally, in myocardial I/R injury the 
opening of the mitochondrial PTP induces caspase-mediated apoptosis in cardiomyocytes. This leads  to 
necrosis in the necrotic core zone and an apoptotic border zone within the infarct area125,244,245. In the 
skeletal muscle, reactions are more complex because of the combination of polynucleated muscles 
fibers and neighboring satellite (presented in the following paragraph) cells within the tissue and their 
specific characteristics. Previously, it was thought that muscle fibers were not able to become apoptotic, 
but recently programmed cell death could be confirmed for polynucleated cells. However, it seems that 
apoptosis proceeds atypically and via caspase-3 independent pathways. It is assumed that single nuclei 
become apoptotic until the whole fiber is irreparably damaged. Otherwise, for satellite cells apoptosis is 
known for a long time. Thus, in summary, in ischemia and particularly I/R injury apoptosis seems to be 
the main cause for cell death246–248; even though underlying pathways remain debatable. Controversial 
results were gained by referring an impact of the Fas/FasL system and possibly indicating a pleiotrophic 
role in myocyte apoptosis and regeneration249. Previously, the Fas/FasL pathway was discovered as a 
pro-apoptotic pathway belonging to the TNF superfamily. Despite that, increasing evidence also backs 
up the bidirectional role of the Fas/FasL system, which is also capable of promoting cytoprotective 
functions. In the current work, it is assumed that under ischemic conditions the Fas/FasL pathway could 
also unfold its cytoprotective, proliferative functions250,251. Particularly in ischemic tissue there is a 
diffuse transition from unsalvageable damaged to injured, but viable cells. Hence, factors able to 
recognize the status of a cell and initiate appropriate pathways seem to be ideal in ischemia. The 
Fas/FasL system could be such a bidirectional acting pathway.  
However, regeneration of the myocardium is restricted. Although, recent work could demonstrate 
that, in humans cardiomyocytes were replaced during life, currently no efficient therapy is known to 
compensate for damage and cell loss in I/R injury252. To date, dead cells can not be substituted. Necrotic 
tissue is supplanted by fibrous scar tissue and remaining cardiomyocytes dilate (hypertrophy) to achieve 
needed power. Finally, the heart is pathologically enlarged and contractile muscle partly makes way for 
collagenous scar leading to functional depression. This process, termed remodeling could cause heart 
failure253.  
4.3 Skeletal Muscle 
In contrast to the myocardium, the skeletal muscle is a very resilient tissue, with high regeneration 
capacity. This restoration potential refers to the satellite cells discovered in 1961 254. Stem cells with 
myogene potential placed adjacent to muscle fibers, beneath basal lamina, accounting for 2 - 5 % of 
nuclear mass of a muscle. The term satellite cell encompasses a heterogeneous population of myogene 
stem cells as different as muscle origin and types, but united in location and regenerative capacity. 
Moreover, it was assumed that beyond the mentioned parameters, at least two subpopulations could 
be distinguished. Differences are apparent based on surface marker expression suggesting a pre-mature 
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population ready for differentiation and an immature population, which is responsible for renewal of 
cell pool and proliferates before its daughter cells differentiate into muscle cells255,256. In health, satellite 
cells rest quiescent in G0 phase, but in response to traumata cells they were activated and re-enter cell 
cycle and begin to proliferate and differentiate, respectively. These activated cells present muscle 
precursor cells, myoblasts, recognizable in increased expression of myogenic markers like MyoD. It is 
assumed that the number of satellite cells is preserved constantly by self renewal and asymmetric cell 
division. During this mitosis, one daughter cell differentiates into a myocyte and the other remains in 
the stem cell status replenishing the satellite cell pool. In the eldery, muscle numbers and regenerative 
capacity of satellite cells is decreased255. Activation is initiated by infiltrating macrophages, which are 
responsible for eliminating cell debris after necrosis and secretion of mitotic growth factors256. Besides, 
muscular injury mobilizes several other BM-derived stem cells, which could support satellite cell driven 
regeneration by myogenic differentiation257. Finally, myoblasts differentiate into fully functional 
myocytes, fusing to fibers, able to replace lost muscle mass to a great extent. However, ischemia 
apoptosis concerns the whole muscle including satellite cells. Subsequently, not only is the adult muscle 
is injured, but regeneration capacity is also impaired. Consequently, approaches geared towards 
increasing viability of satellite cells should be a promising target for muscle preservation and 
regeneration. Instead of this possibilty, intervention during the acute event comes too late as highly 
specialized organs, such as the heart muscle have a limited capacity for renewal. Moreover, the 
presented approach additionally supports vascularization. Thus, cause and symptoms of ischemia are 
affected in parallel by overcome decreased NO bioavailability. Indeed, vascularisation could be 
improved in an acute event, but is not sufficient if delivered tissue is irreparably injured. Thus, it is 
hypothesized that dietary NO3- has the potential to lower symptoms of PAD (and probably CAD) and to 
decelerate progression of disease preventing acute events, as presented in the “Aim of Thesis”. 
5. Aim of Thesis  
Decreased NO bioavailability was shown to be crucial in development of atherosclerosis. Obviously, 
critical incident in progression of atherosclerosis, endothelial dysfunction, is strongly related to 
repressed eNOS function. Furthermore, a correlation between decreased NO levels and increased risk 
endothelial dysfunction and atherosclerosis was determined. As atherosclerosis progresses to life-
threatening diseases, such as PAD, CAD, and particularly myocardial infarction, it should be a goal to 
intervene, as early as possible, in this development. Recent work demonstrated that dietary NO3- could 
be reduced to NO increasing circulating NO pool. Moreover, evaluated beneficial effects of NO3- (e. g. 
blood-pressure lowering) elucidates its beneficial potential. However, mechanisms remain unknown. A 
first hint could be the detected NO dependent Endothelial-regenerating cells mobilization. Over the last 
decade intensive analyses evaluated Endothelial-regenerating cells as BM-derived progenitor cells with 
pro-angiogenic potential, able to increase angiogenesis and neovasculogenesis. In addition, recent 
results determined a high paracrine potential of these cells. Nevertheless, it remains debatable about by 
which key factors or pathways Endothelial-regenerating cells mediate their functions. The Fas/FasL 
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system was originally identified as death receptor pathway initiating apoptosis. Latest studies could 
extend this knowledge by showing that the Fas/FasL system could act as bidirectional initiate apoptosis 
and cytoprotection in parallel. 
Accordingly, the aims of this study are to:  
1. Analyze the beneficial potential of dietary NO3- in vascular ischemia. In the murine hind limb ischemia 
model regeneration after dietary NO3- supplementation will be analyzed.  
- This animal model was chosen as it is no imitation of PAD, but appears to be the best approach to 
study regeneration after peripheral ischemia.   
- Regeneration of blood flow blood is analyzed by measurement of hind limb perfusion. 
2. Histological analysis should reveal potential increase of arterio- and angiogenesis. 
3. Evaluate cytoprotection by determination of tissue necrosis (and apoptosis for a subgroup of 
experiments). 
4. Determine a relation between this beneficial potential and Endothelial-regenerating cell mobilization.  
- Analysis of quantity, migration, and viability should show a possible assiociation. 
5. Verify the FasL expression on Endothelial-regenerating cells, serving as first evidence of a paracrine 
function mediated by the Fas/FasL pathway.  
- Potential relation is analyzed by quantification of FasL expression on Endothelial-regenerating cells 
and plasma level of FasL.  
6. Deepen knowledge of NO concentration and bioavailability in cardiovascular disease (STEMI) by 
descriptive clinical studies.  
- Determination of NO2- and NO3- level in severely ill patients and its correlation to the severity of 
cardiovascular events should increase knowledge about bioavailability in cardiovascular disease and 
strengthen the impact of the results of the animal study.  
It is proposed that dietary NO3- increases NO bioavailability at such a rate that regeneration in the 
model of hind limb ischemia is significantly improved. Furthermore, NO3- mediated regeneration is 
suggested to be supported by Endothelial-regenerating cells. These BM derived cells are probably able 
to differentiate in EC increasing neovasculogenesis, but have also an impact on cytoprotection of 
surrounding tissue by paracrine functions. Regarding this, the current study assumed an involvement of 
the Fas/FasL system in Endothelial-regenerating cells mediated cytoprotection. 
In future, increased knowledge about involved key players in regeneration after ischemia in 
combination with nutritional supplementation could help to improve treatment of cardiovascular 
disease in an early phase preventing interventional treatments. 
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Methods and Materials 
1. Materials 
If not enumerated in a table, chemicals, media, additives, assays and devices are listed in alphabetical order 
with the producer in parenthesis.  
Antibodies 
Table 3. Antibodies and isotypes used in FACS and IHC. 
FACS = flowcytometry; IHC = immunohistochemistry; r.t.u. = ready to use 
 
Assays 
cGMP Enzymeimmunoassay Biotrack (EIA) System (Amersham); In Situ Cell Death Detection Kit, Fluorescin 
(Roche); Mouse G-CSF Immunoassay (R&D); Mouse GM-CSF Immunoassay (R&D); Human MCP-1 Immunoassay 
(R&D); human NAP-2 DuoSet ELISA Development kit (R&D); PromoKine's highly sensitive nonradioactive 
Colorimetric Cell Viability Kit I (CCVK-I, WST-8) (Promokine); RNeasy Fibrous Tissue Mini Kit (Qiagen); 
Mouse/Human SDF-1α Immunoassay (R&D); SuperScript® III First-Strand Synthesis System (Invitrogen); Mouse 
VEGF Immunoassay (R&D); Xanthine Oxidase Assay Kit (Cayman). 
Chemicals and Narcotics 
1 kb Plus DNA Ladder™ (Invitrogen); 2-propanol 99,8% (Roth); ß-mercaptoethanol (Sigma); acetic acid (Roth); 
albumin from bovine serum, fraction V (Sigma); Annexin V (BD); Betaisodona (MundiPharma); Borgal (Virbac); 
Blue Juice Gel Loading Buffer (Invitrogen); CaCl2 (Sigma); carboxy-PTIO (Cayman); citrate acid (Merck); Dako 
Pen (DAKO); depilatory cream (Veet); di-ethyl ether  (Roth); DNase (Roche); dNTP Mix (10mM) (Invitrogen); 
Dulbeccos PBS (Serag Wiesner); EDTA (Sigma); Ethanol, 99%, (Roth); G6P (Roche); HCl (Merck); Heparin 
(Ratiopharm); Hexoral Spray® (McNeil); HgCl2 (Fluka); Histofix (Roth); Hoechst 33342 (Sigma); idodine (Sigma); 
Isofluran (Forene®) (Abbott); 2-propanol (Applichem); Ketanest (Pfizer); Lysing Solution (BD); NaCl, salt 
(Prolabo); NaCl, solution 0.9% (Braun); N-ethylmaleimide (Calbiochem); nitrate reductase  (Sigma); Nonidet P-
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40 (Fluka); paraffin (Roth); PFA (Roth); Platinum® Taq DNA Polymerase (Invitrogen); potassium hexacyanoferrat 
(Fluka); potassium iodide (Merck); RNAse Zap (Sigma); Rompun (Bayer); soda (San-Benedetto); sodium-citrate 
(Applichem); sodium-nitrate (Sigma); sulfanilamide (Sigma); TBE-Puffer (Bio-Rad); Temgesic (Essex Pharma); 
trichloracetic acid (Roth); TRIS (Roth); TRIS-HCL (Roth);  tri-sodium citrate (dihydrate) (Applichem); Triton-X 
(Sigma); Tween (Sigma);  VECTASHIELD Mounting Medium with DAPI (VECTOR). 
Buffers and Solutions 
Table 4. Used buffers and solutions. 
Listed are ingredients and quantities. Chemicals are solved in high purity water unless noted otherwise. 
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Equipment 
Binocular (Leica); breathing apparatus (Penlon & Zenevar); Centrifuges (Hettich); CLD 88e (SunChrom); clean 
bench (Grelaire); coldlight source (Leica); ENO (Eicom); FACS Canto (BD); heating plate (Ika); Histobath (Leica); 
Histoembedder (Leica); incubator (Thermo Scientific); Laser-Doppler-Perfusion-Imager (Perimed); microtome 
(Leica); microwave (Bosch); Nanodrop (Thermo Scientific); Neubauer chamber (Brand); fluorescence 
microscope (Nikon); scale (Sartorius); Speed Vac (Jonan); shaker (Heidolph); suture material (Ethicon & Serag-
Wiesner); vortexer (Ika); water bath (GFL). 
Media and Additives for Cell Culture  
Collagen (0.1%) (Sigma); DMEM (PAA); Dulbeccos PBS (PAA); FCS (Lonza); Ficoll Lympholyte Mammal 
(Cedarlane); fibronectin (Biochrom); goat serum (PAA); Ham’s F10 with glutamine (PAA); Hepes (Sigma); horse 
serum (PAA); MV-2 medium (Promocell); newborn calf serum (PAA); Penicillin/Streptomycin (PAA); Pronase 
(Roche); Trypan-Blue (Gibco); trypsin (PAA) 
Primer 
Table 5. Real-Time PCR primer pairs were ordered from Eurofin. 
Sequences were chosen after Yang et. al182. 
Software 
Chromstar 6.3.19 (SCPA); Citavi 3.1.0 (Swiss Academic Software GmbH); DNA Baser (free test version;  Heracle 
BioSoft S.R.L.); GraphPad Prism 5 (GraphPad Software, Inc.); LDPWin (Perimed); NCBI-Blast 
(www.ncbi.nlm.gov/BLAST); PowerChrom v2 (eDAQ); (http://www.primerfox.com/toolbox.htm) Primerfox ; 
Rest 2009 (M. Pfaffl, Munich & Qiagen). 
2. Animal Model 
2.1 Strains  
All experiments were done with NMRI mice, an outbred strain from Taconic, ordered by the local animal 
facility. The transgene eGFP strain B6-tg(Actß-CMV-eGFP)258 was used for bone marrow transplantation, kindly 
provided by Prof. M. Okabe (Department of Experimental Genome Research, Osaka University). As a control for 
endothelial dysfunction eNOS knock-out mice were used, kindly provided by Prof. Dr. A. Gödecke (Institut für 
Herz- und Kreislaufphysiologie, Duesseldorf University Hospital)259. 
2.2 Supplementation, Treatment, Dietary and Environmental Habit 
Mice were held in groups of two to eight mice dependent on their relationship and cage size. To minimize 
variation in NOx level caused by variation in tap water, the mice received soda with controlled NOx level. Water 
and standard diet were given ad libitum. The NO3- group received drinking water with 1 g/L NO3- in the drinking 
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water. XOR mediated NO2- reduction should be inhibited by 0.6 g/l Allopurinol in drinking water260 which 
corresponds approximately to 100 mg/kg/day. The NO scavenger cPTIO was injected intraperitoneally, which 
means a slower way of application that is both less stressful and painful for the animals. They received 1 µl/g 
(body weight) of a stock solution (1 mg cPTIO diluted in 1ml PBS). To control both the feeding and drinking 
behavior as well as the weight of the animals (in special after surgery), water bottles, food pellets and mice 
were weighed every day. Measurements in a subgroup of single-housed animals excluded differences in dietary 
habit related to supplementation or treatment. A subgroup of animals received NO3- once per gavage (12 mM). 
To inhibit bacterial NO3- reduction mice were treated with an antibacterial mouthspray twice a day; one pump 
dose administered deep into the oral cavity. 
To analyze the effect of the human mouthspray on murine oral flora, an oral smear from three mice before 
and one hour after treatment with mouthspray was taken. The smears were partitioned and cultured on agar 
plates under a) aerobic and b) anaerobic conditions in the department of microbiology of the animal facility. 
There the bacteria were identified and after cultivation, colony forming units (CFU) were determined. 
2.3 Hind limb Model 
All work was conducted in asepsis. Mice were anesthetized with a Ketanest/Rompun combination-narcosis (45 
and 10 mg/kg) which was given intraperitoneally. Hairs from ankle to pelves were removed by a depilatory 
cream. After the thigh was disinfected using Betaisodona, a 1 cm long skin incision was made on the inside of 
the thigh. Skin was detached, put aside, and fixed with retractors. Femoral artery was prepared free from vein 
and nerve. Two ligations were made at the proximal origin of the femoral and the distal end of the saphenous 
artery (with 0.5 mm silk threat), and artery was excised with its attached side-branches as shown in figure 
6261,262. 
Figure 6. A murine hind limb from groin to knee. 
The operative site is shown and visible arteries and veins are labeled. 
Because of the ligations the a. femoralis and a. saphena are not detectable 
and adumbrated by the blue, dashed line. The two ligations are also 
marked. 
 
 
The skin was closed with a continuous suture done with silk. Successful induction of ischemia, defined as 
perfusion ratio < 20 %, was controlled by Laser-Doppler-Perfusion-Imaging (Perimed). For analgesia mice 
received Temgesic (0.05 mg/kg s.c.) as required. 
2.4 Bone-marrow Transplantation 
To trace migration of Endothelial-regenerating cells in ischemic tissue, green fluorescence protein positive 
(GFP+) bone marrow was transplanted in lethally irradiated NMRI mice. Donor mice were 8 week old males 
with enhanced GFP+ (eGFP+) with a C57BL/J6 background258. 
On the first day, the eight week old male recipient NMRI mice were lethally, fractional irradiated with 6,5 Gy 
with 4 h in between the fractions. Irradiation was performed at the clinic for radiation of the Dusseldorf 
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University Hospital, Heinrich-Heine University Dusseldorf. The mice were placed into specially designed acrylic 
glass boxes for 10 mice. After irradiation the mice obtained water suspended with 20 µl/l of the antibiotic 
Borgal® (24 %). To reduce stress the mice stayed in the laboratory overnight, received the transplantation at 
the second day and were transported back to the animal facility. There the mice were caged for four weeks in 
IVC-racks for convalescence. 
On the second day donor mice were anesthetized with urethane (1200 mg/kg). When they had fallen asleep 
and lost consciousness their fur was thoroughly cleaned with 70 % EtOH. At the back of the mouse a small skin 
incision was done and the abdomen and the legs were skinned. The thigh was amputated at the level of the 
pelvis. Muscle and fat were discarded to visualize the dark red line of bone marrow (BM). Due to the fact, that 
the bones must not dry they were collected in a petri dish filled with 1 ml sterile PBS. In the next step the long 
bones were rinsed with sterile PBS. A 20ml syringe with a small cannula (27G) and a sterile filter in between 
was pricked in the lumen of the bone. The bones had to be rinsed until they seemed clear. The BM was 
collected in a 50 ml reaction tube on ice and subsequent steps were performed under a sterile bench. Next, 
cells were separated by resuspending the solution with a 10 ml pipette until no red aggregations were 
apparent. A 40 µm strainer was laid on a new 50 ml reaction tube to filter the suspension. The cells were 
washed by centrifugation for 10 min at 300 g and RT. Supernatant was discarded and the pellet was 
resuspended in 10 ml PBS. 10 µl of this suspension was mixed with 10 µl Trypan-Blue and the cells were 
counted while the remaining cells were centrifuged (10 min, 300 g, RT). After removing the supernatant, cells 
were diluted in PBS to achieve the calculated concentration for an optimal transplantation result (2-10 Mio 
cells/100 µl PBS per mouse). The recipients were anesthetized with gaseous Isofluran© to allow a short but 
deep unconsciousness. Each 100 µl of BM cell suspension was aliquoted in syringes (1 ml, Braun) and injected 
via cardiac puncture. Only five syringes at a time were prepared to avoid agglutination and settling of the cells. 
The success of cardiac puncture should be ensured by aspiration before and after injection. 
2.5 Laser-Doppler-Perfusion-Imaging (LDPI) 
To control success of hind limb operation and trace regeneration of perfusion, LDPI measurements were done.  
In principle, a laser-beam penetrates the tissue. Moving blood cells redirect the stream of light to a photo 
detector. However, moving blood cells lead to Doppler-shift of the incoming light beam dependent from 
concentration and velocity of the cells. The detector records Doppler-shift and scattering and then calculates 
an artificial, color-coded perfusion value. Perfusion is defined as concentration of moving blood cells * mean 
velocity of these blood cells263,264. Figure 7 illustrates the principle established430 and modified according to 
Wardell et al.263 and Perimed264. 
First of all, the laser had to be turned on to warm up. Mice were weighed and then their legs and abdomens 
were depilated with depilation cream. The animals were anesthetized with the combination narcosis described 
in chapter 2.3. The mice were fixed on the green measurement pad lying on their back with parallel thighs and 
upturned soles, with a distance from the laser of 20±1 cm (from mouse surface to laser). Complete list of 
parameters used in LDPI measurement are summarized in table 6. Narcosis was stabilized by Isofluran, which 
should be administered very carefully if required. 
Methods and Materials    
 31 
Figure 7. Concept of Laser-Doppler-Perfusion-Imaging 
Emitted laser beam impinges on moving blood cells. Light is scattered and velocity changes wavelength and 
frequency of the streams of light (Doppler shift). The photo detector records transmitted light and connected 
software calculates perfusion by comparing incoming information with characteristics of emitted light264.  
Table 6. Setting of the LDPI measurement. 
Shown is the adjustment of the software.  
2.6 Necrosis Score 
 
 
 
 
A macroscopic necrosis score was defined to determine tissue damage (modified after265). The score ranges 
from “0” which means healthy to “6” which counts for a complete auto amputation. Figure 8 presents the 
whole score with illustrating photographies. 
Figure 8. Murine necrosis score. 
The score permits the evaluation of 
macroscopic tissue damage after 
hind limb surgery. 
 
 
 
 
3. Analysis of NO and its Metabolites  
Besides NO2- and NO3- RXNOs, RNNOs and NO-heme were also analyzed. Human NO2- and NO3-, and murine 
RXNOs, RNNOs, and NO-heme were quantified with chemiluminescence detection (CLD). Murine NO2- and NO3- 
were determined with the ENO (an instrument using a special HPLC technique see 3.2). All prepared samples 
were held at 4 °C until measurement or stored at -80 °C. 
mm 
mm 
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3.1 Chemiluminescence Detection (CLD) 
In contrast to the ENO, that take advantage of the physical qualities of the analyzed molecules, in CLD a 
chemical reaction is exploited to quantify NOx. Both are sensitive methods for analyzing NO2- and NO3- but only 
CLD allows quantification of more complex nitroso compounds like RxNOs (experimental setup is shown in 
figure 9). In this system NO reacts with Ozone. During the course of the reaction, the electrons of nitrogen 
dioxide which are produced are shifted towards an excited state. While the electrons return back to their 
ground state they emit energy in the form of a photon in proportion to the NO content of the sample shown in 
the formula below. 
To quantify metabolites of NO, mixtures are injected in an appropriate reaction solution which releases NO 
from complex metabolites. This gaseous NO is transported to the detection system with helium as carrier gas. 
On the way, NO passes a NaOH trap (1 M) to catch acids, higher nitric oxides and proteins. 
Two basically different methods have to be distinguished in CLD, the reductive and the oxidative CLD. In the 
oxidative approach ferricyanide-solution oxidizes Fe2+ to Fe3+. This conversion destabilizes NO-heme bonds 
releasing NO in blood or myoglobin rich tissue. In the reductive approach, valid for the detection of NO2-, NO3-, 
RXNOs, and RNNOs, the nitroso species are reduced to NO via the nitrosium ion (NO+) and recorded. To 
quantify NO2- the molecule reacts direct with I3 in the triiodid-solution. In contrast, NO3-, RXNOs, and RNNOs 
have to be pre-treated. NO3- is reduced to NO2-, as explained below. To analyze RXNOs, the sample has to be 
pre-treated with sulphanilamide-solution to remove NO2-. Finally, to determine RNNOs, the sample has to be 
pre-treated with mercury-solution to solve the NO+ from RSNOs. These nitrosium ions rapidly convert to NO2- 
which is intercepted with sulphanilamide-solution. Therefore, only RNNOs react with I3 in the reaction 
chamber.  
For quantification a standard curve is needed. For all measurements except NO3- a NO2- calibration is 
prepared with the concentrations 0, 50, 100, 150, 200 nM NaNO2. The first four stem solutions are prepared 
with 0.069 g NaNO2 in 1 ml NaCl (1 M) and three serial 1:100 dilutions (10 mM, 100 µM and 1 µM). From the 1 
µM solution the calibration dilutions are prepared. Three times 100 µl sample volume was injected in the 
reaction solution. NO3- calibration was prepared with the concentrations 0, 5, 10, 15, 20 nM NaNO3. The first 
three stem solutions are prepared with 0.0849 g NaNO3 in 1 ml NaCl (1M) and two serial 1:100 dilutions (10 
mM, 100 µM). Starting from the 100 µM solution the calibration dilutions are prepared. 
NO3- measurements with chemiluminescence detection require an additional reduction step. To get a 10 mM 
NADPH solution, 120 µl ultrapure water had to be added to 0.003 g NADPH (molecular weight: 833.4 g/mol). 
This stem solution is first diluted 1:10 and secondly 1:25 (final concentration 40 µM). One light protected 
aliquot nitrate reductase (680 µl) solution is diluted with 1320 ml Millipore water and mixed with NADPH in a 
proportion of 5:1 and stored on ice in the dark. 100 µl of this final NO3- reductase solution was added to 300 µl 
sample and incubated 1 h at RT. Calibration curve was equally treated. After incubation the enzymatic reaction 
was stopped by lowering the sample temperature to 4°C. 
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Figure 9. Experimental setup of CLD. 
The carrier gas helium is conducted in the reductive reaction solution in which the sample is injected. The NO 
binds to the helium and flows through the NaOH trap and a sterile filter in the reaction cell. In this compound 
the NO reacts with the supplied ozone. The light arose is detected by the PMT, amplified and recorded by the 
associated computer. 
 
After preparing the set-up, the reaction solution was applied (for reductive measurements: 40 ml 60 °C 
triiodid- and for oxidative analysis 20 ml 37 °C ferricyanide-solution), and calibrating a constant pressure (0 
bar), analysis began with the application of the calibration curve. After successful calibration, injection of the 
samples started. The reaction solution should be renewed if it reached its reduction- or oxidation-capacity, 
respectively (shown in table 7). 
Analysis was done with Chromstar 6.3.19 (human samples) or PowerChrom (murine samples). Both of the 
softwares save a spectrogram with peaks per sample injection. The area under the curve of every peak is in 
proportion to the NO concentration in the sample. First the concentrations of the calibration solutions are 
calculated and a linear regression was done. By calculating the formula: c (nM) = (mean-(dilution factor x 
blank)) x dilution factor concentration was calculated. Regression analysis was done with GraphPad Prism 5. 
Table 7. Renewing of reaction solution and list of injection volumes. 
A Volumes are listed after which the reaction solution has to be changed. B Volumes, which are injected in the 
reaction chamber. 
3.2 High Pressure Liquid Chromatography combined with diazo coupling 
The ENO (Eicom NOx Analyzer, Eicom) combines the sensitive technology of high pressure liquid 
chromatography (HPLC) with diazo coupling accomplishing its high sensitivity. HPLC is a quantitative technology 
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for measuring concentrations of liquid substances by the help of standards. The questionable substance 
passages the stationary phase within a solvent, the mobile phase. The stationary phase consists of a separation 
column which retains NO2- and NO3-. This retention time is specific for the components, allowing identification 
and quantification by calculating the area under the peak. NO2- is first released by the stationary phase flowing 
into the reduction column followed by NO3-. In the reduction column the second, ENO-specific, phase of the 
detection reaction follows. First NO3- is reduced to NO2- with cadmium and copper. Secondly, NO2- reacts with 
the reactor solution producing a diazo compound. As diazo compounds are dyes, absorbance could be 
measured at 540 nm. 
3.3 Sample Collection and Preparation 
 Sample Collection and Whole Blood/Plasma Preparation 
Human blood was drawn from the sheath introducer directly before PCI or by venipuncture at the following 
days. For plasma samples blood was heparinized with 1 µl/ml (5000 IU Heparin), diluted in 4 ml PBS, and 
centrifuged 15 min at 2170 rpm and 4°C. Plasma was drawn and stored at -80 °C until measurement. Whole 
blood was immediately diluted 1:4 in preservation solution to stop further reactions and heparinized with 1 
µl/ml heparin. NO2- in whole blood has a half-life period of 10 min, after that time NO2- is oxidized to NO3- or 
able to nitrosylate other proteins. The ingredients of the preservation solution inhibit these reactions. 
Ferricyanide reacts with hemoglobin producing methemoglobin inhibiting the modification of NO2- to NO3-. The 
detergence NP-40 destroys membranes of erythrocytes allowing the ferricyanide reaction. NEM alkylates 
proteins to mask their thiol groups, which can no longer be nitrosylated. While preparing potassium 
hexacyanoferrat, NEM were completely solved, before NP-40 was added. Vigorous agitation and foaming were 
avoided. The solution could be stored at 4°C for one week266,267. 
In the animal care setting, mice were anesthetized with Urethane and blood was drawn by cardiac puncture 
with a heparinized syringe, with the aim of obtaining up to 1.5 ml blood. 
Blood was centrifuged for 1 min at 18,000 g and 4°C and the supernatant was drawn. Plasma was diluted in 
an equal volume of cold methanol and centrifuged for 10 min at 10,000 g and 4°C. At least 70 µl of the 
supernatant was given to the autoinjector. 
Tissue and RXNO/RNNO Preparation 
After the sacrificing and flaying of the mouse (see chapter 2.4) the complete mass of hind limb muscle was 
prepared free, flattened with a liquid nitrogen cooled gavel, quick-freezed in liquid nitrogen, and stored at -
80 °C.  
On the day of measurement samples are thawed on ice. At least 240 mg tissue was cut and weighed. Tissue 
was diluted 1:5 with stop solution and homogenized under ice cold conditions. Stop solution inhibits further 
reactions. NEM should be added to NaCl and dissolved in an ultrasonic bath. EDTA should be added last. 
Contamination of stop solution with NO2- should not be more than 50 nM because of the low level of RXNOs 
and was determined before sample measurement. NO-heme was directly measured in 37 °C ferricyanide 
reaction solution. 100 µl of the antifoam solution was added before sample injection. In the next step tissue 
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was diluted 1:2 with cold methanol and centrifuged (10,000 g, 4 °C, 10 min). For measuring RXNOs 30 µl 
sulfanilamide solution was added to a part of the sample and incubated 15 min on ice in the dark. The sample 
part for RSNO quantification was mixed with 30 µl mercury solution in 300 µl sample volume and incubated for 
30 min in the dark on ice. After that, 30 µl sulfanilamide solution was added and incubated for an additional 
15 min. Reaction chamber was filled with reducing 60 °C triiodide solution268–271. 
Urine and Feces Preparation 
Fixation means stress for the animals and initiates the urinary reflex. Therefore, mice were fixed at the neck 
and held over a petri dish, exploiting this natural reaction. If the animals urinated less the reflex was supported 
with a massage of the abdomen272,273. Urine was transferred into a reaction tube and diluted 1:50 with Carrier 
solution. 
After the last treatment mice were kept in single cages without litter but with sheets of paper. After 1 h 
about five faeces samples were collected. Half a milligram wet weight was 1:1 diluted with sodium chloride and 
centrifuged for 10 min at 10,500 g at RT. Supernatant was injected into the ENO. 
In general, all solvents are measured for determining blanks too. For calibration two standards were 
measured. All samples were measured in duplicate while 100 µl sample volume was given in the autoinjector. 
3.4 EIA (cGMP) 
cGMP was measured in murine plasma, skeletal muscle tissue and whole blood. Blood was drawn with 
heparinized syringes via cardiac puncture as described in the previous paragraph. It was immediately 
centrifuged for 1 min and 18,000 g at 4 °C.  After the supernatant was recovered the plasma was diluted 1:10 
with assay buffer. Following preparation of working solutions and EIA procedure was done in accordance with 
the acetylating protocol in the manufacturer’s instructions (cGMP Enzymeimmunoassay Biotrak (EIA) System). 
 Muscle tissue was taken from hind limbs as described in chapter 3.1. On the day of measurement a piece of 
the sample, at least 40 mg was cropped and thawed on ice. The tissue was homogenized in cold 6 % (w/v) 
trichloracetic acid to get a final concentration of 10 % and centrifuged for 15 min at 2000 g and 4 °C. The 
recovered supernatant was washed four times with five volumes of water saturated diethyl ether and the 
aqueous extract remaining dried under vacuum at 60 °C for 4 h. The dried extract was diluted in 100 µl assay 
buffer and preparation of working solutions and EIA procedure was done in accordance with the non-
acetylation protocol in the manufacturer’s instructions (cGMP Enzymeimmunoassay Biotrak (EIA) System). 
After calculating the average optical density for each set of replicate wells, the percent bound for each 
standard and sample was calculated using the following relationship: 
%B/B0 = (standard or sample OD-NSB OD) × 100 (zero standard OD-NSB OD) 
Percent B/B0 was plotted as a function of the log cGMP concentration and a two competition fit was done to 
calculate the unknown samples. 
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4. Analyses of Endothelial-Regenerating Cells 
4.1 Isolation and Culture 
To analyze the function of Endothelial-regenerating cells they were isolated from murine spleen. The mouse 
was anesthetized with the already introduced Ketanest/Rompun narcosis. A skin incision in the left, superior 
back of the mouse was done. Skin and muscles were thrust aside to expose spleen, which was lifted and the 
vessels severed. Explanted spleen was placed in a PBS-wetted Petri dish and homogenized with the stamp of a 
syringe (2 ml). Suspension was filled with 3 ml PBS and filtered (40 µm) in a new tube. 
Five milliliter Ficoll were carefully overlaid with the filtered suspension and centrifuged for 20 min at 400 g 
and RT. Important in such Ficoll-density-centrifugation is to run without brake and speed-up. The MNCs were 
recovered between the Ficoll- and the plasma-phase (s. figure 10), transferred into a new reaction tube and 
filled up to 50 ml. Cells were washed by centrifugation (350 g, 10 min, RT, brake: 9, speed-up: 9). 
After removing the supernatant the pellet was resuspended in 1 ml endothelial medium. Cells were counted 
in a Neubauer chamber and directly analyzed or cultured. Five Mio cells were seeded on fibronectin coated 
24 wells (1 ml). Coating was prepared with a fibronectin solution (10 µg/ml); 200 µl of the solution was 
dropped in every well, incubated for 1 h at 37 °C, and then excess fluid was aspirated. After 24 h 500 µl fresh 
medium was added. Subsequent change of medium was done every second day including a washing step with 
PBS. Finally the Endothelial-regenerating cells were harvested after seven days. 
Figure 10 Ficoll density centrifugation.  
Blood was carefully put over the Ficoll. After centrifugation four different phases could be 
seen. The mononuclear cells (MNCs) were found between the top phase consisting of 
plasma and the Ficoll phase. They were carefully aspirated with a small cannula. At the 
bottom of the centrifuge tube the erythrocytes were found. 
 
 
 
4.2 Quantification and Characterization by Flowcytometry (FACS) 
Endothelial-regenerating cells were characterized and quantified by flowcytometric analysis from murine 
whole blood. Endothelial-regenerating cells were defined as CD34+Flk+, a combination referring to the stem cell 
nature (CD34) and the endothelial character (Flk-1) of the cells. Additionally the FasL expression on the 
Endothelial-regenerating cells was analyzed. In a subset of samples vitality of cells was determined with 
Annexin V staining. 
Blood was drawn by cardiac puncture with a heparinized syringe to get at least a volume of 4 x 75 µl. After 
partitioning the blood was stored on ice and lysing solution was diluted 1:10 with distilled water. In case of 
Annexin V staining, cells were centrifuged for 5 min at 250 g and RT. After the supernatant had been discarded, 
the pellet was resuspended in 100 µl binding-buffer. First 10 µl of the antibodies against CD34 and Flk-1 were 
added, the sample was vortexed and incubated for 30 min in the dark on ice. Secondly 5 µl Annexin V was 
added and the sample was incubated 15 min in the dark at RT. The subset of samples which were not stained 
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with Annexin V was mixed with 10 µl of every antibody (CD34, Flk-1, FasL), resuspended in PBS, and incubated 
for 30 min in the dark on ice. Afterwards, erythrocytes were lyzed with 1 ml of lysing solution. The diluted 
buffer was added and the samples were mixed thoroughly four times and incubated 10 min at RT in the dark. 
Afterwards the samples are centrifuged for 5 min at 350 g at RT. The supernatant was removed and the pellet 
resuspended in 500 µl PBS. After washing by centrifugating for 5 min at 350 g and RT, the supernatant was 
removed another time and the sample was resuspended in 400 µl binding buffer (after Annexin V staining) or 
PBS (after Endothelial-regenerating cells and FasL staining). 
Flowcytometric analysis needs one control per antibody.  Two types of control exist which control different 
artifacts. A sample stained with an isotype (immunoglobulin control) of the antibody controls for unspecific 
binding of the antibody. This is important in particular if you test antibodies of unknown quality or known 
unspecific binding. A FMO control determines autofluorescent signals of the cell. It is especially important to 
control that if you want to, for example characterize erythrocytes with a known high autofluorescence. 
Recently in “normal” not especially difficult but multicolor flowcytometric staining the FMO control has 
become routine. FMO is the abbreviation of “fluorescence minus one” and means that all antibodies are used 
minus the one this sample controls. In the described work three controls, in addition to the staining, were 
carried out: 1. CD34+FasL (-Flk-1); 2. Flk-1+FasL (-CD34); 3. CD34+Flk-1 (-FasL). 
Samples were counted in the FACS Canto and gated in a SSC vs. FSC plot. The Endothelial-regenerating cells 
were detected in a gate including monocytes and lymphocytes. In the next step the FITC fluorescence (CD34) is 
plotted versus the APC fluorescence (Flk-1). Double positive events were defined as Endothelial-regenerating 
cells. PE positive Endothelial-regenerating cells were finally quantified as FasL+ Endothelial-regenerating cells 
(figure 11). 
Figure 11. FACS measurement.  
Whole blood was stained with CD34, Flk-1, and FasL. The scatter plot shows the 
different cell populations, and mononuclear cells could be gated separately from 
the neutrophiles. 
 
 
4.3 Immunofluorescent Determination of Angiogenesis and Neoangiogenesis  
After injection of the lethal narcosis (1200 mg/kg Urethane, i.p.), the skin of the thorax was opened and heart 
and liver were prepared. To remove blood from the tissue the mouse was perfused with 20 ml PBS via the 
cardiac apex (using a 20 ml syringe and a 20G cannula). Success of perfusion was controlled by a grey 
discoloration of the liver. Subsequently, the mouse was perfused with 20 ml Histofix to support following 
fixation. 
After skinning has been completed, the legs were amputated at the groin and placed in 10 ml Histofix (10 
ml/g tissue) for 24 h at RT. On the second day, the solution was changed to a decalcifying solution with EDTA in 
which the tissue remained for four to five days. To dehydrate the tissue, samples passed an ascending alcohol 
series: washing 30 min in PBS – swivel in 70 % isopropanol overnight (4 °C) – swivel in 80 % isopropanol for 2 h 
(RT) – in 90 % isopropanol for 2 h (RT) – 96 % isopropanol for 2 h (RT) – 100 % isopropanol for 2 h (RT) and in 
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Histol again overnight. However, before starting with the ascending alcohol series the legs were separated at 
the knee and fringed ends were smoothed cutting the thigh and the calf in square, regular blocks. On the ninth 
day the tissue was penetrated with 37 °C hot paraffin for at least 4 h and thigh and calf were embedded in one 
paraffin block. These paraffin blocks were cut into 8 µm sections. From a whole leg 100 slides were made, 10 
slides in 10 levels. Staining of the capillary system and the Endothelial-regenerating cells was done in the upper 
calf (level 1). For reliable staining of the capillaries (Endothelial-regenerating cells) a double (triple) staining was 
done to exclude CD31+ leukocytes. Thus, capillaries were defined as CD45-CD31+ and Endothelial-regenerating 
cells s were defined as CD45-CD31+GFP+. Antibodies were diluted in TBS with 0.3 M NaCl and 2 % BSA, pH 7.5. 
While the slides passed a descending alcohol series (1. Xylol/Histol: 15 min., 2. Xylol/Histol: 15 min, 1. 100 % 
isopropanol: 5 min, 2. 100 % isopropanol: 5 min, 96 % isopropanol: 5 min, 70 % isopropanol: 5 min, T-TBS: 5 
min) buffers and solutions are prepared. A 20x TRIS, pH 7.5 solution serves as stock for the remaining solutions. 
The washing buffer (T-TBS) additionally contains Tween 20 and NaCl, the blocking buffer BSA and horse serum. 
For antigen retrieval a citrate buffer, pH 6.0 was prepared. 
After hydration the antigens in the tissue were unmasked by boiling in citrate buffer (20 min, 900 W in a 
microwave). After 20 min cooling time and washing twice for 5 min in T-TBS the samples were blocked for 1 h 
and RT in blocking buffer. In the next step the samples were framed with a marking pencil and 50 µl of the first 
antibody was dropped onto the slide. Incubation took place overnight in a humified chamber at 4 °C. On the 
following day the slides were washed three times 5 min in T-TBS and 50 µl of the secondary antibody was 
added. The samples were incubated for 1 h in a humified chamber in the dark at RT. Finally the samples were 
washed another three times for 5 min in T-TBS and mounted in one drop Vectashield® with DAPI. 
Regularly, one day after staining slides were analyzed with a fluorescence microscope. Five pictures of every 
slide and every dye were recorded with 20x magnification, trying to cover the whole slide. During analysis the 
CD45-CD31+ (CD45-CD31+GFP+) cells of every field of view were counted and averaged. This value was 
extrapolated to 1 mm2. 
4.4 Analysis of Viability by Tetrazolium Salt (WST-8) Assay  
The spleen isolated Endothelial-regenerating cells were cultivated for 7 days as described in chapter 2.1. After 
that the cells were trypsinized and a suspension with 300,000 cells/300 µl was prepared. The cells were given in 
a 96well plate in triplicate (3 x 100 µl). In three wells the medium was filled as blank. To every well 10 µl of the 
reaction-solution (CCVK-I) was added and 4 h incubated in the incubator. After that time absorption was read 
at 450 nm. The level of absorbance directly correlates to the viability of the cells. 
4.5 Quantification of sFasL by Enzyme-linked-immunosorbent Assay (ELISA) 
Blood was drawn by cardiac puncture with heparinized syringes and plasma separated by centrifugation for 15 
min at 2170 rpm and RT. Samples were stored at -20°C until analyzing. On the day of analysis all reagents and 
samples were brought to RT and 50 µl assay buffer was added to 50 µl sample filled in the wells. Every sample 
was analyzed in duplicate. The following procedure was done in accordance with the manufacturer’s 
instructions and optical density was read at 450 nm and substract readings at 540 nm. For the calculation the 
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duplicate readings were averaged and the blank was subtracted. A standard curve was generated and 
unknowns were calculated with the slope. 
5. Analysis of Satellite Cells 
5.1 Isolation 
The mice, which were donor animals for the BM transplantation, were sacrificed and the legs amputated as 
described in chapter 2.4. The muscle was separated from bone, fat, and fibrous tissue under the clean bench 
and cut into small pieces with a scissor. With the stamp of a syringe the cells were further homogenized. After 
this mechanic digestion the tissue was brought into an enzymatic digestion solution and incubated for 1 h on a 
shaker at 37 °C. 
Subsequently the homogenate was filtered first with a 100 µm cell strainer and second with a 40 µm cell 
strainer. The suspension was filled up to 50 ml with PBS and centrifuged (10 min, 350 g, RT). After discarding 
the supernatant the pellet was resuspended in 1 ml PBS and filled up to 50 ml. The cell suspension was split 
into five petri dishes (10 cm diameter). Because only fibroblasts are able to adhere to uncoated material in the 
short term, after 1 h incubation (37 °C) the cells could be separated in mainly adhesive fibroblasts and floating 
satellite cells. The enriched satellite cells were washed (centrifugation for 10 min at 350 g and RT), resuspended 
in 1 ml PBS, and counted with a Neubauer chamber. 
 5.2 Characterization by Culture and FACS 
Culture of Satellite Cells 
The cells were first characterized by culturing and qualitative morphologic observation. Isolated cells were 
cultivated on collagen-coated plates for 16 d. Every three days the medium was changed and cells were 
microscopically assessed and photographed. After 11 d satellite cells began to differentiate developing their 
characteristic spindle-like shape as shown in figure 12. In the following week the cells started to fuse into 
polynuclear myofibers which could be seen after 16 d. 
For coating, collagen solution (10 ng/100 µl/cm²) was prepared and 100 µl/cm2 were pipetted on the plates 
and incubated at 4 °C overnight. On the next day, the remaining fluid was aspirated and the plate dried under 
the clean bench. Subsequently 100,000 cells/cm2 were seeded in 6well plates in satellite cell specific medium 
(Ham’s 10 with glutamine, with 100 ml FCS (10 %), 50 ml horse serum (10 %), and 1 ml Penicillin/Streptomycin 
(0.2 %). 
Figure 12. Morphology of primary 
isolated satellite cells.  
Samples derived from cultures after 11 
(A) and 16 (B) days of culturing. After 
11 d the cells began to differentiate 
and the long spindle shape arose. After 
16 d the differentiated cells began to 
fuse forming polynuclear fibers. 
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Flowcytometric Characterization of Satellite Cells 
Secondly, satellite cells were characterized by flowcytometric measurement. The cells were stained with an 
Integrin-α7 antibody which is specific for myocyte progenitors. One million cells suspended in 500 µl PBS were 
introduced in the analysis and washed twice by centrifugation in washing buffer (5 min, 350 g, RT). Next the 
cells were stained with 40 µl of the primary antibody and incubated for 30 min at RT. After another washing 
step with 1 ml washing buffer, 30 µl of the secondary antibody was added and incubation started (15 min, RT, 
in the dark). Finally the cells were washed like before and resuspended in 500 µl PBS. An unstained sample was 
used as control and all cells were gated (s. chapter 4.2). Mean fluorescence intensity was verified in histograms 
similar to those presented for the FasL expression analysis in chapter 4.2. 
5.3 Analysis of Apoptosis by Terminal deoxynucleotidyl transferase dUTP nick 
end labeling (TUNEL) 
The fresh isolated satellite cells were washed three times in 1 ml PBS (centrifugation: 350 g, RT, 5 min). Two 
million cells were resuspended in 100 µl PBS; at least one sample had to be separated into thirds à 2 Mio (1 
unknown, 1 positive control, 1 negative control). After adding 100 µl fixation solution and the cells incubated 
for 1 h at RT on a shaker. Two more washing steps were affiliated with 200 µl PBS (5 min, 300 g, RT). 
Subsequently the cells were resuspended in permeabilisation solution and incubated for 2 min on ice. Two 
additional centrifugation steps in 200 µl PBS followed (5 min, 300 g, RT). At the same time, the positive control 
was resuspended in 50 µl DNase and incubated for 10 min at RT. At the end of this incubation, samples were 
resuspended in 50 µl TUNEL-reaction-mix (enzyme and label solution) and negative control (only label solution 
without enzyme). Samples and controls were incubated for 1 h (37 °C)274. After completing the TUNEL reaction, 
cells were washed twice in PBS (5 min, 350 g, RT) before a Hoechst staining completes the assay. 300 µl of 
Hoechst solution (1:5000 diluted in PBS) was added to the samples and incubated for 5 min. Two more washing 
steps followed as described and the resuspended cells (250 µl PBS) were transferred into a 96-well plate. On 
the next day, the plate was analyzed by fluorescence microscopy. Three fields of view were counted with FITC 
(TUNEL positive nuclei) and UV (DAPI positive nuclei). An apoptotic ratio was calculated. The proportion of 
apoptotic cells from total in the ischemic and the non-ischemic leg was counted and divided. 
6. Immunofluorescent Analysis of Arteriogenesis and iNOS Expression 
The same tissue and procedure which was used for Endothelial-regenerating cells and endothelial cell 
immunohistochemical staining (s. chapter 4.3) was used for the detection of arterioles and inflammation. 
Arterioles were detected by staining for SMA-α in level 1 of the thigh. Inflammation was depicted by iNOS 
(level 1 of the calf). Because iNOS is an intracellular protein, permeabilization of the cell membranes were 
needed and achieved by adding Tween 20 to the antigen retrieval buffer. 
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7. Biochemistry and Molecular Biology 
7.1 Determination of Angiogenic Cytokines by ELISA 
For all enzyme linked immunosorbent assays (ELISA) cardiac blood was drawn with heparinized syringes and 
centrifuged 1 min at maximum speed and 4°C. All immunosorbent assays listed were done in accordance with 
the manufacturer’s instructions and absorbance measured at 450 nm. Differences only occurred in sample 
preparation, thus these steps of the analyses were detailed below. 
GM-CSF 
For analyzing GM-CSF plasma samples were centrifuged a second time for 5 min at 13,000 g and RT to get PpP. 
G-CSF 
For the determination of G-CSF the samples were treated as described for measuring GM-CSF. Plasma samples 
were centrifuged a second time for 5min at 13,000 g and RT to get PpP, but were diluted 1:2 in assay diluent. 
VEGF 
VEGF was determined in plasma and tissue. 30-50 mg of the tissue were homogenized in PBS (1:20 dilution) 
and stored overnight at -20°C. After two freeze-thaw cycles (according to manufacturer’s instructions) to break 
the cell membranes, the homogenates were centrifuged for 5 min at 5000 g and assayed immediately. In 
contrast heparinized plasma was only diluted 1:5 in calibrator diluent and further processed. 
SDF-1 
The samples for SDF-1α detection were centrifuged a second time for 5 min at 13,000 g and RT to get PpP. 
7.2 Quantification of XOR activity by an Enzymatic Assay 
XOR activity was measured in murine skeletal muscle tissue with an enzymatic fluorescence assay. After 
sacrificing and flaying the mouse, the pelage and skin were removed as described in chapter 3.1.  The complete 
mass of hind limb muscle was prepared and 1 g tissue homogenized in 1 ml cold Tris-HCl buffer. Homogenate 
was centrifuged for 15 min at 10,000 g and 4°C and the supernatant was analyzed in the assay, which was done 
in accordance with the manufacturer’s instructions and fluorescence measured at 540 nm. 
7.3 XOR Expression Analysis by Real Time PCR 
In murine skeletal muscle XOR mRNA expression was analyzed. Muscle tissue was raised in the same manner as 
for “Analysis of NO and its Metabolites” (chapter 3.1). Primer pairs were ordered according to Yang et. al182. 
RNA was isolated according to manufacturer’s instructions by the “RNeasy Fibrous Tissue Kit” except for 
three steps. According to the large amount of tissue, it was not homogenized once but 4 times in 200 µl RLT 
buffer. Hereafter, these four aliquots were pooled to two samples given on two RNeasy mini columns. While 
the RNA was eluted from the column with H2O, the samples were incubated for 1 min. Concentration was 
determined with a Nanodrop and quality additionally with a NanoChip 6000. This chip analyzes the quality of 
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the 18s and 28s rRNA, which have to stand at the rate of 1:2. The software then calculates the RIN (RNA 
integrity number), which should be between 7 and 10. 
In the next step cDNA was synthesized with “superscript III” reverse transcription kit (Invitrogen©) according 
to manufacturer’s instructions. In every case 1 µg RNA was introduced into the synthesis. 
Thereafter, Real-Time PCR analysis of XOR with SYBR Green reagent was conducted (PCR settings are listed 
in table 8). The mastermix (for one reaction) contained: 2x SYBR Green reagent (12.5 µl), 3 µl forward primer 
(table 5), 3 µl reverse primer (table 5), 5 µl template, and 1.5 µl molecular biology grade water. The volumes 
guaranteed a final concentration of 2 ng/µl template and 5 µM primers. A primer pair from 18s rRNA served as 
reference control. Analysis was done after Pfaffl et al. with REST software275. 
Table 8. PCR settings were set as shown in the table below. 
8. Clinical Studies  
(“New techniques in cardiac imaging and diagnostic of the 
ischemia/reperfusion-injury in the acute myocardial infarction” and “Serial 
measurements of Whole Blood Nitrite in an Intensive Care Setting”)276,277 
Objective of the studies was to examine NO metabolites of critically ill patients in comparison to organ function 
and inflammatory status. Two sets of patients were assessed. In the first setting, blood was drawn from all ICU 
patients each morning via an 18- or 20-gauge arterial catheter over a period of 10 days. In the second series, 
there was an attempt to track the hemodynamic and inflammatory status, for the period of one week, of 
patients suffering from a STEMI. Blood was drawn directly before PCI, 1 d later and 6 d afterwards. 
8.1 Patient Population 
30 patients of the cardiology ICU were included in the study (“Whole blood nitrite in an intensive care 
setting”1) irrespective of their disease. The sole exclusion criterion was patients who had been administered 
NO-donating drugs less than 8 h before blood collection. The patients were enrolled for a periods of 10 d., 
which was the predefined investigation period.  Patients suffering from a STEMI were included in the second 
study, if they were older than 18 years and when admission occurred less than 12 h after the onset of the 
symptoms. Only patients who had had a first myocardial infarction or if their infarct related artery had been 
affected for the first time were considered.  In the case of chronic kidney disease with a glomerular filtration 
rate below 60 ml/min/1.73 m2 calculated by the Modification of Diet in Renal Disease Study equation419 or 
pregnancy and lactation, patients were excluded from the study. The study was conducted in accordance with 
the provisions of the Declaration of Helsinki and with the International Conference on Harmonization Good 
Clinical Practices, and protocol approval was obtained from the local Ethics Committee. All patients gave 
written informed consent. 
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8.2 Analysis of Nitrite and Nitrate 
Analysis of nitrite and nitrate was done from arterial or venous blood with chemiluminescence detection as 
described in chapter III. Blood was collected in tubes with 1 µl heparin (5000 U) and 4 ml PBS per milliliter 
blood. Immediately after taking the blood sample the fluid was centrifuged (15 min, 2170 rpm, 4 °C) and the 
supernatant stored at -80 °C. 
8.3 Description of Inflammatory and Angiogenic State   
SDF-1, NAP-2, and MCP-1 
Levels of the cytokines SDF-1, NAP-2, and MCP-1 were detected in plasma of STEMI patients. All cytokines were 
quantified in venous blood but the anticoagulant was heparin for SDF-1α, citrate for NAP-2, and EDTA for MCP-
1. Plasma was separated by centrifugation as described above (chapter 7.1). Moreover, the PrP was centrifuged 
a second time for getting PpP for quantification of NAP-2 (5 min, 13,000 g, RT). All assays were done according 
to manufacturer’s instructions. 
Quantification of Endothelial-Regenerating Cells by FACS 
According to the protocol listed in chapter 4.2, whole blood of STEMI patients was stained and Endothelial-
regenerating cells quantified. Variance was given in anticoagulant (citrate), volume (1 ml), controls (isotype-
controls) and human antibodies. In addition to the quantification of Endothelial-regenerating cells, blood was 
stained for CD11b, a marker for activated neutrophiles. 
Clinical Chemistry 
All analyses were performed in the laboratory of the Institute for Clinical Chemistry of the University Hospital 
Aachen. The inflammatory parameters IL-6, (hs)CRP, and TNF-α were determined by serum samples analyzed 
within 30 min after collection. TNF-α and IL-6 were determined by chemiluminescent immunoassay. CRP was 
assessed by immunoturbidimetry and nephelometry (hsCRP), respectively. 
9. Statistics 
Statistics were calculated with GraphPad Prism 5. Firstly, distribution of the data was determined with a 
Kolmogorov-Smirnov test (with Dallal-Wilkinson-Liliefor p value) or D’Agostino and Pearson omnibus normality 
test. Subsequently, two samples were analyzed using a t-test (parametrical data) or a Mann-Whitney test (non-
parametrical data). The paired data of the clinical study was analyzed by a Wilcoxon matched paired test. If 
three or more data sets had to be compared a variance analysis was done. In the case of parametrical data an 
ANOVA with Bonferroni post-test was calculated, but if the data showed a non-parametrical distribution a 
Kruskal-Wallis analysis and Dunn’s post-test was chosen. Three or more data sets of the paired clinical data 
were analyzed by a Friedman-test, including Dunn’s post-test. Outliers were detected by calculating twofold SD 
and fitting the data with non-linear regression and automatic outlier detection with GraphPad Prism278. Real-
Time PCR results were calculated by REST© by a Pair Wise Fixed Reallocation Randomisation Test and S.E. 
estimation via a Taylor algorithm275. 
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Results  
1. Animal Study 
The awareness that in atherosclerosis there is a need for NO and that its’ metabolites NO2- and NO3- could be 
recycled brought about the idea of positively influencing NO metabolism in ischemia with NO3-. As a result, an 
animal study was designed in which a severe ischemia was induced and diet was supplemented with NO3-.  
In the following, the mice, which got soda without supplement, are termed “control”. Subsequently, the 
group, which drunk soda supplemented with NO3-, is named “NO3-”. The animals, which were supplemented 
with NO3- and treated with antiseptic mouthwash, are denoted as “MoW”. Figure 13 clarifies the study design 
for the main series; if other set-ups were designed to analyze special features they are explained coupled with 
corresponding results. 
Figure 13. Study design of in vivo experiments.  
NO3- supplementation began seven days before surgery and persists a further seven days after it. Mice that 
were administered mouthspray twice a day in addition to a NO3- supplementation were used as negative 
control. In the week before surgery, the influence of supplementation and treatment on food and water 
consumption was excluded by determination of NO3- and NO2- levels. Before and four times after surgery 
perfusion was assessed. All other analyses were done seven days after surgery. 
1.1 Dietary and Environmental Habit  
As described, the mice obtained 1 g/l NO3- in drinking water ad libitum (and MoW twice a day). Through regular 
weighing, it was ensured that the supplementation and treatment did not influence water and food 
consumption, and the weight of the mice. As shown in figure 15, water consumption remained invariable over 
the period of experiments and did not differ; the mice got neither NO3--water and antibacterial mouthwash nor 
normal soda and placebo mouthwash. Control mice consumed 0.28±0.04 ml water/g body weight, NO3- mice 
drunk 0.28±0.04 ml water/g body weight, and MoW animals needed 0.29±0.03 ml water/g body weight. An 
analysis of variance did not show a significant difference (p=0.98). At the same time, food consumption 
remained constant independently from the collective (control: 0.18±0.02 g; NO3-: 0.2±0.01 g; MoW: 
0.19±0.01 g; normalized to body weight) as an ANOVA confirmed (p=0.56). Finally, the weight of the mice was 
determined once, in the week before surgery determining the effect of supplementation and treatment and for 
a second time in the week after surgery to detect any effects of surgery. Neither in the first nor in the second 
case could a discrepancy be established. Thus, a variance analysis failed to detect a significant difference 
between the weights of the groups (p=0.42 when supplementation and treatment started; p=0.46 7 d after it). 
The absolute values are listed in table 9. The same applied for the loss of weight seven days after surgery, 
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which amounted to 2.60±0.46 g for the control group, 2.54±0.58 g for the NO3- animals, and 3.48±1.20 g for the 
MoW mice (ANOVA and Bonferroni post-test, ns, p=0.56). 
Table 9. Comparison of weights dependent from collective.  
Shown are weights before the start of supplementation and treatment (day -7) and seven days afterwards (day 
0). In addition to the comparison of different groups at a particular time-point, the groups were tested among 
each other. Weights remained constant among the groups (paired t-test). Data are given as mean ± SEM (n=5). 
 
The success of bacterial inhibition by MoW was analyzed by counting CFU (see figure 14). Only one hour 
after treatment the oral flora quantities decreased significantly compared to basal values (Wilcoxon-matched-
paired test, *, p=0.03). Before MoW 273±35 CFU of aerob and anaerob bacteria were counted and one hour 
after treatment the values decreased to 21±5 CFU. Bacteria were also qualitatively determined and 
Staphylococcus xylosus, Staphylococcus aureus, Diplococcus, Proteus sp., Streptococcus viridans, and spore-
forming bacteria were found in the oral cavity before treatment, but only the two staphylococci and the spore-
forming bacteria were found after treatment. 
Figure 14. Quantification of oral flora.  
Both aerob bacteria (black circles) and anaerob bacteria (grey circles) were cultured and CFU counted. The 
populations did not differ significantly and therefore shown in one graph. The decrease of oral bacteria one 
hour after treatment was significant (Wilcoxon-matched-paired test,*, p=0.03). Data are given as mean ± SEM 
(n=6). 
 
Finally, kinetics of NO3- and NO2- processing was tested. To obtain as many samples as possible from one 
animal and to combine as many animals as possible on one day, sample withdrawal lasted no longer than two 
hours. Subsequent analysis (figure 16) showed that long intervals between last treatment and euthanasia did 
not influence following results. NO3- was given per gavage to equals uptake (12 mM, which refers to the 
average daily uptake); half of the mice were treated with MoW. Nevertheless, NO3- circumvented direct 
reduction in the oral cavity if given per gavage, it is reduced by absorption in the saliva. Six hours after the last 
treatment, no differences in NO3- levels could be measured. In the NO3- group levels started at 44.73±4.05 µM, 
went to 146.10±58.21 µM, and ended at 88.94±18.12 µM (Friedman test and Dunn’s post-test, ns, p=0.19). 
Even more stable were the levels after MoW with 29.33±1.34 µM, 29.789±3.24 µM, and 45.99±4.54 µM 
(Friedman test and Dunn’s post-test, ns, p=0.19). The NO2- measurements showed similar results. The level in 
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the NO3- group ranged from 0.57±0.13 µM, to 0.3±0.04 µM, and 0.33±0.15 µM (Friedman test and Dunn’s post-
test, ns, p=0.19). Although the NO2- level in MoW mice were statistically significant (Friedman test and Dunn’s 
post-test, *, p=0.03) no substantial association was assumed, because of the high variance in the basal 
measurement (0 h: 0.84±0.35 µM; 2 h: 0.13±0.02 µM; 6 h: 0.25±0.04 µM). 
Figure 15. Exclusion of treatment effects on dietary habit.  
A and B Water and food consumption were normalized to body weight. All three groups drunk and ate the 
same amount of soda and pellets independently of supplementation and treatment. Shown are measurements 
determined in the first week of supplementation and treatment before surgery (ANOVA and Bonferroni post 
test, ns, p=0.98 and p=0.56). C and D All animals started the series at a similar weight, which remained equal 
after seven days of supplementation and treatment (ANOVA and Bonferroni post-test, ns, p=0.42 and p=0.46). 
Moreover, the loss of weight was constant among the groups (ANOVA and Bonferroni post-test, ns, p=0.56). 
Data are given as mean ± SEM (n=5). 
Figure 16. Influence of supplementation on plasma NO2- and NO3- level over the experimental course.  
A Study set-up shows that after NO3- supplementation ± MoW blood samples were drawn directly, 2 h, and 6 h 
afterwards. B and C NO3- and NO2- levels stayed mainly constant over 6 h, simulating an experimental day 
(Friedman test and Dunn’s post-test, ns, NO3-: p=0.19 and p=0.19; NO2-: p=0.19 and p=0.03). Data are given as 
mean  SEM (n=3). 
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1.2 NO Metabolism  
1.2.1 Non-ischemic Measurements 
The NOx levels in the analyzed groups were influenced by NO3-, MoW and ischemia. To determine the single 
effect of dietary NO3- and MoW on NOx metabolism, diet was supplemented and mice were treated for seven 
days and plasma, urine and feces were collected at day 0 before surgery. Besides the known groups, a fourth 
group (“basal” without placebo MoW) was introduced to exclude the influence of spraying a fluid twice a day.  
Figure 17 A presents the NO3- levels in plasma. Both, basal and control mice had equal low levels (basal: 
25.8±3.5 µM; control: 23.2±5 µM). With NO3- supplementation the levels rose to the sevenfold (190±20.4 µM). 
However, after additional MoW treatment the levels decreased significantly (59.4±32.3 µM). Put together, all 
control groups showed similar NO3- levels without statistical differences. Conversely, the NO3- animals showed 
significantly higher NO3- levels (ANOVA and Bonferroni post-test, ***, p<0.0001; ***, basal vs. NO3-; ***, 
control vs. NO3-; **, MoW vs. NO3-). 
Additionally, NO2- levels in plasma were determined, shown in figure 17 B. The NO2- levels after NO3- 
supplementation rose significantly (ANOVA and Bonferroni post-test, *, p=0.02; *, control vs. NO3-; *, MoW vs. 
NO3-) compared to the levels in the basal, control and MoW group (NO3-: 1.6±0.35 µM; basal: 0.90±0.13 µM; 
control: 0.78±0.05 µM; MoW: 0.73±0.13 µM). 
Figure 17. NO metabolites measured in plasma before surgery.  
A After seven days of NO3- supplementation, but before induction of ischemia, differences from NO3- 
supplementation and MoW treatment are distinct. Basal and control levels are significantly lower than the 
increased levels in NO3- mice (ANOVA with Bonferroni post-test, ***, p<0.0001; ***, basal vs. NO3-; ***, control 
vs. NO3-; **, MoW vs. NO3-). B At the same time NO2- levels were determined. Levels of NO3- animals increased 
twofold in comparison to basal and control levels. Consequently, after additional MoW treatment, NO2- 
decreased significantly. (ANOVA with Bonferroni post-test, ***, p=0.016; ns, basal vs. NO3-; *, control vs. NO3-
; *, MoW  vs. NO3- ). Data are given as mean±SEM (n=4-5). 
 
At the same time, urinary NO3- and NO2- levels were detected. When tested,  collective NO3- levels rested low 
(1471±324 µM). Conversely, the levels in the NO3- and MoW groups increased significantly (ANOVA and 
Bonferroni post-test, ***, p<0.0001; ***, control vs. NO3-; ***, MoW vs. NO3-) to 9184±125 µM (NO3-) and 
9229±1622 µM (MoW). The analyzed NO2- levels tended to increase after NO3- supplementation and MoW 
treatment, but lacked significance (control: 1.13±0.27 µM; NO3-: 2.21±0.49 µM; MoW: 1.94±0.3 µM; ANOVA 
A B 
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and Bonferroni post-test, ns, p=0.14). These results are shown in figure 18 elucidating that NO3- arrived 
circulation after MoW as shown in figure 18. 
Figure 18. Urinary NO metabolites measured by diazo coupling and  HPLC after supplementation.  
A NO3- levels were, in total, very high after 7 d of supplementation. However, the levels in the NO3- and MoW 
groups were significantly elevated from control mice (ANOVA and Bonferroni post-test, ***, p<0,0001; ***, 
control vs. NO3-; ***, MoW vs. NO3-). B NO2- levels in murine urine are low in comparison to urinary NO3-. The 
levels after 7 d of supplementation and treatment tended to increase but remained statistically indifferent to 
the control collective (ANOVA and Bonferroni post-test, ns, p=0.14). Data are given as mean ± SEM (n=4-5). 
1.2.2 Ischemic Measurements  
For completion of the comprehension of NOx metabolism, NOx levels in ischemia were determined. At the start, 
plasma NO3- (and NO2-) levels showed higher variance than before surgery (figure 19). In particular, data of NO3- 
and MoW mice showed a big scattering and because of that these data are shown as box plots. 
The NO3- levels in the NO3- and MoW groups were significantly increased in contrast to control animals, but 
without significance among these groups (ANOVA and Bonferroni post-test, **, p=0.006; **, control vs. NO3-; *, 
control vs. MoW). The levels of the control group lie at 28.2±3.4 µM, the levels of the NO3- samples at 
173.2±30.7 µM and these of the MoW collective at 127.8±32.3 µM. 
NO2- levels only showed a trend to increase after NO3- supplementation and MoW treatment (ANOVA with 
Bonferroni correction, ns, p=0.27). Levels were 0.3±0.03 µM (control), 0.38±0.03 µM (NO3-), 0.39±0.04 µM 
(MoW). These levels, determined at day 7, seemed lower than the levels determined at day 0 (figure 19). 
Statistical analysis confirmed a significant decrease of NO2- levels in ischemia, independent from observed 
group as shown in figure 19 C (t-test, ***, p<0.0001, control day 0 vs. control day 7; **, p=0.001, NO3- day 0 vs. 
NO3- day 7; **, p=0.006, MoW day 0 vs. MoW day 7). NO2- levels in control mice decrease from 0.78±0.05 µM 
to 0.3±0.3 µM, the levels from NO3- animals from 1.6±0.35 µM to 0.38±0.03 µM, and the levels from MoW mice 
from 0.73±0.13 µM to 0.39±0.04 µM. 
Furthermore, NO metabolites in skeletal muscle were quantified. Paraller, to NO3- and NO2- levels, the 
amount of NO-heme, and RXNOs were determined. All results from the ischemic and the non-ischemic hind 
limb muscle were shown in comparison in figure 20 A-D. 
The stable NO3- levels of control mice were 278.3±87.8 µM (non-ischemic) and 274.6±100 µM (ischemic). The 
not significant but higher levels of NO3- animals were 364.9±148.7 µM (non-ischemic) and 465.3±105.1 µM 
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(ischemic). Finally, the levels of MoW mice were 45.6±6.5 µM (non-ischemic) and 54.6±7.8 µM (ischemic). The 
ischemic level of the NO3- and the MoW group differed significantly (Kruskal-Wallis test with Dunn’s post test, 
*, p=0.01; *, NO3- isc vs. MoW isc). 
Figure 19. Plasma NO metabolites after 14d of supplementation and under ischemic conditions.  
A NO3- levels after surgery were increased as well in NO3- as in MoW mice (ANOVA and Bonferroni post-test, 
**, p=0.006; **, control vs. NO3-; *, control vs. MoW). B In general, NO2- levels after surgery were lower in 
relation to plasma levels before surgery without a difference among the groups (ANOVA and Bonferroni post-
test, ns, p=0.268). C A comparison of the data sets before and after surgery elucidated a significant difference 
amongst the groups between day 0 and day 7 (t-test, ***, p<0.0001, control day 0 vs. control day 7; **, 
p=0.001, NO3- day 0 vs. NO3- day 7; **, p=0.006, MoW day 0 vs. MoW day 7). Data are given as mean ± SEM 
(n=9-12; day 7). 
 
The picture of the NO2- levels was slightly different (figure 20 B). In all three groups a trend of increased 
levels in the ischemic legs in comparison to the non-ischemic legs could be detected, obtaining significance in 
the NO3- collective (Mann-Whitney test, *, p=0.03). In contrast to the NO3- levels, no significance could be 
detected between the groups (ischemic) (Kruskal-Wallis test with Dunn’s post test, ns, 0.08). Levels were 
1.6±0.3 µM (control), 2.7±0.1 µM (NO3-), and 3.8±0.7 µM (MoW) for the ischemic tissue and 1.1±0.09 µM 
(control), 1.2±0.07 µM (NO3-), and 3.4±0.5 µM (MoW) for the non-ischemic legs. 
In figure 20 C, NO-heme levels are shown. Similarly to NO2- levels, the ischemic samples had higher levels of 
NO-heme than the non-ischemic (Mann-Whitney test, **, p=0.008, control; *, p=0.03, NO3-; ns, p=0.2, MoW). In 
contrast, no significant difference could be measured between the three collectives, in spite of an obvious 
trend to increased levels after NO3- supplementation (Kruskal-Wallis test with Dunn’s post-test, ns, p=0.8). 
Detected levels were 14.9±2.6 nM (control), 25.2±15.5 nM (NO3-), and 18.8±4.7 nM (MoW) in the ischemic legs 
and 0.4±0.2 nM (control), 0.7±0.1 nM (NO3-), and 11.4±4 nM (MoW) in the non-ischemic muscle samples.  
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RNNO and RSNO levels were shown in stacked bars (figure 20 D). These two halves result in the entirety of 
protein-bound NO (RXNO). Only control and NO3- animals (ischemic legs) were tested. The first results missed a 
clear shift by supplementation to an alteration between the RNNO-RSNO proportions, which corroborated the 
hypothesis. Therefore, these experiments were closed. Consequently, and because of high scattering, a 
statistical evaluation was resigned, but the results were shown graphically to complete this complex of 
analyses. 
Figure 20. Juxtaposition of NO metabolites in muscle tissue of non-ischemic and ischemic legs.  
A In conclusion, after NO3- supplementation the NO3- levels tended to increase, but were significantly 
decreased after additional MoW treatment (Kruskal-Wallis test with Dunn’s post test, *, p=0.01; *, NO3- isc vs. 
MoW isc). B The ischemic NO2- levels were inclined to increase (in relation to non-ischemic levels), and attained 
significance after NO3- supplementation (Mann-Whitney test, p=0.03, NO3- isc vs. NO3- non-isc). There is a lack 
of significance among the groups (Kruskal-Wallis test and Dunn’s post-test, ns, p=0.08). C In the ischemic legs 
NO-heme levels remained constant independent from analyzed collective (Kruskal-Wallis test with Dunn’s post-
test, ns, p=0.8). Instead of this, the levels in the non-ischemic legs were significantly lower (Mann-Whitney test, 
**, p=0.008, control; *, p=0.03, NO3-; ns, p=0.2, MoW). D In the control group RNNOs and RSNOs were parted in 
two halves amounting 50 %. After NO3- supplementation this proportion lacked an obvious variation, but 
overall the levels appeared higher after NO3- supplementation. Data are given as mean ± SEM (n=3-5). 
1.2.3 cGMP Measurement 
NO acts by binding to the Guanylyl cyclase, which subsequently produces cGMP280. Thus, cGMP is regarded as a 
marker for NO level, whose direct measurement is difficult. Based on this background, cGMP levels in the 
ischemic tissue were analyzed. In contrast to the hypothesis, the samples lacked a difference between control, 
NO3- and MoW mice (ANOVA and Bonferroni post-test, ns, p=0.26). Moreover, the levels after NO3- 
supplementation tended to decrease (4.2±2 fmol/mg tissue) in contrast to the control groups (8±1.5 fmol/mg 
tissue, control; 9.3±2.9 fmol/mg tissue, MoW), as shown in figure 21. 
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Figure 21. cGMP levels determined in ischemic legs.  
Despite a drift to lower levels after NO3- supplementation no significance was 
obtained (ANOVA and Bonferroni post-test, ns, p=0.23). Data are given as mean 
± SEM (n=6). 
 
 
 
 
 
 
 
 
1.3 Outcome – Tissue Injury and Regeneration 
1.3.1 Perfusion, Necrosis and Characterization of Satellite Cells 
In pAOD, the undersupply caused by ischemia in the extremities could lead to severe tissue damage. Therefore, 
a major goal of the study was to recover perfusion in ischemic legs to ensure nourishment and prevent 
necrosis. LDPI measurements, supported by macroscopic evaluation of necrosis, were used to follow the 
regeneration process. 
Perfusion was tracked over one week and the outcome defined as perfusion after seven days, is presented in 
figure 22. Unfortunate restoration in control mice (59±4 %) was significantly augmented by NO3- 
supplementation (73±4 %). Without bacterial NO3-reduction (MoW) the effect disappeared (55±3 %). Indeed, 
both changes were significant (ANOVA with Bonferroni correction, **, p=0.003; *, control vs. NO3-; **, MoW vs. 
NO3-). As described, parallel to perfusion, necrosis was determined and outlined in figure 23. To compare the 
degree of necrosis, a score was developed and every mouse evaluated at the day of the final measurements. 
No significant change in the rate of necrosis was detected (Chi-square test, ns, p=0.13). Nevertheless, the 
difference between the collectives was impressive as figure 23 clarifies. 
Figure 22. Regeneration of perfusion after severe ischemia by dietary NO3-.  
A The histogram illustrates the final perfusion measurement. Without support, perfusion only regenerated to 
about 60 %. This poor outcome is significantly improved by dietary NO3-. After antiseptic MoW the protective 
effect is abolished (ANOVA and Bonferroni post-test, **, p=0.003; *, control vs. NO3-; **, MoW vs. NO3-). Data 
are given as mean ± SEM (n=21-23) B The collage summarizes representative pictures of the measurement of 
perfusion. In the upper row mice are shown before surgery, when both legs were equally perfused. Seven days 
after ischemia-induction (lower row) in the control and the MoW mouse perfusion remained low. In contrast, 
the perfusion in the NO3- mouse was considerably higher. Perfusion is calculated in arbitrary units, and shown 
in pseudo colors (black = low; red = high). 
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Figure 23. Necrosis determined seven days after hind limb surgery.  
A Tabular proportion of healthy to necrotic legs between the groups. Whereas more than 50 % of ischemic legs 
in the control groups were necrotic; in the NO3- group less than 50 % of legs evolved necrosis. B Graphic 
illustration of tabular values (Chi-square test, ns, p=0.13; n=21-23). Necrosis score: 0= no visible necrosis; 1= 
discoloration of the toes/feet; 2= necrosis of the toes; 4= necrosis of the foot; 5= necrosis of the calf; 6= 
necrosis of the thigh 
 
Dietary NO3- supplementation improved perfusion and reduced necrosis. Besides, the question of whether 
viability of muscle progenitor cells (satellite cells) is also positively influenced by NO3- supplementation should 
be answered. To answer this issue, the isolation of satellite cells was established and proved by FACS 
measurement after α7-Integrin staining (shown in figure 24). The results demonstrated a high purity of isolated 
satellite cells, comparable to the result in a myoblast cell line (C2C12) (control: 2.8±0.1%; stained: 94.4±0.9; t-
test, ***, p<0.0001). Subsequently, the examination of the satellite cells for apoptosis and viability was done 
and presented by cand. med. Andreas Schicho whose doctoral thesis was designed and done in close 
collaboration with the presented work.  
Figure 24. Characterization of satellite cells. 
A About 95 % of stained cells were α7-Integrin positive. Thus, it could be concluded, that isolation and 
enrichment was successful. B Representative FACS histograms with C2C12 cells as positive control in 
comparison with histograms of primary isolated satellite cells visualize purity of the isolation (t-test, ***, 
p<0.0001). Data are given as mean ± SEM (n=3). (PE= dye; MFI=mean fluorescence intensity, arbitrary units). 
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1.4 Vascularization  
1.4.1 Isolation, Culture, and Characterization of Endothelial-Regenerating Cells  
Endothelial-regenerating cells are pro-angiogenic progenitor cells. They are mobilized from bone-marrow and 
are involved in angio- and neo-angiogenesis138. Besides, recent work could show that NO acts as 
chemoattractor for Endothelial-regenerating cells80. The following results should demonstrate that Endothelial-
regenerating cells are also concerned in the regenerative effects mediated by dietary NO3-. 
Isolation of Endothelial-regenerating cells from murine spleen was established to investigate vitality of these 
cells after NO3- supplementation. As described in chapter 4.1 (Methods and Materials) the cells were cultured 
for seven days under endothelial conditions. After the seven days, the cells were characterized with a 
DilacLDL/UEA staining to define their endothelial phenotype. From small murine spleens only a small amount 
of cells could be extracted. Nevertheless, figure 25 shows a representative picture of a vital (regularly tested by 
Trypan blue staining during cell counting), typical spindle-shaped culture. 
As described, quality of the culture was ensured by a DilacLDL/UEA lectin staining. Figure 26 exposes the 
single stainings and the merged picture. All stained cells, detectable by the blue nuclei staining, were also 
positive for the red DilacLDL and the green UEA lectin, which become visible in the forth merged picture. 
Figure 25. Representative photography of a splenic Endothelial-
regenerating cell culture.  
The progenitor cells were isolated via Ficoll-density centrifugation 
and subsequently concentrated by culturing under endothelial 
conditions. The characteristic spindle shape of the cells is apparent. 
Magnification, x 100. 
 
 
 
 
 
Figure 26. Representative 
images of DilacLDL/UEA 
lectin stained Endothelial-
regenerating cells.  
A The first picture shows the 
FITC conjugated UEA lectin, 
fluorescing green. B The red 
Dil-ac-LDL staining perfectly 
mirrored the picture of A. C 
The same counts for the 
third photography, which 
shows the Hoechst nuclei 
staining to define real cells. D 
Finally, the last picture 
presents the overlay of 
previous images. 
Magnification, x 100. 
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1.4.2 Endothelial-Regenerating Cell Mobilisation   
In addition to the splenic Endothelial-regenerating cells the progenitors were stained in whole blood and 
quantified by FACS to determine the impact on mobilization by dietary NO3-. 
Figure 27 B illustrates the procedure. According to their size and granularity the Endothelial-regenerating 
cells were assumed within the mononuclear cell (MNC) population, including lymphocytes and monocytes. In 
the next step, APC+FITC+ (Flk-1+/CD34+) double positive cells were defined as Endothelial-regenerating cells. 
Control mice had 0.1±0.03 % MNC Endothelial-regenerating cells and the same pertained for the blood of MoW 
animals (0.1±0.03 %MNC). In contrast, the levels are significantly increased after NO3- supplementation to 
0.4±0.09 %MNC (Kruskal-Walli test and Dunn’s post test, ***, p = 0.0002; **, control vs. NO3-; **, MoW vs. NO3-
). The results were summarized in figure 29 A. 
Figure 27. FACS analysis of Endothelial-regenerating cells in whole blood.  
A Quantitative analysis reveals a significant increase of circulating Endothelial-regenerating cells (CD34+Flk-1+) 
within the MNC population after NO3- supplementation. This increase is abolished by MoW (Kruskal-Walli test 
and Dunn’s post test, ***, p=0.0002; **, control vs. NO3-; **, MoW vs. NO3-). B Representative FACS charts 
point up the stained populations. Data are given as mean ± SEM (n = 13 - 16). (FITC = dye; PE = dye; APC = dye; 
SSC = side scatter; FSC = forward scatter) 
1.4.3 Endothelial-Regenerating Cell Migration 
Bone-marrow transplantation control 
After migration into tissue, Endothelial-regenerating cells begin to differentiate into endothelial cells427. 
Accordingly, differentiated Endothelial-regenerating cells without stem cell character can not be retraced. 
Therefore, bone-marrow transplantation with labeled stem cells was conducted. The scheme in figure 28 
illustrates the experimental set-up. After irradiation and transplantation the mice got four weeks to convalesce. 
After this time, supplementation and treatment were the same as in the previously described series. On day 
seven the hind limbs were explanted and prepared for immunofluorescent staining. 
Success of transplantation was proved qualitatively with blood smears. Figure 29 demonstrates that despite 
the autofluorescence of erythrocytes the green glaring of GFP+ cells is distinctive. In Row I and II photographs of 
a chimera and a transgenic eGFP-mouse are displayed. Both mice had similar amounts of GFP+ blood cells. 
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However, only a part of the visible cells shine green, because erythrocytes do not express the transgene258. 
Instead, the blood smear of the control mice (row III) without GFP+ cells lacked positive cells. 
Figure 28. Scheme of experimental set-up including BM-transplantation.  
Four weeks before starting the NO3- supplementation, the mice were lethally irradiated and GFP+ BM was 
transplanted 24 h later. Mice need four weeks to convalesce and become sufficient healthy to sustain further 
supplementation, treatment, and surgery. 
Figure 29. Quality control of BM transplantation by blood smears. 
I The upper row includes the bright-field photographs of the blood smears. II The lower row contains the green 
fluorescent pictures, determining GFP-fluorescence. A The column demonstrates that in the chimera, six weeks 
after BM transplantation, GFP+ cells outshined the autofluorescent erythrocytes. B The mid-column elucidates 
that the amount of GFP+ cells in the transplanted animals is similar to the transgene eGFP+ animals. C In the 
right column the blood smear of a non-transplanted control mouse is displayed without distinct GFP 
fluorescence. Magnification, x 100. 
 
Endothelial-Regenerating Cell Migration  
Subsequently, migration was determined. Increasing amounts of Endothelial-regenerating cells were not only 
expected in the circulation, but also in the ischemic tissue. These differentiated Endothelial-regenerating cells 
could be detected as GFP+ after bone-marrow transplantation. In addition to this “bone-marrow marker” the 
cells were defined as CD45-CD31+ to exclude lymphocytes and define the endothelial character. Figure 30 and 
31 summarize the results. Figure 30 demonstrates that after NO3- supplementation more Endothelial-
regenerating cells migrated into the ischemic tissue in contrast to control mice and that this increase is 
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abolished by additional MoW. Moreover, in figure 33 the statistical analysis of this staining quantifies the 
significant rise of Endothelial-regenerating cells migration (ANOVA and Bonferroni post-test, **, p = 0.004; **, 
NO3- vs. control; **, NO3- vs. MoW). Indeed, on average 10.52 CD31+GFP+CD45- cells/mm2 were mobilized by 
dietary NO3-. However, in the control mice only 3.50.9 CD31+GFP+CD45- cells/mm2 were identified and in the 
MoW animals only 3.31.1 CD31+GFP+CD45- cells/mm2. 
Figure 30. Migration of Endothelial-regenerating cells in the skeletal muscle. 
I The upper row unifies the red CD31 staining, II The second row presents the amount of green GFP+ cells in the 
hind limbs. III The last row encloses the merged pictures. To exclude false positive staining and lymphocytes, a 
CD45 and a Hoechst staining were done but not shown to improve clarity. The representative photographs 
visualize the difference between the groups. Into the legs of NO3- mice were much more Endothelial-
regenerating cells migrated than into the control limbs. Columns represent the different groups (A = control; 
B = NO3-; C = MoW). Magnification, x 200. 
 
Figure 31. Migration of Endothelial-regenerating cells in murine hind 
limbs.  
Endothelial-regenerating cells were detected as CD31+GFP+CD45-. 
Obviously, after dietary NO3- supplementation Endothelial-
regenerating cell migration into ischemic tissue was significantly 
augmented in contrast to that in MoW and control limbs (ANOVA and 
Bonferroni post-test, **, p = 0.004; **, NO3- vs. control; **, NO3- vs. 
MoW). Data are given as mean ± SEM (n = 6). 
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1.4.4 Angiogenesis 
It is proposed, that migrated Endothelial-regenerating cells participate in angiogenesis. Besides arteriogenesis 
(shown in 2.4.5), the amplification of capillaries by angiogenesis and neo-vascularization are important 
mechanisms promoting regeneration. Thus, angiogenesis was also analyzed. However, instead of in the thigh 
regions, these reactions concentrate on the calf. Consequently, the examination of capillary density was done 
by immunofluorescence in the lower leg. To detect capillaries the endothelial marker CD31 was used as 
illustrated in figure 32. Representative series of photographs of every group were shown, picturing the 
difference in capillary density. Subsequently, the statistical analysis is given in figure 33. Under ischemic 
conditions without supplementation, the capillary density counted for 59.214.7 CD31+CD45- cells/mm2, and in 
MoW mice 56.86.8 CD31+CD45- cells/mm2 were evaluated. In contrast, in NO3- animals the number of 
capillaries rose significantly to 123.419.7 CD31+CD45- cells/mm2 (ANOVA and Bonferroni post-test, **, 
p = 0.009; *, NO3- vs. control; *, NO3- vs. MoW). 
Figure 32. Capillary density in ischemic hind limbs.  
A, B, and C Representative images of immunohistochemical CD31 stainings. CD31 is shown red associated to 
the blue nuclei (arrows). As the pictures are representative for the analyzed groups the difference becomes 
visible. In the NO3- group (B) are much more capillaries stained than in the control groups (A and C). Columns 
represent the different groups (A = control; B = NO3-; C = MoW).The rows contain pictures of one staining 
(I = Cy5+ (CD31); II = UV+ (DAP/nuclei); III = merged). Magnification x 200. 
 
Figure 33. Capillary density in regenerating calfs. 
Paraffin slides of the lower leg were stained with immunofluorescent and 
CD31+CD45- vessels were counted. After NO3- supplementation, quantity of 
endothelial cells was significantly amplified (ANOVA and Bonferroni post-test, **, 
p = 0.009; *, NO3- vs. control; *, NO3- vs. MoW). Data are given as mean ± SEM 
(n = 6). 
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1.4.5 Arteriogenesis  
After severe ischemia in the extremities, regeneration of the tissue is obtained by restoration of nourishment. 
Therefore, perfusion has to be recovered, which is achieved by vasculogenesis. Vascularization is comprised of 
three different mechanisms, which include the growth of arterioles (arteriogenesis), the sprouting of existing 
capillaries (angiogenesis), and the de-novo development of capillaries (neo-vasculogenesis)143, 393, 293. To 
investigate whether one or more of these mechanisms are supported by dietary NO3- the vascular bed of hind 
limbs was analyzed by immunofluorescence. 
Figure 34. Representative immunofluorescence photographs of arterioles in the hind limb.  
A, B, and C demonstrate a comparison of three examined collectives. In all groups arterioles could be 
identified, but no quantitative differences are visible. Arterioles were counted independent from size. Columns 
represent the three different groups (A = control; B = NO3-; C = MoW). The rows contain pictures of one staining 
(I = FITC+ (SMA-α); II = UV+ (DAP/nuclei); III = merged). Magnification, x 200. 
 
To visualize the Arteriogenesis in addition to the shown angiogenesis (2.4.4), smooth muscle cells were 
stained with SMA-α in the thighs of the mice. Three examples, including the collective control, NO3- and MoW 
illustrate the staining and the indifference between the groups (figure 34). Whereas figure 34 visualizes the 
arterioles qualitative, figure 35 provides quantitative information. After NO3- supplementation arteriole density 
tended to increase compared to controls (control: 3.1±0.7 SMA-α+ vessels/mm2; NO3-: 5.9±1.6 SMA-α+ 
vessels/mm2; MoW: 3.8 ±1.2 SMA-α+ vessels/mm2) but without significance (ANOVA and Bonferroni post-test, 
ns, p = 0.25). 
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Figure 35. Arteriole density in ischemic hind limbs. 
Paraffin slides of the thigh were stained with immunofluorescent and SMA-α+ 
vessels counted. No significant change in arteriole density after dietary NO3- could 
be detected (ANOVA and Bonferroni post-test, ns, p = 0.25). Data are given as 
mean ± SEM (n = 7). 
 
 
 
 
 
 
 
1.5 Inflammation 
1.5.1 inducible NOS 
Inflammatory processes are also responsible for a number of stem cell mobilizing pathways345. Furthermore, 
one sign of inflammation could be the up-regulation of iNOS with subsequent NO-dependent effects265, 428. Due 
to these mechanisms, immunofluorescent analyses were done to exclude an impact of inflammation on the 
seen effects, and to ensure that the mobilized stem cells were real Endothelial-regenerating cells and not 
inflammatory cells (CD45+), see also chapter 2.5.3. 
A first series of calf slides were stained for iNOS (see figure 36). The randomly chosen photographs illustrate 
the indifferent low distribution of iNOS in all three groups. Quantification of iNOS expression confirmed the 
impression of the pictures. There is no difference between control, NO3-, and MoW mice concerning iNOS 
expression (shown in figure 37). Levels of iNOS+ cells range from 30.8±6.3 cells/mm2 (control), to 30.3±10.1 
cells/mm2 (NO3-), and 28.9±7.4 cells/mm2 (MoW) (ANOVA and Bonferroni post-test, ns, p = 0.99). 
Figure 36. iNOS expression in ischemic muscle tissue. 
Representative photographs demonstrate that neither NO3- supplementation nor MoW treatment changed the 
iNOS expression in the ischemic hind limbs. I The first row shows the green iNOS staining. II The second row 
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presents blue DAPI+ nuclei. III Finally, the third row unifies the merged pictures. The columns represent the 
different groups (A = control; B = NO3-; C = MoW). Magnification, x 200. 
 
Figure 37. iNOS expression after hind limb surgery.  
Leukocyte count in the regenerating muscle measured by iNOS 
expression is rare seven days after surgery and independent of dietary 
NO3- and MoW (ANOVA and Bonferroni post-test, ns, p=0.99). Data are 
given as mean  SEM (n=6-10). 
 
 
 
 
 
 
 
 
1.5.2 Lymphocytes (CD45) 
Endothelial-regenerating cells were defined as CD45-, therefore CD45+ leukocytes could be quantified 
separately, too. The representative photographs in figure 38 demonstrate the equal low numbers of CD45+ 
leukocytes detected in the examined collectives. An ANOVA with Bonferroni post-test corroborates the 
impression, that inflammation has no impact (ANOVA and Bonferroni post-test, ns, p=0.2) presented in figure 
39 associated with absolute values. In control mice 3.7±1.1 cells/mm2 were counted, in NO3- animals 5.8±1.3 
cells/mm2 were detected, and in MoW mice were 3.3±1 cells/mm2 stained. 
Figure 38. Number of CD45+ leukocytes in ischemic hind limbs.  
Representative photographs demonstrate that neither NO3- supplementation nor MoW treatment changed the 
amount of CD45+ leukocytes in the ischemic hind limbs. I The first row shows the red CD45 staining. II The 
second row presents blue DAPI+ nuclei. III Subsequently, the third row encloses the merged pictures. The 
columns represent the different groups (A = control; B = NO3- treted; C = MoW). Magnification, x 200. 
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Figure 39. Leukocyte count in murine hind limbs after induction of ischemia.  
In all examined samples, independent from supplementation or treatment, the number of CD45+ leukocytes lay 
beyond 15 cells per millimeter (ANOVA and Bonferroni post-test, ns, p=0.2). Data are given as mean  SEM 
(n=10-11). 
1.6 Paracrine Mediators and Angiogenic Chemokines 
1.6.1 Endothelial-Regenerating Cells and Stem Cell Mobilising Chemokines 
Probably, NO does not mobilize Endothelial-regenerating cells directly, but does so through a cytokine cascade. 
To test the impact of chemoattractors, plasma and tissue samples were tested for their levels. Endothelial-
regenerating cells are mobilized from BM139. Accordingly, the stem cell factors GM-CSF and G-CSF were 
analyzed. Furthermore, Endothelial-regenerating cells are known to act pro-angiogen differentiate into EC, 
because of that, VEGF was tested as well as SDF-1 α. The experimental set-up limited the number of points in 
time for taking blood samples, so all samples were gained on day 7. 
GM-CSF and G-CSF are known stem-cell mobilizing factors156, but in the actual study neither an impact on 
GM-CSF nor on G-CSF by NO3- or MoW could be detected. Figure 40 shows that the levels of GM-CSF were 
equally distributed (control: 43.1±0.6 pg/ml; NO3-: 46.9±1.1 pg/ml; MoW: 43.9±2.7 pg/ml; ANOVA and 
Bonferroni post-test, ns, p=0.18). Similarly, the G-CSF levels remained constant, but with a slight trend to 
amplification after NO3- supplementation (control: 160.5±25.7 pg/ml; NO3-: 293±69.5 pg/ml; MoW: 176.4±79.3 
pg/ml; ANOVA and Bonferroni post-test, ns, p=0.22). 
Next, pro-angiogen and Endothelial-regenerating cells -mobilizing known factors were examined (presented 
in figure 40). VEGF is one the most potent angiogenic cytokines393, 351 and SDF-1α is the most prominent factor 
for Endothelial-regenerating cells release365, 327. However, no significant increase of VEGF (illustrated as ratio 
from the ischemic and the non-ischemic leg) was measured (control: 1.3±0.2 pg/ml; NO3-: 1.6±0.3 pg/ml; MoW: 
1.1±0.1 pg/ml; ANOVA and Bonferroni post-test, ns, p=0.33). 
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Solely SDF-1α was significantly augmented after a 14 d lasting supplementation with dietary NO3- (control: 
0.2±0.04 ng/ml; NO3-: 0.4±0.05 ng/ml; MoW: 0.3±0.04 ng/ml; ANOVA and Bonferroni post-test, ns, p=0.09; *, 
control vs. NO3-).Figure 40. Ccytokines tested on their impact in hind limb ischemia after dietary NO3-.  
A and B Both, the stem cell factors GM-CSF and G-CSF were equally distributed independently from 
supplementation or treatment (GM-CSF: ANOVA and Bonferroni post-test, ns, p=0.18; G-CSF: ANOVA and 
Bonferroni post-test, ns, p=0.22). C The same counted for the pro-angiogen growth-factor VEGF (ANOVA and 
Bonferroni post-test, ns, p=0.33). D SDF-1α increased significantly from control to NO3- mice (ANOVA and 
Bonferroni post-test, ns, p=0.09; *, control vs. NO3-). Data are given as mean  SEM (n = 3 - 10). 
1.6.2 sFasL as paracrine Mediator 
Another aim of the study was the evaluation of the paracrine potential of Endothelial-regenerating cells. 
Besides the examined chemokines in 2.7.1 the Fas/FasL pathway appeared to be a promising candidate, 
because FasL acts pro-apoptotic as well as proliferative429. To date, it is unknown if Endothelial-regenerating 
cells express membrane-bound FasL (mFasL). Accordingly, by FACS analysis the Endothelial-regenerating cells 
were quantified and analyzed for mFasL expression. Indeed, figure 41 revealed that Endothelial-regenerating 
cells expressed mFasL. Moreover, this expression seemed to be influenced by dietary NO3-. In the control group 
a mean FasL expression of 39.1±5.6% was detected, which was significantly depleted to 15.4±3.6% after NO3- 
supplementation (ANOVA and Bonferroni post-test, **, p=0.007; **, control vs. NO3-) and subsequently 
increased after extra MoW treatment to 29.9±5.9%. 
Consequently, an ELISA was performed to detect systemic variations in soluble FasL (sFasL) plasma levels 
mirroring the shift in mFasL expression (see figure 41). Basal levels of sFasL were determined and compared 
with levels from control and NO3- mice. Basal levels lay by 30.8±1.9 pg/ml. After surgery a significant increase 
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of sFasL was observed (ANOVA and Bonferroni post-test, ***, p=0.0003, *, basal vs. control; ***, basal vs. NO3-
), but without significant difference between the control and the NO3- mice (control: 125.5±28.1 pg/ml; NO3-: 
156.5±32.4 pg/ml). 
Figure 41. FasL expression on Endothelial-regenerating cell membranes and circulating in plasma.  
A Every third Endothelial-regenerating cell of control mice expressed FasL on its surface. This expression was 
significantly modified by NO3- supplementation, lowered to about the half. MoW treatment again augmented 
the expression, but without reaching significance (ANOVA and Bonferroni post-test, **, p=0.007; **, control vs. 
NO3-; n=18-20). B Ischemia augmented sFasL levels, but this increase was not significantly progressed after 
dietary NO3- (ANOVA and Bonferroni post-test, ***, p=0.0003, *, basal vs. control; ***, basal vs. NO3-; 
n = 17 - 23). C This figure extends the charts of figure 29 B. FasL was determined in the population of double 
positive MNC, referred to as Endothelial-regenerating cells. Data are given as mean ± SEM. 
1.7 XOR mediated Reduction 
In addition to the bacterial NO3- reduction, a mammalian NO3- reduction is discussed. Recently, a Swedish 
group postulated the identification of this mammalian NO3- reductase as the Xanthine oxidoreductase (XOR)23. 
In the actual set-up the cytoprotective effects were abolished by antiseptic MoW, indicating the bacterial 
reduction as major mechanism. However, in some cases inhibition was not complete, which could be an 
indicator of a second reductive process. The current work was not focused on this issue, but first started 
experiments concerning this hypothesis. 
In the beginning, like for the control, NO3- and MoW groups, the NOx metabolism was analyzed for AP 
(Allopurinol supplemented) mice. Allopurinol as inhibitor for the XOR was given to the drinking water ad 
libitum. Figure 42 summarizes the results. Indeed, systemic NO3- levels (47.7±6.2 µM), measured in non-
ischemic tissue, decreased significantly after AP supplementation (Mann-Whitney test, *, p=0.03). 
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In contrast, NO2- levels were unaltered systemically, but locally changed. The local shift was determined by 
calculating the difference between the ischemic and the non-ischemic tissue (presented as percentage change 
from non-ischemic tissue). In control mice, NO2- increased about 45±18%, but nearly no increase was measured 
after AP supplementation (7±15%). Instead of this, measured decrease was not significantly (Mann-Whitney 
test, ns, p=0.09) different from NO-heme levels, which differed significantly (Mann-Whitney test, *, p=0.02). 
Altogether, the same pertained for NO-heme as for NO2- delta: they were increased in control (7778±2379%) 
and unaltered in AP mice (163±125%). 
Figure 42. NOx metabolism determined after XOR inhibition.  
A Systemic NO3- levels were significantly decreased after XOR inhibition (Mann-Whitney test, *, p=0.03). B 
Regarded locally, NO2- levels were unchanged by AP inhibition, but diminished in contrast to the control group 
(Mann-Whitney test, ns, p=0.09). C NO-heme levels remained constant after AP supplementation, in contrast 
to the increase in control mice (Mann-Whitney test, ns, p=0.02). Data are given as mean ± SEM (n=4-5). 
 
In the next step the mRNA expression of XOR and its activity in the muscle were tested, shown in figure 43. 
Both, expression and activity were diminished by dietary NO3- supplementation. Expression was significantly 
downregulated to 0.34 (NO3-) (calculated by REST© by a Pair Wise Fixed Reallocation Randomisation Test and 
S.E. estimation via a Taylor algorithm, normalized to control, *, p=0.01, SE range = 0.214-5.41)275. 
The markedly active XOR in control mice (14,800±2255 µU/ml/mg) was significantly inhibited by AP 
(4510±898 µU/ml/mg) and inclined to decrease after NO3- supplementation (9757±1780 µU/ml/mg) (Kruskal-
Wallis test and Dunn’s post-test, *, p=0.046; *, control vs. AP). 
Finally, the impact on regeneration was determined with similar assays as for NO3- supplementation. The low 
impact of XOR inhibition on NO2- and NO-heme, and the negative effect of NO3- supplementation on expression 
and function of XOR, revised the expectations. Indeed, no measurable effect could be detected in regeneration 
of perfusion, Endothelial-regenerating cell levels, and in apoptosis (see figure 44). The perfusion ratio remained 
unaltered in AP (61±4%) animals compared with control mice (t-test, ns, p=0.79). Parallel, Endothelial-
regenerating cell levels in whole blood were unaffected by AP supplementation (0.05±0.01% MNC) (Mann-
Whitney test, ns, p=0.26). Finally, the apoptotic ratio rested at the levels of control mice after XOR inhibition 
(187±45%) (t-test, ns, p=0.79). 
Results  
 65 
Figure 43. Expression and function of XOR in ischemic muscle.  
A mRNA expression analysis by Real-Time PCR revealed a significant downregulation in NO3- animals (calculated 
by REST© by a Pair Wise Fixed Reallocation Randomisation Test and S.E. estimation via a Taylor algorithm, 
normalized to control, *, p=0,01, SE range = 0.214-5.41). B Parallel, an enzymatic assay measured a reduction in 
activity after NO3- supplementation. This reduction was confirmed by a significant reduction after AP 
supplementation, which affirmed the functionality of the assay and the success of AP supplementation 
(Kruskal-Wallis test and Dunn’s post-test, *, p=0.046; *, control vs. AP). Data are given as mean ± SEM 
(n = 3 - 5). 
Figure 44. Impact of XOR on regeneration after induction of ischemia.  
A Perfusion measured seven days after surgery was not decreased after AP supplementation (t-test, ns, p=0.79; 
n=10). B Additionally determined Endothelial-regenerating cell levels remained constant (Mann-Whitney test, 
ns, p=0.26; n=8). C In the end, the apoptotic ratio was unaffected by AP (t-test, ns, p=0.79; n=4). Data are given 
as mean ± SEM. 
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2. Clinical Studies 
In the following, the results of two descriptive, clinical studies will be described. Both were performed in close 
cooperation with the clinic, combining two goals. The participating clinicians gained deep insights into different 
imaging tools and possibilities of new molecules as diagnostic or prognostic markers (not presented here) and 
information concerning the NO metabolism in ischemia was collected. The results were published in two 
manuscripts including the clinical data276, 277. The following paragraphs focus on the NO metabolism and 
associated pathways, molecules, and cells.   
2.1 Serial Measurements of Whole Blood NO2- in an Intensive Care setting276 
NO is one of the most important vasodilators in the cardiovascular system280, therefore the question arose 
whether its’ metabolites, NO2- and NO3- could be used as markers for cardiovascular health. Kleinbongard et al. 
revealed an association between plasma NO2- levels and a number of risk factors for endothelial dysfunction5. 
The current work was designed to extend this work to the collective of seriously ill patients in an intensive care 
setting and NO2- in whole blood. The patient population consists of patients of the intensive care unit 
(University hospital Aachen, department of cardiology, pneumology, and angiology) and is characterized in 
table 10. Only patients who got NO-donating drugs or who showed symptoms of refractory shock were 
excluded. 
Blood samples were taken for 10 days every morning. Afterwards, the highest NO2- levels were determined. 
These maximum levels were grouped in low CK-MB level (<3.7(female)/6.7(male) µg) and high CK-MB level 
(>3.7(female)/6.7(male) µg), representing “no damage” or “myocardial damage”. Separated like this, the mean 
NO2- levels differ significantly with 432±95 nM for low CK-MB level and 200±53 nM for high CK-MB level (Mann-
Whitney test, *, p=0.039). Results are presented in figure 45. A cut off value like this has been also looked for in 
other tested parameters, but only with CK-MB and NO2- did an association between parameter and NO2- 
emerge. 
Figure 45. NO2- levels of seriously ill patients separated by CK-MB levels. 
Patients with low CK-MB levels (no myocardial damage) had significantly higher NO2- levels than patients with 
high CK-MB levels (myocardial damage) (Mann-Whitney test, *, p=0.039). Data are given as mean ± SEM 
(n=14+13). 
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Table 10. Patient characteristics.  
Population enrolled at the intensive care unit in February 2007. (BMI = body mass index) 
2.2 New techniques in cardiac imaging and diagnostic of the ischemia/reper-
fusion-injury in the acute myocardial infarction277 
The results of the first study gave insights into the importance of NO in myocardial infarction, leading to an 
expanded series of experiments, embedded in a study concerning new imaging and diagnostic tools of the 
ischemia/reperfusion-injury.  
Study population consisted of STEMI (ST-segment elevation myocardial infarction) patients received PCI 
(pericutaneous coronary intervention) within 12 h after symptom onset. From this moment, the patients were 
observed for one week, and three bloods, and echocardiographic analyses, and one CMR (cardiovascular 
magnetic resonance) examination to trace regeneration of myocardial function, inflammation, and NO 
metabolism (explained in figure 46) were carried out. 
Table 11 summarizes the patient characteristics. Only first-infarctions were included and as expected, the 
group was composed mainly of elderly men with a conglomeration of risk factors, but only rare pre-existing 
conditions. Most infarctions occurred in the RCA (right coronary artery) and were cured with Stent 
implantation. 
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Figure 46. Study set up. 
Patients were enrolled in the study if PCI took place within 12 h after symptom had onset. Before PCI the first 
blood sample was drawn, echocardiographic examination followed within 2 h after PCI. The second series of 
analyses happened 24 h later and the last examination, including CMR test, was done on day six before 
discharge. (3DE = three dimensional echocardiography; 2DE = two dimensional echocardiography; 
ceEcho = contrast-enhanced Echocardiography; CMR = cardiovascular magnetic resonance; PCI = Percutaneous 
coronary intervention; ICU = intensive care unit). 
Table 11. Patient characteristics of the STEMI collective. 
Patients were excluded if symptom onset amounted to more than 12 h infarction and the occluded artery was 
not closed for the first time. Data are given in percentage terms or as mean ± SEM. (BMI = Body mass index; 
CAD = coronary artery disease; PCI = Percutaneous coronary intervention; CABG = coronary artery bypass graft 
surgery;   GP = glycoprotein; LAD = left anterior descending artery; LCX = left circumflex artery;  RCA = right 
coronary artery; BMSE = bare metal stent; DES = Drug Eluting Stent; TIMI = Thrombolysis In Myocardial 
Infarction; CK = creatine kinase; CK-MB = creatine kinase myocardial band). 
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2.2.1 NO Metabolism 
Similiar to the first study, NO metabolites were analyzed. However, NO3- and NO2- levels of STEMI patients 
remained constant over the observation period, as shown in figure 47 (Repeated measured ANOVA and 
Bonferroni post-test; NO3-: ns, p = 0.26; NO2-: ns, p = 0.69). NO3- levels ranked between 30.04±3.6 µM (0 d), 
25±3.4 µM (1 d), and 26.7±2.7 µM (6 d). NO2- levels started with 143±29 mM (0 d), rose to 1689±33.9 nM (1 d), 
and stayed at 163±25.8 nM (6 d). 
Figure 47. NO3- and NO2- levels determined in patients suffered from a STEMI. 
A NO3- levels lacked a difference within the first week after the ischemic event (Repeated measured ANOVA 
and Bonferroni post-test, ns, p = 0.26). B In parallel, NO2- levels remained constant (Repeated measured ANOVA 
and Bonferroni post-test, ns, p = 0.69). Data are given as mean ± SEM (n = 22-25). 
 
2.2.2 Endothelial-Regenerating Cells and Chemokines 
As the presented animal study revealed an association between NO3- and Endothelial-regenerating cells, level 
of KDR+CD34+ cells in whole blood were also determined in the clinical setting (figure 48). Endothelial-
regenerating cell levels of STEMI patients remained low from the beginning (0.08±0.02 % MNC) to the end 
(0.09±0.02 % MNC) of the observation period. After a lapse of 24 h, levels did not exceed 0.07±0.02 % MNC and 
remained low after six days (0.09±0.02 %MNC) (Friedman test and Dunn’s post test, ns, p = 0.77). 
Subsequently, two cytokines associated with inflammation and Endothelial-regenerating cells were analyzed. 
Shown in figure 49 A-D are SDF-1α, a known mobilizing cytokine, and NAP-2, which activates adhesion of 
neutrophiles. SDF-1α even decreased on admission (1739±60.1 pg/ml) and declined further significantly within 
the first day (1522±48.9 pg/ml), but rose to 2077±90.8 pg/ml at day six (Repeated measured ANOVA, ***, 
p < 0.0001; **, 0 d vs. 1 d; **, 0 d vs. 6 d; ***, 1 d vs. 6 d). In comparison, the levels of CAD patients were 
determined (2077±90.8 pg/ml), which were significantly augmented in contrast to the minimum SDF-1α level in 
STEMI patients (t-test; ***, p < 0.0001). Instead, NAP-2 level seemed to be elevated while infarction 
(2420±512.4 pg/ml) and diminished in the following (1 d: 1485±352.3 pg/ml; 6 d: 946.7±198.4 pg/ml). The 
decline to day six was significant (Repeated measured ANOVA, *, p<0.012; *, 0 d vs. 6 d). They corresponded to 
the levels determined in CAD patients (1405±183.5 pg/ml), which were significantly lower than the elevated 
levels in STEMI patients on day 0 (t test, *, p = 0.04). 
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Figure 48. Endothelial-regenerating cells determined by FACS.  
Endothelial-regenerating cells were stained as fast as possible after blood 
taking. At all points in time levels show similar niveau (Friedman test and 
Dunn’s post test, ns, p=0.77). Data are given as mean ± SEM (n=13). 
 
 
 
 
Figure 49. Cytokines in the context of 
cardiovascular disease.  
A and D SDF-1α level decreased 
significantly in the course of infarction and 
tended to increase to the level of CAD 
patients within one week (Repeated 
measured ANOVA, ***, p < 0.0001; **, 0 d 
vs. 1 d; **, 0 d vs. 6 d; ***, 1 d vs. 6 d; t-
test; ***, p < 0.0001, CAD vs. 1 d). B and C 
NAP-2 level were significantly augmented 
in STEMI patients, decreasing in six days 
towards the level measured in CAD 
patients (Repeated measured ANOVA, *, 
p < 0.012; *, 0 d vs. 6 d; t test, *, p = 0.04, 
CAD vs. 0 d). Data are given as mean ± SEM 
(n = 18-29). 
 
 
 
 
 
 
 
 
2.2.3 Inflammation  
It is known that PCI leads to the ischemia/reperfusion (I/R) injury125. Indeed, the reperfusion of the infarcted 
heart, leads to a second injury, which impairs the heart aggravating the damage of the infarction. One of the 
mechanisms, which is involved in this process, is inflammation. Therefore, several participating parameters 
were determined. Figure 50 presents the most important mediators TNF-α, IL-6, and CRP.  
TNF-α levels were elevated in the first sample (7.7±0.6 ng/l). The continued increase over the observation 
period (8.5±0.7 ng/l (1 d); 9.4±0.8 ng/l (6 d)) reached significance after six days (Repeated measured ANOVA 
and Bonferroni post-test, *, p = 0.01; **, 0 d vs. 6 d).  
In contrast, IL-6 reached its peak after 24 h (2.7±0.2 ng/l) and begun to decrease after 6 d (2.2±0.2 ng/l). The 
variable started with 1.5±0.2 ng/l on admission, rising significantly, tested with a parametrical analysis after 
transforming the data into their natural logarithm (Repeated measured ANOVA and Bonferroni post-test, ***, 
p < 0.0001; ***, 0 d vs. 1 d; *, 0 d vs. 6 d; *, 1 d vs. 6 d). 
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Similarly, CRP (transformed to its natural logarithm) rose after 1 d (from 1.4±0.2 mg/l on admission to 
2.7±0.2 ng/l after 24 h), but stayed elevated after six days (2.2±0.2 ng/l). Variance analysis revealed significance 
(Repeated measured ANOVA and Bonferroni post test, ***, p < 0.0001; ***, 0 d vs. 1 d; ***, 0 d vs. 6 d). 
Figure 50. Time course of TNF-α, IL-6, and CRP over six days after myocardial infarction. 
 A TNF-α elevated within the first hours of infarction, rising continuously during the following week (Repeated 
measured ANOVA and Bonferroni post-test, *, p = 0.01; **, 0 d vs. 6 d) B IL-6 increased after 24 h with a fast 
subsequent decrease (Repeated measured ANOVA and Bonferroni post-test, ***, p < 0.0001; ***, 0 d vs. 1 d; *, 
0 d vs. 6 d; *, 1 d vs. 6 d) C CRP levels were augmented after 24 h, but stayed elevated (Repeated measured 
ANOVA and Bonferroni post test, ***, p < 0.0001; ***, 0 d vs. 1 d; ***, 0 d vs. 6 d). Data are given as 
mean ± SEM (n = 32-37). 
 A second series of blood samples was taken from CAD (coronary artery disease) patients before PCI as 
control (figure 51). Unexpectedly, TNF-α levels of CAD patients were significantly increased (14.8±1 ng/l) in 
contrast to the levels of STEMI patients on admission (t-test, ***, p < 0.0001). However, IL-6 level were 
significantly diminished in CAD patients (1.2±0.1 ng/l) (t-test, ***, p < 0.0001). Similarly, the CRP levels of CAD 
patients (0.2±0.2 ng/l) were compared to the peak levels in STEMI patients (1 d) elucidating a significant 
decrease (t-test, ***, p < 0.0001). 
Figure 51. TNF-α, IL-6, and CRP levels of CAD patients in comparison with STEMI patients.  
A TNF-α levels were significantly increased in CAD patients (t-test, ***, p < 0.0001). B and C IL-6 and CRP levels 
were significantly decreased (t-test, ***, p < 0.0001). Data are given as mean ± SEM (n = 26-32).  
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Discussion 
NO3- is a ubiquitous molecule. People avoid ingesting too much of it in soda. Nevertheless, only a minority 
really knows why NO3- levels are regulated by the administration, and how manifold NO3- sources – exogene 
and endogene are. The current work tries to rescind some of the reservations showing that supplementation 
with dietary NO3- could strengthen regeneration after an acute event of hind limb ischemia and that this 
supplementation increases the level of NO whose balance is potentially disturbed in ischemia. In science,it was 
considered, for a long time, that NO3- was toxic, carcinogen, and had low reactivity. In the one-way street of NO 
metabolism it was the blind end without turning area. Moreover, in contrast to NO2-, which was used as a 
marker for NO, NO3- could not be used in this context, because of its high suggestibility by nutrition.  
Studies from the forties46 demonize NO2- but also NO3- to be toxic causing methemoglobenia. More recent 
work discussed the carcinogen potential of NO2- and NO3- by the reaction of NO2- with secondary amines to 
nitrosamines. However, analyzing these articles, data are inconclusive and questionable; the results concerning 
methemoglobenia are true, but exaggeratedly presented and not adapted to the situation19,53,57,60,64,70,279. It is 
improbable that dietary NO3- could influence adult NO2- levels in a toxic way, because NO2- and NO3- are 
currently produced endogenously. For NO3- to be toxic, it has to be reduced to NO2-, but up to 70 % of ingested 
NO3- is excreted (on average 67.3 mg/day from 104 mg/day, meaning that only 36.7 mg/day NO3- are absorbed 
and available to be metabolized to NO2-). In addition, 1 mg/kg NO3- are produced endogenously every day (e. g. 
80 mg/day for an 80 kg man). Instead of this, only 1 – 2 g NO2- is considered to be acute toxic. Just the adult 
methemoglobin-reductase will experience problems to detach NO2- from haemoglobin, permitting the binding 
to O2, which finally leads to methemoglobemia. Only in babies, whose methemoglobin-reductase is not as 
active as the adult one, should the NO2- and NO3- intake be restricted53. The carcinogen potential of 
nitrosamines is generally accepted, but epidemiological studies analyzing potential associations between NO3- 
and NO2- consumption and cancer are controversial. Michaud et al. found no connotation between NO3- or 
NO2- intake and tumor growth70. In conclusion NO3- was considered to be an inert molecule without benefit, 
but only risks. Recent work has shed new light on NO2-, discovering it as NO reservoir available in ischemia, and 
there are considerations to broadcast this concept on NO3-, which would be refillable by healthy diet! Why 
would this be useful? NO is one of the most potent vasodilators and signaling molecules in the cardiovascular 
system, but has a very short half-life and must be produced permanently280. However, in ischemia regular NO 
synthesis is impaired, because O2 is a necessary cofactor for eNOS, the NO synthesizing enzyme117. Thus, under 
these conditions an oxygen independent NO synthesis is needed, which could be attained by reduction of NO3- 
to NO2-, and further to NO. Orally ingested NO3- is reduced in the oral cavity by bacterial nitrate reductase281. 
Resulting NO2- arrives circulation, tissue, and stomach where it is further reduced to NO by acidic and 
enzymatic reduction. Indeed, patients with atherosclerosis show diminished NO2- levels, lacking enough 
endogenous NO2- to fulfil the NO demand282. Therefore, a controlled high intake of NO3- could have the 
potential to intervene in the progress of disease. 
To develop guidelines and beneficial strategies, the mechanisms behind a protective effect should be 
investigated. Vasodilatation initiated by NO occurs by activating the GC, which produces cGMP280, but it is 
unknown whether the same reaction is responsible for cytoproctection mediated by NO2- derived NO in 
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ischemia. It is known that stem cells and cytokines act protective by pro-angiogenic reactions. One of the most 
prominent populations is the group of Endothelial-regenerating cells. They leave their stem cell niche in BM, 
enter circulation and migrate into the ischemic tissue. In vitro studies could show that this chemotactic 
migration is supported by NO80. Arrived there, Endothelial-regenerating cells differentiate into EC mediating 
angiogenesis and neo-vascularization. Whether Endothelial-regenerating cells build up capillaries by itself, or 
secrete angiogenic factors supporting vascularization, is a matter of debate179,180,187,283. Many studies in the last 
decade investigated the paracrine potential of these progenitors, showing that Endothelial-regenerating cells 
transmit hematopoietic and angiogenic effects145,284, depress oxidative Stress179, and influence inflammatory 
responses181. The question arose by which pathway Endothelial-regenerating cells in hind limb ischemia 
operate. The Fas/FasL pathway was discovered as a death-receptor pathway initiating apoptosis285. However, 
recent work could show that this pathway is not as unidirectional as was originally thought. A membrane-
bound and a soluble form of the receptor and the ligand could be distinguished and particularly the sFaL 
molecule supports proliferative effects. 
Clinical studies confirmed that the mentioned processes and factors are impaired in cardiovascular disease. 
Thus, this specific combination of activators, progenitor cells, and pathways seems to be convenient to aid in 
cardiovascular disease, offering a promising target for beneficial intervention. 
Indeed the current work presents an approach to increase regeneration in ischemia by dietary NO3- 
supplementation and evaluates NOx metabolism, Endothelial-regenerating cells, and angiogenic cytokines in 
severe ill patients. It could be shown that in ischemic disease, NOx metabolites are diminished and that a 
nutritional supplement of NO3- is able to fill the lacking mediating regenerative effects. Furthermore, the data 
show that the protective effects of NO3- are associated with an increase in Endothelial-regenerating cells, which 
express FasL. The illustration in figure 52 summarizes the proposed mechanism of protection mediated by 
dietary NO3-.  
Figure 52. Cytoprotection augmented by dietary NO3-.  
In the oral cavity, orally ingested NO3- is reduced to NO2-. The accrued NO2- is metabolized further to NO by 
hemoglobin in erythrocytes and myoglobin in skeletal muscle tissue. Subsequently, Endothelial-regenerating 
cells are mobilized from BM and migrate into the ischemic tissue mediated by the originated NO. Finally, the 
Endothelial-regenerating cells support invigoration of vascularization and protection of muscle progenitors. The 
strengthened capillary network delivers new O2, which increases endogenous production of NO by eNOS. 
Moreover, initiating this pathway the synthesized NO reenters the circuit supporting regeneration. The model 
does not claim to be complete, but only summarizes the stations which were analyzed in the current work.  
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1. NO Bioavailability is Replenished by Dietary NO3- 
The first idea to increase endogenous NO level is to medicate with NO, of course. However, NO is a very 
instable molecule, which is only chemical-bond obtainable. Recent work could show that hemoglobin and 
myoglobin are able to reduce NO2- to NO under hypoxic conditions24,32, and NO2- is an ubiquitous molecule in 
food and water. Nevertheless, it could be problematic to administer NO2- because of its toxicity and the 
suspicion that it contains carcinogen53,286. Considering that, the presented work favored to deliver NO in the 
form of NO3- in drinking water. Indeed, NO3- is reduced to NO2- too, but the fact that one additional reaction is 
needed, that about three quarter of ingested NO3- are directly excreted, and that NO3- usually is a component 
of “healthy” foods lessen the inappropriate concern about NO3-. Another advantage of dietary NO3- is the 
redundancy of pills and injections, avoiding the problem of complications and compliance. 
Figure 15 illustrate that, in a mouse model a 14 d-long administration of NO3- in drinking water amended 
endogenous NOx-levels without influencing constitution. A subpopulation of animals was held separately and 
daily food and water consumption as well as weight were controlled, confirming autonomy of dietary NO3-. 
Additionally, quantitative and qualitative determination of oral flora affirmed the success of inhibiting bacterial 
NO3- reduction by antiseptic mouthspray, presented in figure 14. Hence, MoW treatment was established as 
suitable negative control.  
NO metabolites were determined in healthy and ischemic animals. It was expected that NO levels in 
ischemic animals were decreased in comparison to the levels in healthy animals.  
Indeed, figure 19 C compares NO2- levels of healthy and ischemic mice. Independent from collective the 
ischemic levels were significantly lower, supporting the hypothesis of a lack of NO in ischemia. Subsequently, 
clinical studies could show that ischemia also has a strong impact on NO2- levels276, which is discussed below (5. 
NO Balance is disturbed in Ischemic Syndromes). 
In relation to NO2- plasma concentrations in control animals, shown in figure 19 B, it could be proposed, that 
ischemic levels even decline under basal levels. Additionally, in figure 17 A (NO3- levels) and B (NO2- levels) all 
collectives (basal, control, NO3-, MoW) are contrasted with each other before induction of ischemia. The bar 
graphs prove that endogenous NO3- and NO2- levels were increased by enhanced ingestion of dietary NO3-. NO2- 
levels show, that this dietary NO3- is reduced to NO2- and forwarded into circulation by commensal bacteria in 
the oral cavity, proven by the abolishing of the process by antiseptic MoW. The effect which could be seen 
after MoW could be ascribed to the drug, but could not be ascribed to the spraying.  Surprisingly, NO3- levels 
were diminished after MoW treatment. Since MoW treated mice could not metabolize and recycle NO3- it must 
circulate unchanged. Thus, missing NO3- in plasma, urine and feces were analyzed. Feces levels were negligible 
and indifferent (data not shown), as confirmed by literature22. The same accounts for NO2- levels in urine, 
which could be disregarded22 and, indeed, levels remained unchanged, independent from supplementation or 
treatment (figure 18 B). In contrast, urinary NO3- levels obviously increased after NO3- supplementation and 
MoW treatment (from about 1500 µM to > 9000 µM). Physiological NO3- levels in human urine fluctuate 
between 250-2000 µM22 elucidating a huge range. Therefore, urinary levels could not be used as sensitive 
marker for NO metabolism or bioavailability, but intake could be estimated22,287–289. Indeed, the results shown 
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in figure 18 A illustrate a significant increase in NO3- concentrations after NO3- supplementation, but no 
difference between the two collectives supplemented with NO3-. Amplification in NO3- and NO2- levels after 
NO3- supplementation should also be corroborated after induction of ischemia. Instead of this, the data shows 
that the extra parameter – ischemia – augmented variance and diminished levels in such a manner that, NO3- 
levels after NO3- supplementation and MoW treatment were significantly augmented, compared to the 
concentrations in control mice. However, no difference could be determined between the NO3- and MoW 
groups, shown in figure 18 A. Moreover, no difference in NO2- levels could be detected (figure 18 B). 
Next, NO3- and NO2- levels were determined in tissue (figure 20 A and B). Overall, the increasing effect of 
dietary NO3- is blurred, but nevertheless the NO3- group had the highest NO3- level, declined after MoW. 
Considering elevated ischemic NO2- levels, it became clear, that NO2- is accumulated in ischemic tissue in 
comparison to healthy control tissue (muscle tissue from the non-operated leg). Additionally, this difference is 
significant in NO-heme data, suggesting a reduction to NO, shown in figure 20 C. Summarized, the data 
illustrate that dietary NO3- is reduced to NO via NO2-and arrives at regions of demand. However, the effect is 
not as clear as it is before the induction of ischemia and in plasma. Fo this reason, ischemia represents an 
additional parameter and a loss of NO metabolites from plasma to tissue. Finally, the levels of protein-bound 
NO were determined and displayed in figure 20 D. Without supplementation, RNNO and RSNO levels were 
separated in two halves amounting to 50 %, and this proportion remained relatively constant after NO3- 
supplementation. The levels seemed to be higher and a bit postponed to more RNNOs, but huge variance 
hampered a statistical analysis and a clear statement.  
Furthermore, cGMP levels were determined. In the endothelium, NO activates the sGC which produces 
cGMP280. Thus, increased cGMP levels suggest increased NO level and mechanistic action via the sGC. However, 
the cGMP data in figure 21 does not differ between the various groups. Seemingly, under these conditions NO 
acts via another pathway. These results confirmed a former study, in which a pro-angiogenic effect of NO2- was 
analyzed81.  
2. Dietary NO3- Augments Regeneration in Hind limb Ischemia 
2.1 Perfusion and Necrosis 
Aim of the present work was not only to show, that dietary NO3- is suitable to enhance NO bioavailability, but 
also to prove the beneficial effect of ischemia. Over the last decade, much research was done recognizing a 
beneficial potential of the NO metabolites NO2- and NO3-. Duranski et al. and Bryan et al. suggested a benefit of 
dietary NO2- in liver ischemia and I/R injury84,85. Furthermore, in a model of hind limb ischemia i. p. injected 
NO2, attained an increased regeneration in relation with angiogenesis81. Subsequently, several studies could 
determine an impact in host defense and protection from gastric ulcer17,281,290. Finally, a blood-pressure 
lowering effect of dietary NO3- was shown281. All finished studies proposing a beneficial and cytoprotective 
effect of NO metabolites laid the foundation for the present work. Here, the approach of dietary 
supplementation and a model of chronic ischemia were combined. NO3- was chosen instead of NO2- because of 
its lower toxicity. PAD and chronic ischemia as model were preferred, as the long-term goal is an early 
intervention, preventing severe acute events like an infarction. Indeed, figure 22 A illustrates that dietary NO3- 
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amplified regeneration in a significant, physiologic relevant manner. The bar chart shows that through dietary 
NO3- an improvement of regeneration of about 15 % is achieved. The presentation of representative LDPI 
pictures in figure 22 B before and seven days after surgery clarifies that perfusion remained low in control and 
MoW mice, in contrast to the enhanced perfusion after NO3- supplementation.  
Overall, regeneration appears to be relatively low, but the results have to be regarded along with other 
studies. Comparison of papers in literature show great differences, dependent on mouse strain. Many studies 
used the C57BL/6J strain for experiments, which is characterized by a well regeneration81,265,291–294. On the 
other hand, a series exists in which impaired strains were used like immunodeficient mice159. In the present 
work, the NMRI strain was chosen; a mouse with less regeneration than the C57BL/6J strain but healthy in 
contrast to e. g., nude mice. This, in health and regeneration, intermediate strain seemed to be best 
transferable for PAD. Besides, the impairment of transgenic or immunodeficient mice, the differences are 
probably attributable to diverse vessel architectures295. However, no literature is known to analyze the 
architecture for NMRI mice, but genealogy shows the narrow relationship to CD1 mice, thus a similar vessel 
architecture could be suggested296,297. This outbred strain shows a mixture of the two extreme types Balb C and 
C57BL/J6, reflected in regeneration capacity. Balb C mice show many independent vessel trees with no 
connection to neighboring ones, hampering regeneration. In contrast, C57BL/J6 mice have one big vessel tree, 
in which many neighboring collaterals are able to compensate for a deficiency. Scheme in figure 53 tries to 
visualize the principle variation. Additionally, differences in immune system are responsible. C57Bl/J6 mice 
show much more lymphocytes than BalbC mice, which is reflected in better regeneration in C57Bl/J6 mice240. 
Figure 53. Visualization of vessel architecture in C57BL/J6 and Balb C mice 
The operative site of the used NMRI strain is shown, but overlaid circles should demonstrate the different 
vessel architectures in C57BL/J6 and Balb C mice. Every circle denotes a vessel tree, different colors strengthen 
the independency of the single trees. In the C57BL/J6 strain one vessel tree subserves a big area of the leg. In 
contrast, in the Balb C strain many single vessel trees exist, every one responsible for a small tissue area. The 
scheme is not anatomically correct, but should clarify the principle, transferring the results from the murine m. 
spinotrapezius to the murine hind limb295. 
 
Furthermore, varieties in surgery lead to different results261,294,298. Under current conditions the chosen 
strain regenerates to about 60 %, which includes LDPI measurements until seven days after surgery. The 
12 week old, male mice were held in groups including BM-transplanted animals. Although maximum 
regeneration is not obtained after seven days, this point in time was chosen to plan experiments to be as short 
as possible and as long as needed. Indeed, after seven days a significant improvement in perfusion could be 
detected. In other set-ups, no difference emerged after seven days159 or disappeared after longer observation 
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periods265. In general, the huge interindividual differences have to be considered, which are even bigger in 
outbred strains like NMRI than in inbred strains like C57BL/J6292. 
In addition to perfusion, necrosis was determined as a second outcome parameter. In total, 63.6 % of the 
mice developed necrosis, although average percentage for the control and MoW groups was above this (65 % 
and 77 %), whereas the NO3- mice showed lower levels (48 %). Overall, necrosis was common but minor in 
most cases (necrotic toes but no dead leg), which appeared to be the reason for lacking significance. The 
mouse strain influences the results, if another mouse strain had been analyzed the results could be different. 
Taking that into consideration, the results are quite good.  
After induction of a severe ischemia in a healthy animal, an improvement of perfusion by 15 % could be 
achieved by dietary NO3- supplementation which more often than not is the decisive factor of necrosis. 
Increased perfusion and reduced necrosis leads to the salvage of the leg, which mainly means protection of the 
skeletal muscle299–302. Although the skeletal muscle is one of the most ischemia resistant tissues, a severe lack 
of O2 engenders in necrotic and apoptotic cells, including satellite cells244,246,303,304. These are stem cells, 
activated by trauma or ischemia, differentiate into myoblasts and hence, are responsible for muscle 
regeneration254,256,305,306. Mauro et al. discovered the satellite cells in 1961254, but it has only been clear since 
the 1990’s, that really satellite cells are mainly responsible for regeneration, supported by BM-derived stem 
cells after severe damages257,307. Parallel studies focused on a definite characterization of this heterogeneous 
population255,257,308 and the evidence that satellite cells are real stem cells with the potential to self-renewal307–
312. 
Due to this, in ischemia it should be a goal to protect the satellite cells. Thus, to get an image of regeneration 
capacity of the skeletal muscle after dietary NO3- supplementation, coming as close as possible to the in vivo 
status, isolation and direct ex vivo analysis of satellite cells was established313,314. Necrosis was determined by 
the presented macroscopic score, thus satellite cells were analyzed for apoptosis. Meanwhile, it is known that 
satellite cells become necrotic and apoptotic too244,246,303,304. However, it is a matter of debate by which 
pathway apoptosis is mounted and conducted247–249. Therefore, a TUNEL assay was chosen, detecting all 
apoptotic cells by fragmented DNA, irrespective of initiating stimulus and underlying pathway.  
Concerning the skeletal muscle, the role of myoglobin in dietary NO3- mediated regeneration is taken into 
account. Two recent studies show increased muscle apoptosis in myoglobin over-expressing mice, suggesting a 
detrimental role for myoglobin, explained by its NO-scavenging function315,316. However, both studies used a 
transgenic mouse model (Mb+/+) for analysis in comparison to wild-type mice. This strain shows a less dense 
capillary network316, potential trigger for the results. Additionally, transgenic mice are often weaker than their 
wild-type littermates. Instead of this, a work from our laboratory evaluated a protective role of NO2- in I/R 
injury mediated by a NO2- reduction function of myoglobin32. Moreover, this study stated that under hypoxic 
conditions myoglobin prefers to reduce NO2- than to scavenge NO32. In a parallel study of van Weel et al. ,it was 
proposed that VEGF increased myoglobin expression supports regeneration after hind limb ischemia317. Indeed, 
actual results show, that necrosis is reduced by dietary NO3- supplementation (figure 23) and further work of 
our laboratory also show a significant reduction of apoptosis431. The analysis demonstrates that necrosis 
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increases in response to ischemia, evaluated by the increased necrosis in control mice. However, in NO3- mice 
necrosis is diminished. Subsequently, this protection is reduced after MoW treatment. Only in the presence of 
functional myoglobin, which can reduce NO2- to NO effectively, does this protective reaction becomes possible. 
The hypothesis presented included this reaction, which is further increased by a positive feedback, in the case 
of satellite cell protection. Viable satellite cells account for new muscle fibers, expressing more myoglobin, 
expanding NO2- reduction.  
Summarized, investigation of necrosis corroborated the protective effect of dietary NO3- on muscle tissue. In 
addition to the increased perfusion, the results illustrate that the affected tissue is protected. 
2.3 Arteriogenesis and Angiogenesis 
The mentioned protection of satellite cells and subesquent improved regeneration is probably attributable to 
two mechanisms. First, bioactivated NO acts as paracrine transmitter directly mediating muscle protection by 
activation of signal transduction pathways or stimulation of protective acting cells, which will be discussed 
later. Secondly, the muscle is supported by improved nourishment, accomplished by augmentation of arteriolar 
and capillary network. Indeed, much works concerning the hind limb model focused on investigation of 
vascularization under diverse conditions and after several treatments81,177,224,300,302,317–321.    
Vascularization includes three different mechanisms of vessel synthesis. In the thigh, origin of the 
conductance arteries of the leg, occlusion and ischemia increases shear stress inducing arteriogenesis 293,318. 
This process is triggered by shear stress, which leads to an outgrowth of small arterioles to arteries143,318. 
In ischemia, as in hind limb model, loss of one major artery is followed by increased shear stress in 
neighbouring arterioles. To pick up increased blood flow these arterioles grow out to arteries. Thus, it is 
undisputed that in hind limb model, arteriogenesis is a major mechanism restoring perfusion234,293, 
nevertheless, results are controversial. Therefore, it is unclear if increasing arteriogenesis is a promising target 
to improve regeneration. Apart from many studies, which ignore arteriogenesis81,261,265,302,317, there are works 
showing no difference in arteriogenesis dependent on treatment315,321,322. On the other hand, in many studies 
positive effects on arteriogenesis could be initiated177,224,323. To explain these differences in results, one has to 
distinguish between the effects of treatment317,322,324, and the detrimental effects of disease234,318 or knock-out 
genes177,315,323. Studies using knock-out models are always difficult to interpret and to transfer to humans, 
because effects of a knock-out are often pleiotrop and do not imitate human diseases. Hidden compensatory 
effects additionally influence results. Such studies give important insights into concerning mechanisms, but can 
not simply be translated into treatment recommendations. Studies with immune impaired or diabetic animals 
could also be problematic. Immunodeficient animals do not show physiological reactions, which has to be 
considered for interpretation325. Diabetes promotes the development of PAD, as a result many diabetic 
patients suffer from PAD, but not all PAD patients have diabetes. Both are forms of PAD, but with different 
origins leading to different treatment strategies. Interpreting results in literature against this background of 
arteriogenesis seems to be influenced by inflammation238 and induced by shear stress, which activates 
eNOS177,318. Furthermore, significant differences could be detected by analyzing different strains and different 
ages of mice295,326. Finally, it is not the absolute number of arterioles that seems to be the optimal parameter 
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for analysis rather the size168,324,327 and seems not to be a promising target for therapy in otherwise healthy 
mice317,322. The present work could not show differences in arteriole density (figure 34 and 35). Dietary NO3- 
delivers NO independently from eNOS, probably initiating different pathways, which is why no eNOS 
dependent effects could be detected. Also, eNOS does not seem appropriate for treatment, because this 
enzyme does not work without O2, as in ischemia. Moreover, after treatment, no substantial inflammation pre-
exists after seven days (figure 36-39), which is needed for considerable arteriogenesis238. Additionally, the LDPI 
results suggest a CD1-like vessel architecture, with minor arterioles able to grow-out to arteries295. 
In the calf, other mechanisms of vascularization dominate. Here, the capillary network is solidified by 
angiogenic processes293. In the adult organism, new capillaries are formed by the sprouting of existing capillary 
networks (angiogenesis) or de-novo vessel formation (neo-vasculogenesis)143. These most analyzed parameters 
in hind limb ischemia seem to be promising targets for increasing regeneration as they are associated with 
tissue preservation and reduced necrosis and susceptible by dietary supplementation223,261,265,317,320,328,329. 
Moreover, many studies suggest an association between NO and angiogenesis81,226,234,330–332. Thus, in the 
present work it was hypothesized that dietary NO3- increases angiogenesis, which could be confirmed. Figures 
32 and 33 demonstrate a profound increase in CD31 positive endothelial cells. After NO3- supplementation the 
amount of EC detected was twice as high as that found in control legs were and this angiogenic effect was 
abolished by antiseptic MoW. To exclude the counting of false positive inflammatory cells, staining was 
combined with the leukocyte marker CD45 (EC were defined as CD45-CD31+), and the photographs in figure 30 
and the bar graph in figure 31 present the  analysis of CD45- cells.  
Kevil et al. suggest an impact on ICAM expression in endothelial cells by NO, positively influencing its 
polarity331, but most analyses stopped at the level of NO, and do not investigate by which mechanisms NO 
promotes angiogenesis. Murohara et al. wrote that the detailed processes “remained enigmatic”226, Kumar et 
al. and Katayama et al. only converse on the “NO-pathway” and the numerous positive effects on EC81,330. The 
present work tried to close this gap to some degree. Apart from treatment with known angiogenic factors, e. g. 
VEGF, therapy with stem cells is one of the major research issues in this field. The 1997 discovered EPC show 
potential to differentiate into EC and to incorporate into sites of ischemia138, and research focused on this 
population. Based on recent work, in this work the population is called Endothelial-regenerating cells144. In 
2005 our laboratory could demonstrate a direct proliferative and moblizing effect of NO on EPC136, and in 2008 
a NO-dependent pathway was suggested in the pro-angiogenic, EPC-mobilizing function of pleiotrophin137. 
Recently, the chemotactic response from Endothelial-regenerating cells on chemokines was combined with a 
chemokinetic response on NO80. Taken together, in the current study it was hypothesized that dietary NO3- 
supports angiogenesis by indirect mobilisation of Endothelial-regenerating cells.  
3. Endothelial-Regenerating Cells are Mobilized by Dietary NO3- 
3.1 Endothelial-Regenerating Cells in Plasma and Tissue 
Already in 1998, it was postulated that angiogenesis is an eNOS dependent process; impaired in eNOS-/- mice, 
and blocked by NOS-inhibitors in WT mice226,227. It was concluded that defective eNOS, referred to endothelial 
dysfunction, is responsible for disturbed angiogenesis in CAD. However, it is a debatable point whether 
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promoting eNOS (with its substrate L-arginine e. g.) would be an effective treatment, because of the essential 
cofactor O2, which is lacking in ischemia. Aicher et al. analyzed the reduced angiogenesis in eNOS-/- mice from 
another point of view, discovering that it is due to depressed Endothelial-regenerating cells mobilization177. 
Moreover, in 2005 a first relation to CAD patients was found. Increased plasma levels of the endogenous NOS 
inhibitor ADMA correlated with decreased EPC mobilization, function, and differentiation333. Additionally, in 
diabetes mellitus, which is a known risk factor for CAD, EPC are reduced in a NO-dependent manner229,334. 
Therefore, attempts were done to strengthen the EPC-NO axis, but independently of eNOS. Asaki et al. treated 
mice with infrared light daily for five days, which increased angiogenesis and regeneration in hind limb 
ischemia significantly79. However, such therapy seems to be very time-consuming and therefore difficult to 
transfer to patients. Thum et al. increased NO levels medicinally with organic nitrates in rats and humans233. 
Even treatment with benfotiamine (vitamine B3 derivate) obtained valid results234. Other approaches include 
hyperoxia and treatment with angiogenic cytokines (e. g. SDF-1α)335. However, all medicinal treatments need 
high compliance by patients. Thus, the positive impact of moderate intake of red wine on EPC and NO was 
investigated in vitro, and in vivo in an animal model and a clinical study (healthy volunteers)72,225. A second 
study, focusing on nutrition, tried to increase Endothelial-regenerating cells level with Stem-Kine (Aidan 
Products, Chandler AZ)336. However, neither alcohol (although in moderate dimensions) nor an expensive food 
supplement seem to be ideal for sustained support, different from dietary NO3-.  
To determine the impact of dietary NO3-, in the present work CD34+KDR+ and DilacLDL/UEA positive cells, 
isolated from MNCs were analyzed as described by Asahara et al.138 and redefined as Endothelial-regenerating 
cells (and CFU-EC) by Prater et al.144. In figure 25 and 26 representative photographs of the culture and the 
characterizing staining with Dil-acLDL/UEA are exposed. Following characterization quantification was done 
with FACS, gating all mononuclear cells (figure 27 B). Bar graph in figure 27 A elucidates a fourfold increase in 
Endothelial-regenerating cells in blood after NO3- supplementation. Subsequently, it should be investigated, 
whether Endothelial-regenerating cells migration is also improved by dietary NO3-. Therefore, BM-
transplantation was established and controlled by blood smear (figure 29). Leukocytes of transgene GFP+ mice 
are fluorescence green. Blood smear analysis proves similar fluorescence by GFP+-BM transplanted mice. Next, 
transplanted GFP+ cells even could be discovered and characterized as Endothelial-regenerating cells after 
differentiation in tissue, by its GFP-fluorescence in combination with the endothelial marker CD31 and the 
exclusion of leukocytes by a negative CD45 staining. Figure 30 and 31 illustrate that dietary NO3- 
supplementation increased the number of Endothelial-regenerating cells in tissue threefold. The mobilization 
of Endothelial-regenerating cells is increased and the migration into ischemic areas is also increased after NO3- 
supplementation. In conclusion, it could be revealed that dietary NO3- increases Endothelial-regenerating cells, 
plasma and tissue levels, indicating amplified number and function of the cells. Through corroborating 
literature79,80,136,137,226 it could be assumed that NO3- is reduced to NO, increasing its bioavailable levels, 
subsequently mediating mobilization and chemokinesis on Endothelial-regenerating cells. Moreover, Heiss et 
al. showed that chemokinetic function of NO possibly initiates a positive feedback loop in Endothelial-
regenerating cells, which are able to independently produce NO 80.  
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Further effects including, increased survival, diminished apoptosis, enhanced dispersal and adhesion direct 
referable to the NO3--NO- Endothelial-regenerating cell axis could be supposed but still need to be investigated. 
One cell can not fulfil all these functions by replacing damaged cells. Nonetheless, many of such cytoprotective 
effects were seen after improving Endothelial-regenerating cells function or number, which was why the 
paracrine capacity of Endothelial-regenerating cells was analyzed171,179,180,337,338. In ischemia we have different 
sides of hypoxia, the necrotic core and the border zone. The border zone includes necrotic and apoptotic cells, 
unsalvageably damaged, but also injured cells, which could be preserved. As a consequence, such tissue need 
a) a mechanism that destroys the necrotic cells and remove its residues, b) a process able to recognize 
damaged cells and initiate apoptosis (if it is not initiated by endocellular pathways), and c) a mechanism which 
supports injured cells to survive and the tissue to regenerate. The following paragraphs will examine this 
question, discussing paracrine suggestibility and potential of Endothelial-regenerating cells.  
3.2 Inflammation 
Briefly, inflammation has two important functions, first to recognize and destroy pathogens and secondly to 
remove remnants of pathogens or dead cells339. Thus, the occurrence of inflammatory processes was 
presumed, but two analyses should give an insight in the extent of these processes in hind limb ischemia. To 
determine inflammation directly in the affected tissue, and to get a quantifiable parameter, 
immunofluorescent analyses were chosen. iNOS and CD45 positive cells were stained in the lower ischemic leg.  
The inducible NOS originally cloned in macrophages, is expressed in various cell types including endothelial 
cells, smooth muscle cells, and cardiac myocytes340,341. Different from the constitutive expressed eNOS, iNOS 
expression is induced by special stimuli, initiating inflammation, respectively342,343. Thus, the number of iNOS 
expressing cells in the ischemic leg should give an insight into the extent of inflammation seven days after 
induction of ischemia. Additionally, a big iNOS expression should have an impact on the NO level in the tissue, 
influencing outcome and interpretation of NOx analyses.  
The actual work shows that iNOS expression is low seven days after surgery (figure 36). In healthy limbs iNOS 
expression is rare but detectable, and multiplied in acute inflammation344. In comparison, cell counts of about 
thirty cells per millimeter (figure 37) indicate a persisting inflammation but also in abeyance. Additionally, 
levels remained constant independently from supplementation or treatment, confirming that dietary NO3- has 
no influence on inflammation and no impact on enzymatic iNOS-derived NO. Furthermore, to exclude false 
positive results in capillary density and Endothelial-regenerating cell migration analyses, slides were also 
stained with CD45. This control staining was interpreted solely, to use the possibility to determine the number 
of leukocytes in the injured tissue, by extending iNOS analysis. Despite transplantation and surgery, leukocyte 
levels were low (after 7 d), presented in figure 38 and 39, corroborating iNOS analysis. Besides, these results 
are important for interpretation of the results for capillary density (CD31 staining in figure 32 and 33). Levels of 
CD31 positive cells differ a lot in literature222,224 and were rather low in the current work. It could be assumed, 
that CD31 expression differs based on the inflammatory status of the tissue. The second name of CD31 – 
PECAM (platelet endothelial cell adhesion molecule) – identifies the marker as adhesion molecule, whom 
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expression is increased in inflammation to enable adhesion of leukocytes345. Following that, the presented 
rather low levels of CD31 positive EC refers to a low inflammatory state.  
3.3 Angiogenic Cytokines 
After analyzing inflammatory processes, responsible for detritus removing, mechanisms for regeneration and 
survival remained enigmatic. Protective and proliferative effects could be mediated by cytokines, mobilising 
immune and progenitor cells. Besides, these cytokines could be secreted by Endothelial-regenerating cells 
itself179. This implies that increased cytokine levels portend to augmented mobilization of Endothelial-
regenerating cells and amplified secretion of cytokines by this cell population.  
GM-CSF and G-CSF are stem-cell mobilizing factors regulating hematopoiesis and are thus potential 
Endothelial-regenerating cell mobilizing molecules346. Indeed, a clinical study showed a protective effect of 
GM-CSF treatment in AMI347. However, in the present study no increase of GM-CSF and only a trend to 
increased levels after NO3- supplementation in G-CSF levels were determined (figure 40 A und B). As the 
outcome in the present study was determined one week after induction of ischemia, these analyses were done 
seven days after surgery. Probably, the impact of GM-CSF and G-CSF finds expression at an earlier date of 
ischemia346 and that is the reason why no association could be detected here and in other studies327.  
VEGF, discovered in the eighties of the last century, is a growth factor mediating angiogenesis348–351. In 
addition, VEGF attracts Endothelial-regenerating cells to sides of ischemia80,146. After transplantation 
adenoviruses encoding VEGF-D angiogenesis is improved in diabetic rabbits and increased VEGF-D expression is 
detectable six days after transplantation352. In the hind limbs of ischemic mice injected with myoblasts 
expressing VEGF, increased levels of the growth factor were determined three days after surgery353. In 
addition, this study focused on the distribution of VEGF in tissue, suggesting an impact of allocation on success 
of angiogenesis353. In samples of infarct patients, VEGF could only be detected in muscle biopsies but not in 
plasma354. Subsequently, VEGF levels were determined in muscle tissue from ischemic hind limbs. Figure 40 C 
illustrates the measurement. The rather low levels lack a significant increase after NO3- supplementation, 
showing only a trend to it. Possibly, VEGF is acting following the stem cell markers GM-CSF and G-CSF, but good 
data is not available to support this hypothesis. Another explanation could be that, the compartment in which 
VEGF was measured was sub-optimal for determination differences in VEGF concentration353.  
Finally, SDF-1α levels were analyzed in plasma. This chemokine induces mobilization of BM-derived 
progenitor cells355, by reversing its gradient356,357. Normally, SDF-1α is produced by BM stromal cells in high 
concentration358,359, retaining BM progenitor cells in their BM niche360. In ischemia this gradient is disrupted 
and concentration rises in the target tissue attracting BM cells into it356,357. Moreover, animal and clinical 
studies proposed a protective effect of SDF-1α in ischemia173,361–364. The important role of SDF-1α in 
Endothelial-regenerating cell mobilization became obvious365,366. Indeed, results (figure 40 D) elucidate a 
significant increase in SDF-1α plasma levels after dietary NO3- supplementation. Thus, SDF-1α results 
corroborated and amplified the trend seen for G-CSF and VEGF to significance. After MoW treatment, SDF-1α  
tended only to decrease back to basal levels, probably, because of taking blood samples. SDF-1α is a 
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chemotactic factor, which attracts Endothelial-regenerating cells to sides of ischemia via a positive gradient 
with a suggested maximum concentration in the ischemic tissue.  
However, in the clinical study a drop of SDF-1α level in STEMI patients, 24 h after infarction was detected 
(figure 49). How does that match to the data in the animal study? The results of the STEMI patients gave an 
insight in the complexity of SDF-1α regulation. As mentioned above, in a healthy state, SDF-1α adheres 
Endothelial-regenerating cells in their niche by maintaining a positive gradient with high concentrations in the 
BM360. Under pathological conditions like ischemia, this gradient is reversed to mobilize Endothelial-
regenerating cells to the side of ischemia, with the need of increased plasma levels in comparison to BM, but 
with maximum in tissue. Apparently, this gradient is build up in CAD patients, and maintained after induction of 
acute ischemia, and perpetuated beyond the acute phase. It is proposed, that within this period, a narrow 
timeframe exists, in which the gradient is shifted extremely to the side of ischemia, and this shift leads to 
decreased plasma levels 24 h after infarction in STEMI patients, compared to admission, discharge (6 d), and 
seven days after surgery in the hind limb model. In parallel, the animal study compared collectives, not at 
different points of time, illustrating an impact of dietary NO3- on SDF-1α levels. In summary, all these cytokines 
support Endothelial-regenerating cells and thus angiogenesis, but there remains the question of which process 
or factor supports the muscle? The muscle needs mechanisms and pathways able to detect apoptotic cells and 
to promote survival. Recent studies show that the Fas/FasL pathway could perform both250, 367–370. Of course, 
one pathway communicating with a cell in both directions appears to be ideal to accomplish this demand. 
3.4 Endothelial-Regenerating Cells Express FasL  
Apoptosis in contrast to necrosis occurs physiologically. During the so called programmed cell death, mutated, 
senescent or damaged cells were eliminated without producing toxic cell detritus, initiating inflammation 371. In 
principle, two different ways to start apoptosis exist. In the intrinsic or mitochondrial pathway the cell itself 
commits suicide, in contrast to the extrinsic way, which is started by other cells via death receptors372. The 
Fas/FasL system belongs to the TNF superfamily and therefore to the family of death receptor 
pathways285,369,373,374. FasL is mostly expressed on T-cells. One of the more important functions of FasL is to 
eliminate autoreactive T-cells369,370. Otherwise, the ubiquitous expression of Fas presumes multifaceted 
functions of this pathway369,370,375. Beyond the classical function of inducing apoptosis, non-apoptotic 
mechanisms regulated by Fas/FasL were discovered376. There are results describing an impact in angiogenesis 
and inflammation, a supportive role in lympho- and erythropoiesis, and an upregulation of VEGF and MCP-1 in 
fibroblasts250,377–379. Tumor growth and invasiveness are increased by Fas/FasL380–382. The pathway could act 
regenerative in the nervous system383, but increases keratinocyte proliferation in psoriasis384. Endothelial 
overexpression of FasL reduces the I/R injury385 and the study by Date et al. emphasizes the differential role of 
membrane-bound (mFasL) and soluble FasL (sFasL) in I/R injury251. Besides the research focusing on different 
functions of membrane-bound and soluble forms of Fas and FasL, other works concentrated on the affected 
cell. They demonstrated that, the decision of death or survival is contingent on the status of the cell386,387. This 
result supports the hypothesis that, in ischemia the Fas/FasL pathway could be the pathway of choice to 
manage apoptosis and regeneration in variably severe damaged cells.  
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It is known, that FasL is expressed on immunomodulatory cells, but it could be shown that it is also 
expressed on CD34+ cells388 and on EC367. Therefore, the expression of FasL on Endothelial-regenerating cells, 
which originated from hematopoietic CD34+ stem cells, and are able to differentiate into EC, seems probable. 
Indeed, current work could show for the first time that Endothelial-regenerating cells express FasL. This 
expression enables the progenitor cells to communicate with Fas-expressing muscle cells and myoblasts249. In 
detail, the results of the presented work demonstrates that about 40 % Endothelial-regenerating cells of 
control mice express FasL on their surface (figure 41 A). This expression significantly declined after NO3- 
supplementation, which could originate from downregulation or shedding. As literature suggests, a protective 
role for shed sFasL251, 367,389 plasma level of sFasL in ischemic mice was analyzed. Figure 41 B shows a significant 
rise in sFasL in ischemic mice, but only a trend to a further increase after NO3- supplementation. Although 
significance is missing between the ischemic groups, the increased plasma levels support the concept of FasL as 
important mediator of death and survival in ischemia, proposing an association. Accordingly, it is assumed that 
shedding of FasL is increased after NO3- supplementation, lowering FasL+ Endothelial-regenerating cells count 
in FACS measurement. Certainly, the low number of Endothelial-regenerating cells in total has to be involved in 
the interpretation of results. Consequently, three questions remained unresolved. Are Endothelial-
regenerating cells able to secrete sufficient amounts of sFasL to be measurable in plasma? Do both 
subpopulations secrete Endothelial-regenerating cells in the circulation and Endothelial-regenerating cells in 
the tissue sFasL, or only one of them? Finally, could sFasL have synthesized from such a rare cell population an 
impact on regeneration? 
Endothelial-regenerating cell levels in plasma were 0.1 %, and 3 – 4 cells/mm2 could be detected in skeletal 
muscle (control mice) (figure 27 and 30). Many scientists doubt that these low numbers of cells are able to 
deliver enough cells for successful capillarisation187, focusing on paracrine functions145,284,324,337. Acting as 
paracrine, one cell could influence the fate of a multitude of target cells. Subsequently, the current study 
hypothesizes a great importance on paracrine functions of Endothelial-regenerating cells, which must not 
preclude the direct support of neo-vasculogenesis by differentiation. Furthermore, it could be suggested that 
the reduced number of FasL+ Endothelial-regenerating cells after NO3- supplementation is related to the 
increased plasma level, indicating a secretion of FasL (in contrast to a decreased expression). Whether only one 
or both of the analyzed Endothelial-regenerating cells populations (in plasma and tissue) secrete FasL is 
secondary in this context, but should be analyzed in detail in future. 
Nevertheless, it has to be mentioned that the presented hypothesis is only one possible way for Endothelial-
regenerating cells to act paracrine. Endothelial-regenerating cells secrete various protective and angiogenic 
cytokines and molecules. A detailed cytokine array revealed a higher secretion of 108 from 174 tested 
cytokines in EPC, in contrast to human umbilical vein endothelial cells (HUVEC) presenting a great beneficial 
potential179. Cited work concentrated on the protection of endothelial cells against oxidative stress. The 
authors could show that in vitro HUVEC treated with EPC-derived conditioned medium are more resistant to 
oxidative stress than without treatment179. Two other works were focused on angiogenesis in ischemia. They 
proposed that the increased secretion and expression of the angiogenic (growth) factors VEGF, HGF, G-CSF, 
FGF, IGF, Ang-1, and SDF-1 promised a beneficial effect mediated via these humoral proteins145,337. 
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In conclusion, it could be shown that dietary NO3- improves regeneration in the ischemic hind limb by 
increasing Endothelial-regenerating cells in plasma and tissue. Furthermore, it could be recommended that 
these cells do not only differentiate into EC build up capillaries, but also mediate regeneration in a paracrine 
manner. The supplied evidence that Endothelial-regenerating cells express FasL and that this expression is 
regulated by dietary NO3-, could suggest that sFasL is one of the paracrine mediators secreted by Endothelial-
regenerating cells. 
4. The Impact of XOR on Reduction of NO3- in Ischemia   
The fact that, in oral flora NO3- reducing bacteria exist has been known for a long time390, 391, and thought to be 
the only option for mammals to reduce NO3-. However, recent work supposed a NO3- reducing function in the 
Xanthine oxidoreductase (XOR) representing first a mammalian NO3- reductase, described in 200823. The 
current work focused on dietary NO3- and its reduction in the oral cavity by bacteria. Therefore, antibacterial 
MoW was used as negative control, but single results in this group appeared to presume an “incomplete” NO3- 
reduction. One example is the SDF-1α concentration in figure 40. The significant worsening of the apoptotic 
rate in myoblasts, does not achieve control levels, despite the significant increase compared with NO3- mice. 
Similarly, SDF-1α concentrations were lowered after MoW, in contrast to the concentrations after NO3- 
supplementation, but failed to reach control levels. Several reasons could explain this phenomenon. Above all, 
antibacterial MoW kills most but not every single bacterium, which is why it is possible that remnants 
influenced results. This was shown in literature and confirmed here (figure 14)281,391. It is conceiveable that not 
all analyzed parameters are supported by NO3- or NO only, but also by other trigger factors. Thus, repression of 
NO3- reduction does not inhibit the complete reaction. An example for redundant pathways is mobilization of 
Endothelial-regenerating cells, which is regulated by a plethora of factors283,392,393. Finally, the possibility of a 
second, mammalian NO3- reductase exists! 
To get the first insights referring the last, hypothetical option, regeneration was analyzed after inhibiting 
XOR. A new collective of allopurinol (AP) supplemented mice was introduced, in which allopurinol depressed 
the reducing domain of the enzyme394, 395. Just as in the main experiments, NO metabolism was analyzed, 
determining NO3-, NO2-, and NO-heme tissue levels. The NO3- level (figure 42 A) decreased significantly after AP 
supplementation. Based on the proposed inhibition of NO3- reduction the NO3- concentrations had to be higher 
than in control mice. However, in common with the MoW group it is presumed that un-reduced NO3- is 
excreted in great quantities and not detectable in plasma or tissue. Figure 42 B shows the difference in NO2- 
levels between the ischemic and the non-ischemic leg. The left bar illustrates that, in control mice the NO2- 
levels are much higher in the ischemic than in the non-ischemic leg. In the AP group no increase of NO2- in the 
ischemic tissue was detected, possibly indicating a lack of NO3- reduction. The same applies for NO-heme level. 
In the control group, NO-heme concentration rose from about non-detectable (non-ischemic) to multiplies 
(ischemic), but remained constant in AP mice. The decreased NO3- tissue levels in AP animals as in MoW mice, 
and the lack of reduction-products of NO3- (NO2- and NO-heme) indicate that NO3- reduction could be inhibited 
by AP supplementation, and that XOR reduces NO3- in mammalian tissue. Additionally, the complex results of 
NO metabolites after NO3- supplementation and MoW treatment could be partly explained by this second 
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reductive mechanism (e. g. the lack of significance in decrease in NO2- and NO-heme levels in tissue after MoW 
treatment in figure 20 B and C). 
The second experimental XOR-series tried to determine, whether there is a relation between dietary NO3- 
supplementation and XOR function. Thus, we measured mRNA expression of XOR and activity in the ischemic 
tissue (figure 43). Both, expression and activity were repressed by dietary NO3-. It is recommended that, after 
dietary NO3- supplementation there is no need for XOR mediated NO3- reduction. The oral flora is activated in 
such a great manner, that the reductive function of XOR is dispensable. Otherwise in control mice, the demand 
of NO2- and NO is not covered by oral NO3- reduction, and XOR encourages the delivery of NO.  
The results describing regeneration and impact of Endothelial-regenerating cells after NO3- supplementation 
were unambiguous, which is why analysis after AP supplementation would be exciting. It was decided to repeat 
the three key experiments to show the outcome (LDPI measurement), the impact on Endothelial-regenerating 
cells by that indirectly on vascularization (Endothelial-regenerating cell quantification by FACS), and dimension 
of muscle regeneration (apoptosis in myoblasts). Not one of these analyses yielded a significant result. Indeed, 
data of control and AP mice were similar. In conclusion, it could be supposed that XOR is able to reduce NO3-, 
but this capacity is such low in contrast to the bacterial one, that it loses importance in severe ischemia. 
Perhaps, in local ischemic events, e. g. after small vessel lesions by trauma, XOR intervenes positively. Future 
research should work out this in detail.   
5. NO Balance is Disturbed in Ischemic Syndromes 
5.1 Impact of Inflammation and Endothelial-Regenerating Cells in AMI  
At a cardiologic intensive care unit most patients suffer from the most severe cardio-vascular diseases to 
cardiogenic shock. In the majority of these patients, the disease began with endothelial dysfunction and 
atherosclerosis. This impairment of endothelial function is associated with diminished NO bioavailability, 
although it is unclear, whether decreased bioavailability is the cause or result of the syndrome112–114,117,396–399. 
Reduced NO bioavailability refers to disturbed eNOS function119, 120, resulting from declined 
expression78,117,400,401 and destroyed enzymatic activity. Oxidative lipids such as oxLDL can uncouple eNOS, 
depleting its functionality, increasing synthesis and availability of arginase II, and eliminating the substrate for 
NO production117, 402–404. In turn, these processes potentate the negative effects with the production of reactive 
oxygen species and the conversion of NO to peroxynitrite by uncoupled eNOS117, 402–404. In addition, the 
inflammatory response also induced by oxidized lipids, progresses endothelial dysfunction leading to 
atherosclerosis117. 
Atherosclerosis aggravates over decades, with a worsening condition of the arteries. The first build up 
lesions initiate an inflammatory process in which the fatty streak originates. Lipids, cartilage, thrombi, and 
several inflammatory cells migrate to the lesion and deposit there affecting the intima of the artery. These 
atheromas narrow the lumen of the artery until no remodeling can compensate limited perfusion. If an 
ischemia (in peripheral arteries) becomes chronic, the patient becomes a PAD. Acutely, the nucleus of the 
atheroma could break up, circulate as thrombus, and occlude an artery. The patient suffers from a myocardial 
Discussion  
 87 
infarction, a stroke or similar acute event118. In case of a myocardial infarction, perfusion could be restored by 
blood thinners or by percutaneous intracoronary intervention (PCI). In the latter, perfusion is fast and as 
complete as possible reconstituted, but a second injury impairs regeneration. The ischemia-reperfusion-injury 
(I/R-injury) is characterized by the O2-paradox, the Ca2+-paradox, the pH-paradox, increased inflammation, and 
mitochondrial re-energization. Despite the need of O2, Ca2+, and restoration of pH, the sudden reaction triggers 
the injury by producing a transient overflow of these factors125. 
Many studies focused on reduction of this injury, but on the other hand an attempt can be made to prevent 
or at least to retard the initial acute event. In this regard, NO bioavailability comes to the fore. In an animal 
model of hypercholesteremia Mathew et al. show that NO bioavailability is decreased. They measured an 
impaired response to L-NMMA and a diminished eNOS expression in the coronary arteries405. The same group 
could present an association between oxidative stress and NO bioavailability. Basal NO release remained 
constant between patients with endothelial dysfunction and controls but,  in patients a local increase in 
oxidative stress markers, which influenced NO bioavailability was determined406. In addition, a previous study 
of our group, transferred the results to humans, showing a positive correlation between decreasing NO2- levels, 
as marker for NO bioavailability, and decreasing flow-mediated-dilation (FMD), as marker for endothelial 
function, after inhibiting eNOS activity407. Furthermore, a study from 2006 determined a negative correlation 
between increasing risk factors for endothelial dysfunction and decreasing NO2- levels in combination with 
decreasing FMD282. Finally, the presented animal study could also show that NOx levels are diminished in 
ischemia and that supplementation with dietary NO3- could increase regeneration in the hind limb model. Thus, 
an association between raising NOx level and regeneration could be assumed. 
The present work extends the results mentioned above to severe cardiovascular ill patients. In the first study 
patients from the intensive care unit were analyzed. The collective was separated into patients who suffered 
no or small myocardial infarctions and patients who suffered big infarcts by CK-MB level. Figure 45 elucidates a 
relation between CK-MB and NO2- levels. Patients with CK-MB concentrations > 3.7 (female)/6.7 (male) µg had 
significantly less NO2- circulating than patients with CK-MB levels < 3.7 (female)/6.7 (male) µg. In addition, this 
study confirmed that NO2- level also could be reliably determined in whole blood276. Thus, it is suggested that 
not only NO derived from endothelial NOS is involved in endothelial dysfunction but, also erythrocyte NOS 
originated NO, was discovered in our laboratory5. The second clinical study presented here focused on NO 
balance in I/R injury. Therefore, STEMI patients were enrolled in the study and blood was examined before and 
after PCI. The aim was to investigate whether NO2- levels further decline during STEMI and whether PCI had an 
additional impact on NO availability277. During the course of the study both NO3- and NO2- levels remained 
constant. This suggests that an impact on I/R injury is precluded, but not on STEMI. Parallel, the data showed 
that no regeneration of NO homeostasis occurred within one week after infarction, illustrated in figure 47. 
Moreover, the NOx levels were obviously overall low. The data collected in 2006282 ascertained NO2- 
concentrations of 351±13 nM for healthy persons and 171±29 nM for persons with four risk factors for 
endothelial dysfunction. Current data show NO2- levels of 143±29 nM, suggesting a further decrease of NO2- in 
acute cardiovascular events. Besides, the relation between NO2- level and inflammation had to be investigated, 
because inflammation is a hallmark of I/R injury125. It could be shown that suppression of inflammation 
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increases eNOS function, augmenting protein level and enzyme activity408. Furthermore, the eNOS promoter 
possesses a binding site for the inflammatory mediator IL-6, and with increased TNF-α level mRNA stability of 
eNOS is decreased409. Thus, it could be assumed that there is an association between NO2- and inflammatory 
factors. Therefore, the present work included the measurement of TNF-α, IL-6 and CRP from STEMI patients 
and CAD controls. Furthermore, the analysis of the neutrophile-activating peptide-2 (NAP-2) was added. This 
inflammatory, platelet-derived chemokine is known to influence angiogenesis and atherosclerosis410–412, but its 
function in STEMI remains open.  
Overall, TNF-α concentrations were increased, but in comparison to CAD patients the levels decrease after 
STEMI. These results sustain many studies lacking an increase in TNF-α levels and a deleterious effect of the 
molecule especially in animal models of AMI413–416. However, other studies let suppose a high increase of TNF-α 
in AMI347,417–419. Three cited reviews describe the problem of conflicting data concerning TNF-α420–422. In 
summary, the effects of TNF-α seemed to be pleiotrop. Additionally, TNF-α acts in a temporal and spatial 
manner. Together, these characteristics could lead to confusing results in individual, differential set-ups. 
Concerning this, more specific planned animal or in vitro studies are needed to explain the possible relation 
between NO and TNF-α. The present data reveal a chronic, systemic inflammation in CAD mediated by TNF-α, 
but not by IL-6 and CRP. Despite this, in STEMI this chronic reaction seemed to be replaced by an acute reaction 
supported by IL-6 and CRP. These two inflammatory mediators were low in CAD patients, but significantly 
increased in STEMI patients. Time course elucidated the well-matched interplay. Both, IL-6 and CRP rose until 
day 1 after infarction, but different to IL-6, which decreases subsequently towards admission level, CRP stayed 
elevated at least one week. These results amend the image of inflammation caused by I/R-injury. Supporting 
the data, the current study could show that NAP-2 was increased in STEMI in contrast to CAD patients. 
Immediately after admission the levels peaked, falling down to CAD level in the course of one week. Gained 
data refined the knowledge of inflammation in I/R injury and expanded it to the new fellow player NAP-2. 
Presumably, IL-6 and CRP do not acutely influence NO bioavailability. Despite this, chronic alteration of TNF-α 
and NO2- in parallel suggested a relation, which should be intensively analyzed in future studies.  
During inflammation different leukocytes were mobilized from BM to support the inflammatory process, but 
also to enhance regeneration. Within this heterogeneous group Asahara et al. discovered a progenitor cell 
(EPC), which is mobilized under ischemic conditions, involved in vascularization, and differentiates into 
EC138,138,139,139. With this in mind, EPC seemed to be predestined to mediate regeneration in cardiovascular 
disease. However, clinical studies demonstrated that with increasing risk factors and endothelial dysfunction 
EPC number decreases160, 165. Moreover, Werner et al. detected an inverse correlation between increasing EPC 
number and a lowered risk of death caused by cardiovascular events202. On the other hand, examinations of 
EPC in unstable angina or AMI detected an obvious elevation of EPC level in correlation with systemic 
inflammation199, 423 (but independent from PCI57), reflecting regeneration capacity166. Our laboratory postulated 
a relation between renamed EPC (Endothelial-regenerating cells) and NO levels in CAD80. Analyzed population 
should represent Endothelial-regenerating cells, an angiogenic population involved in vasculogenesis and 
angiogenesis144.  
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In the present study we found low Endothelial-regenerating cell levels over the whole observation period, 
confirming the suggestion that Endothelial-regenerating cells in patients with cardiovascular disease had 
decreased in number and function197. However, it is suggested that mobilization occurred, but was not 
detectable. A study from 2005 shows such an increase from low basal concentrations only has a limited 
regenerative capacity compared to SA (stable angina) patients and elderly, healthy controls166. 
Endothelial-regenerating cells were attracted to the ischemic tissue by chemokines, where one of the most 
prominent is SDF-1α327, 357, and in vitro studies confirmed the migratory effect on stem cells424. SDF-1α and its 
receptor CXCR4 are constitutively expressed in several tissues like BM and skeletal/myocardial muscle tissue422. 
But despite intensive research, data concerning the mobilizing mechanisms is controversial. Both, animal 
models and clinical studies suggest a mobilization of stem cells by elevation of plasma levels64,356,363. In 
contrast, another theory proposes that SDF-1α decreases in BM and increases in the tissue of demand more 
than in plasma173,357,361,362. Current data supports a second hypothesis, shown in figure 49. In plasma, STEMI 
patients had decreased SDF-1α levels compared to CAD patients. Moreover, the presented study revealed a 
drop of SDF-1α in a temporally narrowly defined manner, 24 h after infarction. Data presumes that SDF-1α 
levels are chronically increased in CAD, because of the current hypoxic stimulus. In the acute event, gradient  
shifts in favour of the infarct area, diminishing plasma concentrations.  
In conclusion, clinical studies presented here show that NO bioavailability is decreased in myocardial 
infarction. Besides, a relation between this deficiency and inflammation could be suggested. Moreover, the 
decreased NO bioavailability is associated with impaired Endothelial-regenerating cell mobilization. In future, 
therapeutic approaches should try to fulfil the NO reservoir to support the complex mechanism of regeneration 
in ischemia at its origin.  
6. Conclusions and Outlook 
Aim of the study was to analyze the beneficial potential of dietary NO3- in severe ischemia, carried by two 
pillars. First, the importance of NO homeostasis was shown in elucidating NO disturbance in patients suffering 
from AMI. Second, an animal study evaluated feasibility and efficiency of dietary NO3- as a nutritional 
supplement. Additionally, current work gave an insight in the mechanisms by which NO3- is reduced and acts.  
The pleiotropic signaling molecule NO has important functions in diverse organs from immune defense to 
act as neurotransmitter to the regulation of a plethora of functions in the cardiovascular system17,280,425,426. 
Subsequently, disturbances in NO homeostasis could lead to an impaired regeneration or a severe progress of 
disease117, and supplementation aimed to recover homeostasis should be promising. Even though NO is not the 
only and original cause of disease, NO imbalance is one of the first events in the progress of disease, e. g. in 
atherosclerosis caused by hyperlipidemia amongst other things. The lipids like oxLDL, uncouple eNOS and 
increase synthesis of arginase II, destroying functionality of the NO-synthesizing enzyme and its substrate for 
NO production117,402,404. Therefore, besides a change of life style, regulation of NO metabolism seems to be a 
promising target for therapy.  
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However, NO is a gaseous molecule with a short half life. Thus, deviates have to be found, “storing” NO in 
another chemical form. Its physiological oxidation products, currently endogenous produced by ourselves, 
were presumed to be ideal after discovering its reactivity24,32. Moreover, the reduction back to NO preferably 
occurs under ischemic conditions like atherosclerosis, PAD, or AMI24,32. Nevertheless, there are voices and 
guidelines which caution against toxicity and cancerogen potential of NO2- and NO3-, albeit with contradictory 
results53,57,279. Thus, NO3-, which is less toxic and more stable than NO2-, seems to be the most promising 
candidate. Besides tolerance, the compliance is an important quality of a drug, which is another advantage of 
NO3-. It is ubiquitous in diet and daily uptake could be easily increased by adapting composition of food.  
The present study underscores the dimension of NO imbalance beyond endothelial dysfunction. It is shown 
that in severe cardiovascular disease NO homeostasis is severely perturbed. Additionally, it is proposed that 
this imbalance stands in relation with increased inflammation, decreased Endothelial-regenerating cell 
mobilization, and SDF-1α concentration. Subsequently, the animal study supplied evidence that 
supplementation with dietary NO3- is feasible and able to modify NO metabolism in vivo. Moreover, dietary 
NO3- significantly improves outcome after severe hind limb ischemia. Perfusion was increased by parallel 
decreased necrosis, achieved by improved vascularization. The scheme presented in figure 54 summarizes the 
mechanism of protection by dietary NO3-. 
In detail, not only angiogenesis but also vasculogenesis are supported by dietary NO3-, mediated by 
increased Endothelial-regenerating cell mobilization. Furthermore, it could be assumed that Endothelial-
regenerating cells not only migrate into the ischemic tissue and differentiate into EC, but act paracrine 
protective to skeletal muscle tissue. For the first time it was determined that Endothelial-regenerating cells 
express FasL and that this expression is influenced by dietary NO3-. As growing evidence, implicit paracrine 
functions in Endothelial-regenerating cells179 delivers new support to this hypothesis, suggesting paracrine 
effects mediated by the Fas/FasL pathway. Recent data propose a proliferative role of FasL, in addition to its 
function in apoptosis376. Particularly, the shed sFasL is believed to act as an anti-apoptotic251,367. Thus, the 
decreased FasL expression on Endothelial-regenerating cells after dietary NO3- supplementation in combination 
with increased sFasL plasma levels, indicate a paracrine effect on the muscle tissue mediated by sFasL shed by 
Endothelial-regenerating cells. Subsequently, it is shown here that dietary NO3- has a protective impact on 
muscle tissue and thus myoblasts. It is presumed that the decreased necrosis of the tissue and diminished 
apoptosis431 is associated with improved vitality, augmenting regenerative capacity of the muscle. Thus, the 
current study present dietary NO3- as a feasible and potent method to combat against ischemia and gave 
insights into ensuing mechanisms. Further studies should focus on Endothelial-regenerating cells and its 
functions. Combinations of in vitro and in vivo studies could analyze the role of FasL expression. Its modulation 
by NO3- and its impact on the skeletal muscle, i. e. myoblasts, myocytes, and surrounding cells (e. g. fibroblasts 
and EC), would elucidate underlying mechanisms and additional beneficial options. 
Finally, the completed analyses concerning the produced NO, pave the way for further studies. For the 
development of therapeutic strategies underlying mechanisms have to be investigated in detail. The current 
results suggest that XOR mediated NO3- reduction does not have a great impact on severe ischemia and that 
endogenous NO3- production and reduction is not sufficient to neutralize NO imbalance and cover the demand. 
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Future work should try to close the mechanistic gap between NO3- and Endothelial-regenerating cells, analyzing 
whether how and via which pathways NO acts. In this context analysis of the impact of eNOS, XOR and 
endogenous NO should be intensified. 
Figure 54. Chemical reactions and involved factors in biocativation of dietary NO3-.  
Orally ingested NO3- is reduced to NO2- in the oral cavity by bacteria. Additionally, endogenous produced NO3- is 
concentrated in saliva and reduced, but not to the same extent as dietary NO3-. Reduction could also be 
performed by XOR in tissue, but is not the major mechanism. Incurred NO2- is further reduced to NO by 
hemoglobin in blood and myoglobin in muscle tissue. Subsequently, NO mobilizes Endothelial-regenerating 
cells from BM to circulation and tissue, supported by SDF-1α. Finally, the Endothelial-regenerating cells support 
invigoration of vascularization and protection of muscle tissue. Protective functions of Endothelial-regenerating 
cells are presumably mediated by FasL. The presented model raises no claim to completeness, but only 
summarizes the stations analyzed in the presented work. *NO2- is also reduced by XOR, protons, ascorbate, and 
polyphenols. §SDF-1α is one of several chemokines influencing mobilization of Endothelial-regenerating cells 
and secreted of them. 
 
Clinical studies which focus on the relation between NO and Endothelial-regenerating cells in severe 
ischemia could expand on the results obtained here in a sensible way. Possibly, long-term clinical studies could 
be commenced on CAD or PAD patients. By increasing their daily NO3- intake and observing the hopefully 
slower progress of disease and prevention of severe consequences (e. g. necrosis, amputation, or AMI), the 
results gathered here could be transferred to a clinic set-up. 
 
Bibliography  
92 
 
Bibliography  
1. Ignarro LJ et al. EDRF produced and released from artery and vein is nitric oxide, PNAS (1987). 
2. Bruckdorfer R. The basics about nitric oxide, Mol Aspects of Med 26, 3–31 (2005). 
3. Mayer B et al. Brain nitric oxide synthase is a biopterin- and flavin-containing multi-functional oxido-
reductase, FEBS Letters 288, 187–191 (1991). 
4. Nussler AK et al. Inflammation, immunoregulation, and inducible nitric oxide synthase. 
5. Kleinbongard P et al. Red blood cells express a functional endothelial nitric oxide synthase, Blood 107, 2943–
2951 (2006). 
6. Moroz LL et al. Parallel evaluation of NO signaling: Diversity of synthesis pathways, Frontiers in Bioscience, 
2008–51 (2011). 
7. Lundberg JO et al. NO Generation From Nitrite and Its Role in Vascular Control, ATVB 25, 915–922 (2005). 
8. Bryan N et al. Cellular targets and mechanisms of nitros(yl)ation: An insight into their nature and kinetics in 
vivo, PNAS 101, 4308–13 (2004). 
9. Lundberg JO et al. The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics, Nat Rev Drug 
Discov 7, 156–67 (2008). 
10. Lundberg JO et al. Roles of dietary inorganic NO3- in cardiovascular health and disease, Cardiovasc Res (2010). 
11. Spiegelhalder B et al. Influence of dietary nitrate on nitrite content of human saliva: possible relevance to in 
vivo formation of n-nitroso compounds, Fd Cosmet Toxicol 14, 545-548. (1976). 
12. Lundberg JO et al. Inorganic Nitrate is a possible source for systemic generation of nitric oxide, FRBM 37, 
395–400 (2004). 
13. Tannenbaum SR et al. The Effect of Nitrate Intake on Nitrite ormation in Human Saliva, Fd Cosmet Toxicol 14, 
549–52 (1976). 
14. Li H et al. Nitrate-Reducing Bacteria on Rat Tongues, APPL ENVIRON MICROBIOL 63, 924–30 (1997). 
15. Allaker RP. Antimicrobial effect of acidified nitrite on periodontal bacteria, Oral Microbiol Immunol 16, 253–
56 (2001). 
16. Benjamin N et al. Stomach NO synthesis, Nature 368, 502 (1994). 
17. Lundberg JO et al. Intragastric nitric oxide production in humans: measurements in expelled air, Gut 35, 
1543–46 (1994). 
18. Sobko T et al. Gastrointestinal bacteria generate nitric oxide from nitrate and nitrite, Nitric Oxide 13, 272–
278 (2005). 
19. Hord NG et al. Food sources of nitrates and nitrites: the physiologic context for potential health benefits, Am 
J Clin Nutr 90, 1–10 (2009). 
20. Schultz DS et al. Pharmacokinetics of nitrate in humans: role of gastrointestinal absorption and metabolism, 
Carcinogenesis 6, 847–52 (1985). 
21. Lundberg JO et al. Urinary Nitrite: More Than a Marker of Infection, Urology 50, 189–191 (1997). 
22. Kelm M et al. Nitric oxide metabolism and breakdown, BBA - Bioenergetics 1411, 273–289 (1999). 
23. Jansson EÅ. et al. A mammalian functional nitrate reductase that regulates nitrite and nitric oxide 
homeostasis, Nat Chem Biol 4, 411–17 (2008). 
24. Cosby K et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation, Nat 
Med (2003). 
25. Shiva S. et al. Deoxymyoglobin Is a Nitrite Reductase That Generates Nitric Oxide and Regulates 
Mitochondrial Respiration, Circulation Research 100, 654–61 (2007). 
26. Kozlov AV et al. Various intracellular compartments cooperate in the release of nitric oxide from glycerol 
trinitrate in liver, BJP 139, 989–97 (2003). 
27. Webb A et al. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia–
reperfusion damage, PNAS 101, 13683–88 (2004). 
28. Brooks J et al. The Action of NO2- on Haemoglobin in the Absence of O2, Proc R Soc Med 123, 368–82 (1937). 
29. Doyle B et al. Kinetics and Mechanism of the Oxidation of Human Deoxyhemoglobin by Nitrites*, J Biol Chem 
256, 12393–98 (1981). 
30. Rassaf T. et al. Nitrite Reductase Function of Deoxymyoglobin: Oxygen Sensor and Regulator of Cardiac 
Energetics and Function, Circ Res 100, 1749–54 (2007). 
31. Larsen FJ et al. Effects of dietary nitrate on oxygen cost during exercise, Acta Physiol 191, 59–66 (2007). 
32. Hendgen-Cotta U et al. Nitrite reductase activity of myoglobin regulates respiration and cellular viability in 
myocardial ischemia-reperfusion injury, PNAS 105, 10256–61 (2008). 
33. Kozlov AV et al. Nitrite reductase activity is a novel function of mammalian mitochondria, FEBS Letters 454, 
127–30 (1999). 
Bibliography  
 93 
34. Vanin AF et al. Nitric oxide synthase reduces nitrite to NO under anoxia, Cell. Mol. Life Sci 64, 96–103 (2007). 
35. Trujillo M et al. Xanthine Oxidase-mediated Decompososition of S-Nitrosothiols, JBC 273, 7828–7834 (1998). 
36. Godber BLJ et al. Reduction of Nitrite to NO Catalyzed by Xanthine Oxidoreductase, JBC 275, 7757–63 (2000). 
37. Millar TM et al. Xanthine oxidoreductase catalyses the redcution of nitrate and nitrite to nitric oxide under 
hypoxic conditions, FSEB Letters 427, 225–28 (1998). 
38. Zweier JL et al. Non-enzymatic nitric oxide synthesis in biological systems, BBA 1411, 250–62 (1999). 
39. Samouilov A et al. Evaluation of the Magnitude and Rate of Nitric Oxide Production from Nitrite in Biological 
Systems 1. 
40. Bryan N et al. Nitrite is a signaling molecule and regulator of gene expression in mammalian tissues, Nat 
Chem Biol 1, 290–97 (2005). 
41. Francis CA et al. New processes and players in the nitrogen cycle: the microbial ecology of anaerobic and 
archaeal ammonia oxidation, ISME J 1, 19–27 (2007). 
42. Moncada S et al. NO: Physiology, Pathophysiology, and Pharmacology, Pharmacol Rev 43, 109–42 (1991). 
43. Menshikova EB et al. Nitric Oxide and NO-Synthases in Mammals in Different Functional States, Biochemistry 
(Moscow) 65, 485–503 (2000). 
44. Mensinga T et al. Health Implications of Exposure to Environmental Nitrogenous… : Toxicological Reviews, 
Toxicol Reviews 22, 41–51 (2003). 
45. Tannenbaum SR et al. Nitrate and gastric cancer risks, Nature 317, 675–76 (1985). 
46. Cornblath M et al. Methhemoglobinemia in young infants. Available at http://www.jpeds.com/article/S0022-
3476(48)80200-3/references (1948). 
47. Pidwirny M et al. The Nitrogen Cycle. Available at http://www.physicalgeography.net/fundamentals/9s.html 
(2006). 
48. Richardson DJ et al. Introduction: nitrate reduction and the nitrogen cycle, CMLS, Cell. Mol. Life Sci. 58, 163–
64 (2001). 
49. WHO. Chemical Facts Sheet: Guideline for Nitrates and Nitrites. Available at 
http://www.who.int/water_sanitation_health/dwq/chemicals/nitratenitritesum.pdf (2005). 
50. Trinkwasserverordnung (2001). 
51. DGE info: Fachinformationen der Deutschen Gesellschaft für Ernährung e.V. Nitrat und Nitrit eher nützlich als 
schädlich? 12, 180–181 (2010). 
52. Lundberg JO et al. Nitrate, bacteria and human health, Nat Reviews 2, 593–602 (2004). 
53. Weiß C. Nitrat, Nitrit, Nitrosamine, Ernährungs Umschau 4, 236–240 (2008). 
54. Appel LJ et al. A Clinical Trial of the Effects of Dietary Patterns on Blood Pressure, NEJM 336, 1117–24 (1997). 
55. Sacks FM et al. Effects on Blood Pressure of Reduced Dietary Sodium and the Dietary Approaches to Stop 
Hypertension (DASH) Diet, NEJM 344, 3–10 (2001). 
56. Huang A et al. Methemoglobinemia Following Unintentional Ingestion of Sodium Nitrite - New York, 
Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5129a2.htm (2002). 
57. McKnight GM et al. Dietary nitrate in man: friend or foe?, Brit J Nutrition 81, 349–58 (1999). 
58. Greer FR et al. Infant Methemoglobinemia: The Role of Dietary Nitrate in Food and Water, PEDIATRICS 116, 
784–86 (2005). 
59. Ward MH. et al. Workgroup Report: Drinking-Water Nitrate and Health—Recent Findings and Research 
Needs, Environ Health Perspect 113, 1607–14 (2005). 
60. Hord NG et al. Dietary Nitrates, Nitrites, and Cardiovascular Disease, Curr Atheroscler Rep 13, 484–92 (2011). 
61. Hampel R et al. Zur Jodversorgung und Belastung mit strumigenen Noxen in Deutschland, Ernährungs 
Umschau 51, 132–137 (2004). 
62. Bogovski P et al. Animal Species in which N-nitroso compounds induce cancer, Int J Cancer 27, 471–74 
(1981). 
63. Lijinsky W et al. N-Nitroso compounds in the diet. Mutat Res 443, 129–38 (1999). 
64. Fraser P et al. Nitrate and Human Cancer: A Review of the Evidence, Int J Epidemiol 9, 3–11 (1980). 
65. Dietrich M et al. A review: dietary and endogenously formed N-nitroso compounds and risk of childhood 
brain tumors. Cancer Causes Control 16, 619–35 (2005). 
66. Norat T et al. Meat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and 
nutrition, J Natl Cancer Inst 97, 906–16 (2005). 
67. Belanger CF et al. The nurses´ health study, Am J Nurs 78, 1039–40 (1978). 
68. Zhang SM et al. Dietary Fat in Relation to Risk of Multiple Sclerosis among Two Large Cohorts of Women, Am 
J Epidemiol 152, 1056–64 (2000). 
69. Rimm EB et al. Prospective study of alcohol consumption and risk of coronary diesease in men, Lancet 338, 
464–68 (1991). 
Bibliography  
 94 
70. Michaud DS et al. Prospective study of meat intake, dietary nitrates, nitrites, and nitrosamines and risk of 
adult glioma, Am J Clin Nutr 90, 1–8 (2009). 
71. Eyre H et al. Preventing Cancer, Cardiovascular Disease, and Diabetes: A Common Agenda for the American 
Cancer Society, the American Diabetes Association, and the American Heart Association, Circulation 109, 
3244–55 (2004). 
72. Huang PH et al. Moderate intake of red wine improves ischemia-induced neovascularization in diabetic 
mice—Roles of endothelial progenitor cells and nitric oxide, Atherosclerosis 212, 426–35 (2010). 
73. Ohga N et al. Inhibitory effects of epigallocatechin-3 gallate, a polyphenol in green tea, on tumor-associated 
endothelial cells and endothelial progenitor cells, Cancer Science 100, 1963–70 (2009). 
74. Balzer J et al. Sustained Benefits in Vascular Function Through Flavanol-Containing Cocoa in Medicated 
Diabetic Patients, JACC 51, 2141–49 (2008). 
75. Knekt P et al. Flavonoid intake and risk of chronic diseases, Am J Clin Nutr 76 (2002). 
76. Azzini E et al. Mediterranean Diet Effect: an Italian picture, Nutr J 10, 125 (2011). 
77. Rebello SA et al. Coffee and tea consumption in relation to inflammation and basal glucose metabolism in a 
multi-ethnic Asian population: a cross-sectional study, Nutr J 10, 61 (2011). 
78. Napoli C & Ignarro LJ. Nitric Oxide and Atherosclerosis, Nitric Oxide 5, 88–97 (2001). 
79. Asaki Y et al. Repeated Thermal Therapy Up-Regulates Endothelial Nitric Oxide Synthase and Augments 
Angiogenesis in a Mouse Model of Hind limb Ischemia, Circ Res 70, 463–70 (2006). 
80. Heiss C et al. Nitric Oxide Synthase Expression and Functional Response to Nitric Oxide Are Both Important 
Modulators of Circulating Angiogenic Cell Response to Angiogenic Stimuli, ATVB 30, 2212–8 (2010). 
81. Kumar D et al. Chronic sodium nitrite therapy augments ischemia-induced angiogenesis and arteriogenesis, 
PNAS 105, 7540–45 (2008). 
82. Appel LJ et al. Dietary Approaches to Prevent and Treat Hypertension: A Scientific Statement From the 
American Heart Association, Hypertension 47, 296–308 (2005). 
83. Petersson J et al. Dietary nitrate increases gastric mucosal blood flow and mucosal defense, AJP: 
Gastrointestinal and Liver Physiology 292, G718–24 (2006). 
84. Duranski MR et al. Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver, 
JCI 115, 1232–40 (2005). 
85. Bryan N et al. Dietary nitrite supplementation protects against myocardial ischemia-reperfusion injury, PNAS 
104, 19144–49 (2007). 
86. Silva Mendez LS et al. Antimicrobial effect of acidified nitrite on cariogenic bacteria. Oal Microbiol Immunol 
14 (1999). 
87. Doel JJ et al. Protective effect of salivary nitrate and microbial nitrate reductase activity against caries, Eur J 
Oral Sci 112, 424–28 (2004). 
88. Wallace JL et al. NO in mucosal defense: a little goes a long way, Gastroenerology 119, 512–20 (2000). 
89. Lanas A et al. Nitrovasodilators, Low-Dose Aspirin, Other Nonsteroidal Antiinflammatory Drugs, and the Risk 
of Upper Gastrointestinal Bleeding, NEJM 343, 600–7 (2000). 
90. Jansson EA et al. Protection from nonsteroidal anti-inflammatory drug (NSAID)- induced gastric ulcers by 
dietary nitrate, FRBM 42, 510–18 (2007). 
91. Dykhuizen RS et al. Antimicrobial Effect of Acidified Nitrite on Gut Pathogens: Importance of Dietary Nitrate 
in Host Defense, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 40, 1422–5 (1996). 
92. Björne H et al. Intragastric nitric oxide is abolished in intubated patients and restored by nitrite*, Crit Care 
Med 33, 1722–7 (2005). 
93. Richardson G et al. The ingestin of inorganic nitrate increases gastric S-nitrosothiol levels and inhibits platelet 
function in humans, Nitric Oxide 7, 24–29 (2002). 
94. Weller R et al. Antimicrobial effect of acidified nitrite on dermatophyte fungi, Candida and bacterial skin 
pathogens, J Appl Microbiol 90, 648–52 (2001). 
95. Carlsson S et al. In vitro evaluation of a new treatment for urinary tract infections caused by nitrate-reducing 
bacteria, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 47, 3713–8 (2003). 
96. Modin A et al. Nitrite-derived nitric oxide: a possible mediator of `acidic±metabolic' vasodilation, Acta Physiol 
Scand 171, 9–16 (2001). 
97. Kozlov AV et al. Mechanisms of vasodilatation induced by nitrite instillation in intestianl lumen: possible role 
of hemoglobin Antioxid Redox Signal, 515–21 (2005). 
98. Tsuchiya K et al. Nitrite is an alternative source of NO in vivo, AJP: Heart and Circulatory Physiology 288, 
H2163–70 (2005). 
99. Hunter CJ et al. Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary 
vasodilator, Nat Med 10, 1122–7 (2004). 
Bibliography  
 95 
100. Diaz-Junior CAC et al. Low-dose intravenous nitrite improves hemodynamics in a canine model of acute 
pulmonary thromoembolism, FRBM 41, 1764–70 (2006). 
101. Emanueli C et al. Nitropravastatin stimulates reparative neovascularisation and improves recovery from limb 
ischaemia in type-1 diabetic mice, Brit J Pharmacol 150, 873–82 (2007). 
102. Lü P et al. Nitrit-derived nitric oxide by xanthine-oxidoreductase protects the liver against ischemia-
reperfusion injury, Hepatobiliary and Pancreatic Disease International 4, 350–55 (2005). 
103. Tripatara P et al. Nitrite-Derived Nitric Oxide Protects the Rat Kidney against Ischemia/Reperfusion Injury In 
Vivo: Role for Xanthine Oxidoreductase, Journal of the American Society of Nephrology 18, 570–80 (2007). 
104. Jung KH et al. Early Intravenous Infusion of Sodium Nitrite Protects Brain Against In Vivo Ischemia-
Reperfusion Injury, Stroke 37, 2744–50 (2006). 
105. Pluta RM et al. Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid 
hemorrhage, JAMA 293, 1477–84 (2005). 
106. Kinsella JP et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure, NEJM 355, 
354–64 (2006). 
107. Clementi E et al. Persistent inhibition of cell respiration by nitric oxide: Crucial role of S-nitrosylation of 
mitochondrial complex I and protective action of glutathione, PNAS 95, 7631–36 (1998). 
108. Burwell LS et al. Direct evidence for S-nitrosation of mitochondrial complex I, Biochem J 394, 627 (2006). 
109. Shiva S et al. Nitrite mediates cytoprotection after ischemia/reperfusion by modulating mitochondrial 
function, Basic Res Cardiol 104, 113–19 (2009). 
110. Chen Z et al. Identification of the enzymatic mechanism of nitroglycerin bioactivation, PNAS 99, 8306–1 
(2002). 
111. Campell NA et al. Biologie. 1st ed. (Spektrum Akademischer Verlag GmbH, Berlin, 1998). 
112. Ignarro LJ et al. Biological actions and properties of endothelial-derived no formed and released from artery 
and vein (1989). 
113. Kelm M et al. Endothelial dysfunction in human coronary circulation: relevance of the L-arginine-NO pathway 
(2001). 
114. Rassaf T et al. Plasma nitrite reserve and endothelial functin in the human forearm circulation, FRBM 41, 
295–301 (2006). 
115. Knowles JW et al. Genetic Susceptibility to Peripheral Arterial Disease: A Dark Corner in Vascular Biology, 
ATVB 27, 2068–78 (2007). 
116. Golomb BA et al. Peripheral Arterial Disease: Morbidity and Mortality Implications, Circ 114, 688–99 (2006). 
117. Napoli C & Ignarro LJ. Nitric oxide and pathogenic mechanisms involved in the development of vascular 
diseases, Arch. Pharm. Res 32, 1103–08 (2009). 
118. Bartholomew JR et al. Pathophysiology of peripheral arterial disease and risk factors for its development, 
CLEVEL CLIN J MED 73, S8-14 (2006). 
119. Kelm M et al. Serum nitrite sensitively reflects endothelial NO formation in human forearm vasculature: 
evidence for biochemical assessment of the endothelial L-arginine-NO pathway, Cardiovasc Res 41, 765–72 
(1999). 
120. Kleinbongard P et al. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals, FRBM 35, 
790–96 (2003). 
121. Cantus DS et al. Ischemic heart disease in women, Rev. Latino-Am. Enfermagem 19, 1462–69 (2011). 
122. Nabel EG et al. A Tale of Coronary Artery Disease and Myocardial Infarction, NEJM 366, 54–63 (2012). 
123. Federman DG & Kravetz JD. Peripheral arterial disease: diagnosis, treatment, and systemic implications, 
Clinics in Dermatology 25, 93–100 (2007). 
124. Hamm CW. Leitlinien: Akutes Koronarsyndrom (ACS), Zeitschrift f�r Kardiologie 93, 72–90 (2004). 
125. Yellon DM. Myocardial Reperfusion Injury, N. Engl. J. Med 357, 1121–35 (2007). 
126. Barbotin-Larrieu F et al. Prevention of ischemia-reperfusion lung injury by inhaled nitric oxide in neonatal 
piglets, J Appl Physiol 80, 782–88 (1996). 
127. Zha Z et al. Inhibition of myocardial apoptosis reduces infarct size and improves regional contractile 
dysfunction during reperfusion, Cardiovascular Research 59, 132–42 (2003). 
128. Weyrich AS et al. The role of L-arginine in ameliorating reperfusion injury after myocardial ischemia in the 
cat, Circ 86, 279–88 (1992). 
129. Bolli R et al. Myocardial Protection at a Crossroads: The Need for Translation Into Clinical Therapy, Circ Res 
95, 125–34 (2004). 
130. Piper HM et al. A fresh look at reperfusion injury, Cardiovasc Res 38, 291–300 (1998). 
131. Zweier J & Talukder M. The role of oxidants and free radicals in reperfusion injury, Cardiovasc Res 70, 181–90 
(2006). 
132. Lemasters JJ et al. The pH paradox in ischemia-reperfusion injury to cardiac myocytes, EXS 76, 99–114 (1996). 
Bibliography  
 96 
133. Vinten-Johansen J et al. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion 
injury, Cardiovascular Research 61, 481–97 (2004). 
134. Griffiths EJ et al. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon 
reperfusion, Biochem J 307, 93–98 (1995). 
135. Keely EC et al. Primary angioglasty versus intravenous thrombolytic therapy for acute myocardial infarction: a 
quantitative review of 23 randomised trials, Lancet 361, 13–20 (2003). 
136. Özüyaman B et al. Nitric oxide differentially regulates proliferation and mobilization of endothelial progenitor 
cells but not of hematopoietic stem cells, Thromb Haemost 94, 770–2 (2005). 
137. Heiss C et al. Pleiotrophin induces nitric oxide dependent migration of endothelial progenitor cells, J Cell 
Physiol 215, 366–73 (2008). 
138. Asahara T et al. Isolation of Putative Progenitor Endothelial Cells for Angiogenesis, Science 275, 964–66 
(1997). 
139. Asahara T et al. Bone Marrow Origin of Endothelial Progenitor Cells Responsible for Postnatal Vasculogenesis 
in Physiological and Pathological Neovascularization, Circulation Research 85, 221–28 (1999). 
140. Asahara T et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived 
endothelial progenitor cells, EMBO 18, 3964–72 (1999). 
141. Pardanaud L et al. Relationship between vasculogenesis, angiogenesis and haemopoiesis during avian 
ontogeny, Developmental Biology 105, 473–85 (1989). 
142. Folkman J et al. Angiogenesis, J Biol Chem 267, 10931–34 (1992). 
143. Heil M et al. Arteriogenesis versus angiogenesis: similarities and differences, JCMM 10, 45–55 (2006). 
144. Prater DN et al. Working hypothesis to redefine endothelial progenitor cells, Leukemia 21, 1141–9 (2007). 
145. Rehman J et al. Peripheral Blood "Endothelial Progenitor Cells" Are Derived From Monocyte/Macrophages 
and Secrete Angiogenic Growth Factors, Circulation 107, 1164–9 (2003). 
146. Hristov M et al. Adult progenitor cells in vascular remodeling during atherosclerosis, Biol Chem 389, 837–44 
(2008). 
147. Han JK et al. Peroxisome proliferator-activated receptor-  activates endothelial progenitor cells to induce 
angio-myogenesis through matrix metallo-proteinase-9-mediated insulin-like growth factor-1 paracrine 
networks, EHJ (2011). 
148. Heissig B et al. Recruitment of Stem and Progenitor Cells from the Bone Marrwo Niche Requires MMP-9 
Mediated Release of Kit-Ligand, Cell Biol Toxicol 109, 625–37 (2002). 
149. Kalka C et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial 
progenitor cells in human subjects, Circ Res 86, 1198–1202 (2000). 
150. Falco E et al. Altered SDF-1-mediated differentiation of bone marrow-derived endothelial progenitor cells in 
diabetes mellitus, JCMM 13, 3405–14 (2009). 
151. Heeschen C et al. EPC Participate in Nicotine-Mediated Angiogenesis, JACC 48, 2553–60 (2006). 
152. Qin G et al. Functional disruption of  4 integrin mobilizes bone marrow-derived endothelial progenitors and 
augments ischemic neovascularization, JEM 203, 153–63 (2006). 
153. Ruifrok WT et al. Estradiol-induced, endothelial progenitor cell-mediated neovascularization in male mice 
with hind-limb ischemia, Vasc Med 14, 29–36 (2009). 
154. Chavakis E et al. Role of  2-integrins for homing and neovascularization capacity of endothelial progenitor 
cells, JEM 201, 63–72 (2005). 
155. Hirschi KK et al. Assessing Identity, Phenotype, and Fate of EPC, ATVB 28, 1584–95 (2008). 
156. Brixius K et al. Endothelial Progneitor cells: a new target for the prevention of cardiovascular diseases, Eur J 
Cardiovasc Prev Rehabil 13, 705–10 (2006). 
157. Fadini GP et al. Technical notes on endothelial progenitor cells: Ways to escape from the knowledge plateau, 
Atherosclerosis 197, 496–503 (2008). 
158. Dimmeler S et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-
kinase /Akt pathway, JCI 108, 391–97 (2001). 
159. Kalka C et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic 
neovascularization, PNAS 97, 3422–7 (2000). 
160. Hill JM et al. Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk, NEJM 348, 
593–600 (2003). 
161. Lin Y et al. Orignis of circulating endothelial cells and endothelial outgrowth from blood, JCI 105, 71–77 
(2000). 
162. Fadini GP et al. Critical Reevaluation of Endothelial Progenitor Cell Phenotypes for Therapeutic and 
Diagnostic Use, Circ Res 110, 624–37 (2012). 
163. Assmus B et al. Acute myocardial infarction activates progenitor cells and increases Wnt signalling in the 
bone marrow, EHJ (2011). 
Bibliography  
 97 
164. Distler JHW et al. EULAR Scleroderma Trials and Research group statement and recommendations on 
endothelial precursor cells, Annals Rheum Dis 68, 163–8 (2009). 
165. Vasa M et al. Number and Migratory Activity of Circulating Endothelial Progenitor Cells Inversely Correlate 
With Risk Factors for Coronary Artery Disease, Circ Res 89, e1–e7 (2001). 
166. Massa M et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of 
acute myocardial infarction, Blood 105, 199–206 (2005). 
167. Fadini GP et al. Effects of androgens on EPC in vitro and in vivo, Clin Sci 117, 355–64 (2009). 
168. Yan J et al. Recovery from hind limb ischemia is less effective in type 2 than in type 1 diabetic mice: Roles of 
endothelial nitric oxide synthase and endothelial progenitor cells (2009). 
169. Gill M et al. Vascular Trauma Indcues Rapid but Transient Mobilization fo VEGFR2+AC133+ Endothelial 
Precursor Cells, Circ Res 88, 167–74 (2001). 
170. George J et al. Number and Adhesive Properties of Circulating Endothelial Progenitor Cells in Patients With 
In-Stent Restenosis, ATVB 23, 57e–60 (2003). 
171. He T et al. Transplantation of Circulating Endothelial Progenitor Cells Restores Endothelial Function of 
Denuded Rabbit Carotid Arteries, Stroke 35, 2378–84 (2004). 
172. Heeschen C et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization, 
Blood 102, 1340–6 (2003). 
173. Askari AT et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in 
ischaemic cardiomyopathy, The Lancet 362, 697–703 (2003). 
174. Hattori K et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by 
recruitment of vasculogenic and hematopoietic stem cells, JEM 93, 1005–14 (2001). 
175. Doyle B et al. Endothelial Progenitor Cells, Endothelium 13, 403–10 (2006). 
176. Purhonen S et al. Bone marrow-derived circulating endothelial precursors do not contribute to vascular 
endothelium and are not needed for tumor growth, PNAS 105, 6620–5 (2008). 
177. Aicher A et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells, 
Nat Med 9, 1370–6 (2003). 
178. Fadini GP et al. Peripheral Blood CD34+KDR+ Endothelial Progenitor Cells Are Determinants of Subclinical 
Atherosclerosis in a Middle-Aged General Population, Stroke 37, 2277–82 (2006). 
179. Yang Z et al. Paracrine factors secreted by endothelial progenitor cells prevent oxidative stress-induced 
apoptosis of mature endothelial cells, Atherosclerosis 211, 103–9 (2010). 
180. Xia L et al. Endothelial progenitor cells may inhibit apoptosis of pulmonary microvascular endothelial cells: 
new insights into cell therapy for pulmonary arterial hypertension, Cytotherapy, Informa Healthcare, 
Cytotherapy 11, 492–502 (2009). 
181. Zhang Y et al. Release of proinflammatory mediators and expression of proinflammatory adhesion molecules 
by endothelial progenitor cells, AJP: Heart and Circulatory Physiology 296, H1675–82 (2009). 
182. Yang H et al. Inhibition of Thymic Adipogenesis by Caloric Restriction Is Coupled with Reduction in Age-
Related Thymic Involution, J  Immunol 183, 3040–52 (2009). 
183. Murasawa S & Asahara T. Review: Cardiogenic potential of endothelial progenitor cells, Therapeutic 
Advances in Cardiovascular Disease 2, 341–8 (2008). 
184. Fujiyama S et al. Bone Marrow Monocyte Lineage Cells Adhere on Injured Endothelium in a Monocyte 
Chemoattractant Protein-1-Dependent Manner and Accelerate Reendothelialization as Endothelial 
Progenitor Cells, Circ Res 93, 980–9 (2003). 
185. Young PP et al. Biological Properties Of Endothelial Progenitor Cells (EPCS) AND Their Potential For Cell 
Therapy, Prog Cardiovasc Dis 49, 421–9 (2007). 
186. Chakroborty D et al. Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow 
in tumor vascularization, JCI 118, 1380–9 (2008). 
187. Ribatti D et al. The discovery of endothelial progenitor cells, Leukemia Res 31, 439–44 (2007). 
188. Laufs U et al. Physical Training Increases Endothelial Progenitor Cells, Inhibits Neointima Formation, and 
Enhances Angiogenesis, Circulation 109, 220–6 (2004). 
189. Herbrig K et al. Endothelial dysfunction in patients with rheumatoid arthritis is associated with a reduced 
number and impaired function of EPC, Annals of the Rheumatic Diseases 65, 157–63 (2006). 
190. Fox A et al. Mobilization of endothelial progenitor cells into the circulation in burned patients, Br J Surg 95, 
244–51 (2008). 
191. Sangidorj O et al. Bone marrow-derived endothelial progenitor cells confer renal protection in a murine 
chronic renal failure model, AJP: Renal Physiology 299, F325–35 (2010). 
192. Park K et al. Simvastatin enhances endothelial differentiation of peripheral blood mononuclear cells in 
hypercholesterolemic patients and induces pro-angiogenic cytokine IL-8 secretion from monocytes, Clinica 
Chimica Acta 388, 156–66 (2008). 
Bibliography  
 98 
193. Patschan D et al. LDL lipid apheresis rapidly increases peripheral endothelial progenitor cell competence, J 
Clin Apheresis 24, 180–85 (2009). 
194. Esposito K et al. Circulating CD34+ KDR+ Endothelial Progenitor Cells Correlate with Erectile Function and 
Endothelial Function in Overweight Men, J Sex Med 6, 107–14 (2009). 
195. Heiss C et al. Brief Secondhand Smoke Exposure Depresses Endothelial Progenitor Cells Activity and 
Endothelial Function, JACC 51, 1760–71 (2008). 
196. George J et al. Transfer of Endothelial Progenitor and Bone Marrow Cells Influences Atherosclerotic Plaque 
Size and Composition in Apolipoprotein E Knockout Mice, ATVB 25, 2636–41 (2005). 
197. Heeschen C et al. Profoundly Reduced Neovascularization Capacity of Bone Marrow Mononuclear Cells 
Derived From Patients With Chronic Ischemic Heart Disease, Circulation 109, 1615–22 (2004). 
198. Werner N et al. Endothelial progenitor cells correlate with endothelial function in patients with coronary 
artery disease, Basic Res Cardiol 102, 565–71 (2007). 
199. George J et al. Circulating endothelial progenitor cells in patients with unstable angina: association with 
systemic inflammation, EHJ 25, 1003–8 (2004) 
200. Güven H et al. The Number of Endothelial Progenitor Cell Colonies in the Blood Is Increased in Patients With 
Angiographically Significant Coronary Artery Disease, JACC 48, 1579–87 (2006). 
201. Leone AM et al. Endogenous G-CSF and CD34+ cell mobilization after acute myocardial infarction, Int J Cardiol 
111, 202–8 (2006). 
202. Werner N et al. Circulating EPC and Cardiovascular Outcomes, NEJM 353, 999–1007 (2005). 
203. Schmidt-Lucke C et al. Reduced Number of Circulating Endothelial Progenitor Cells Predicts Future 
Cardiovascular Events: Proof of Concept for the Clinical Importance of Endogenous Vascular Repair, Circ 111, 
2981–7 (2005). 
204. Coppolino G et al. Perioperative Iloprost and Endothelial Progenitor Cells in Uremic Patients With Severe 
Limb Ischemia Undergoing Peripheral Revascularization, J Surg Res 157, e129–35 (2009). 
205. Stein A et al. Circulating endothelial progenitor cells decrease in patients after endarterectomy, J Vasc Surg 
48, 1217–22 (2008). 
206. Yoon CH et al. Intercellular Adhesion Molecule-1 Is Upregulated in Ischemic Muscle, Which Mediates 
Trafficking of Endothelial Progenitor Cells, ATVB 26, 1066–72 (2006). 
207. Oliveras A et al. Putative endothelial progenitor cells are associated with flow-mediated dilation in refractory 
hypertensives, Blood 17, 298–305 (2008). 
208. Magen E et al. Circulating Endothelial Progenitor Cells, Th1/Th2/Th17-Related Cytokines, and Endothelial 
Dysfunction in Resistant Hypertension, Am J Med Sci 339, 117–22 (2010). 
209. Valgimigli M et al. CD34+ and Endothelial Progenitor Cells in Patients With Various Degrees of Congestive 
Heart Failure, Circ 110, 1209–12 (2004). 
210. van Craenenbroeck EM et al. Exercise acutely reverses dysfunction of circulating angiogenic cells in chronic 
heart failure, EHJ 31, 1924–34 (2010). 
211. van Craenenbroeck EM & Conraads VM. Endothelial progenitor cells in vascular health: Focus on lifestyle, 
Microvascular Research 79, 184–92 (2010). 
212. Fadini GP et al. Diabetes impairs progenitor cell mobilisation after hind limb ischaemia–reperfusion injury in 
rats, Diabetologia 49, 3075–84 (2006). 
213. Kang L et al. Decreased mobilization of endothelial progenitor cells contributes to impaired 
neovascularization in diabetes, Clin Exp Pharmacol Physiol 36, e47–e56 (2009). 
214. Shintani S et al. Mobilization of Endothelial Progenitor Cells in Patients With Acute Myocardial Infarction, Circ 
103, 2776–9 (2001). 
215. Thomas HE et al. Local vessel injury following percutaneous coronary intervention does not promote early 
mobilisation of endothelial progenitor cells in the absence of myocardial necrosis, Heart 95, 555–8 (2008). 
216. Mills NL et al. Dissociation of phenotypic and functional endothelial progenitor cells in patients undergoing 
percutaneous coronary intervention, Heart 95, 2003–8 (2009). 
217. Numaguchi Y et al. The Impact of the Capability of Circulating Progenitor Cell to Differentiate on Myocardial 
Salvage in Patients With Primary Acute Myocardial Infarction, Circ 114, I-114–9 (2006). 
218. Wojakowski W et al. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ Stem Cells, and Mononuclear Cells 
Expressing Early Cardiac, Muscle, and Endothelial Markers Into Peripheral Blood in Patients With Acute 
Myocardial Infarction, Circ 110, 3213–20 (2004). 
219. Valgimigli M et al. Use of granulocyte-colony stimulating factor during acute myocardial infarction to 
enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile, EHJ 26, 
1838–45 (2005). 
220. Schächinger V et al. Intracoronary Bone Marrow–Derived Progenitor Cells in Acute Myocardial Infarction, 
NEJM 355, 1210–21 (2006). 
Bibliography  
 99 
221. Madeddu P et al. Transplantation of low dose CD34+Kdr+ cells promotes vascular and muscular regeneration 
in ischemic limb, FASEB (2004). 
222. Walter DH et al. Impaired CXCR4 Signaling Contributes to the Reduced Neovascularization Capacity of 
Endothelial Progenitor Cells From Patients With Coronary Artery Disease, Circ Res 97, 1142–51 (2005). 
223. Chen F et al. combination of VEGF165/Angiopoietin-1 gene and endothelial progenitor cells for therapeutic 
neovascularization, EJP 568, 222–30 (2007). 
224. Foubert P et al. PSGL-1-mediated activation of EphB4 increases the proangiongenic potential of endothelial 
progenitor cells, JCI 117, 1527–37 (2007). 
225. Huang PH et al. Intake of Red Wine Increases the Number and Functional Capacity of Circulating Endothelial 
Progenitor Cells by Enhancing Nitric Oxide Bioavailability, ATVB 30, 869–77 (2010). 
226. Murohara T et al. Nitric Oxide Synthase Modulates Angiogenesis in Response to Tissue Ischemia, JCI 101, 
2567–78 (1998). 
227. Lee PC et al. Impaired wound healing and angiogenesis in eNOS-deficient mice, Am J Physiol Heart Circ 
Physiol 277, 1600–8 (1999). 
228. Ma FX et al. Oxidized low density lipoprotein impairs endothelial progenitor cells by regulation of endothelial 
nitric oxide synthase, J Lipid Res 47, 1227–37 (2006). 
229. Hamed S et al. Nitric oxide and superoxide dismutase modulate endothelial progenitor cell function in type 2 
diabetes mellitus, Cardiovasc Diabetol 8, 56 (2009). 
230. Landmesser U et al. Statin-Induced Improvement of Endothelial Progenitor Cell Mobilization, Myocardial 
Neovascularization, Left Ventricular Function, and Survival After Experimental Myocardial Infarction Requires 
Endothelial Nitric Oxide Synthase, Circ 110, 1933–9 (2004). 
231. Leone AM et al. Effect of intensive vs standard statin therapy on endothelial progenitor cells and left 
ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute 
myocardial infarction and PCI (STRAP) trial, Int J Cardiol 130, 457–62 (2008). 
232. Heiss C et al. Dietary inorganic nitrate mobilizes circulating angiogenic cells, FRBM 52, 1767–72 (2012). 
233. Thum T et al. Differential Effects of Organic Nitrates on Endothelial Progenitor Cells Are Determined by 
Oxidative Stress, ATVB 27, 748–54 (2007). 
234. Gadau S et al. Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein 
kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis, Diabetologia 49, 405–20 
(2006). 
235. Ross R et al. Atherosclerosis - an inflammatory disease, NEJM 340, 115–26 (1999). 
236. Storck M & Wagner HJ. Periphere arterielle Verschlusskrankheit und akute Extremitätenischämie, Chirurg 78, 
611–19 (2007). 
237. Mees B et al. Endothelial Nitric Oxide Synthase Activity Is Essential for Vasodilation During Blood Flow 
Recovery but not for Arteriogenesis, ATVB 27, 1926–33 (2007). 
238. Bergmann CE et al. Arteriogenesis depends on circulating monocyytes and macrophage accumulation and is 
severly depressed in op/op mice, J Leukocyte Biol 80, 59–65 (2006). 
239. Kinnaird T et al. Marrow-Derived Stromal Cells Express Genes Encoding a Broad Spectrum of Arteriogenic 
Cytokines and Promote In Vitro and In Vivo Arteriogenesis Through Paracrine Mechanisms, Circ Res 94, 678–
85 (2004). 
240. Cai W & Schaper W. Mechanisms of arteriogenesis, Acta Biochimica et Biophysica Sinica 40, 681–92 (2008). 
241. Persson AB & Buschmann IR. Vascular Growth in Health and Disease, Front Mol Neurosci 4, 1–15 (2011). 
242. Carmeliet P et al. Angiogenesis in health and disease, Nat Med 9, 653–60 (2003). 
243. Eckert R et al. Tiephysiologie. 3rd ed. (Thieme, Stuttgart, 2000). 
244. Lin CH et al. Attenuating Ischemia-Induced H9c2 Myoblasts Apoptosis by Therapeutic Hypothermia, Am J 
Med Sci 339, 258–65 (2010). 
245. Haustetter A et al. Apoptosis: Basic Mechanisms and implications for cardiovascular disease, Cardiovasc Res 
82, 1111–29 (1998). 
246. Wang WZ et al. Ischemia/reperfusion-induced necrosis and apoptosis in the cells isolated from rat skeletal 
muscle, J Orthop Res 26, 351–56 (2008). 
247. Dupont-Versteegden EE et al. Apoptosis in skeletal muscle and its relevance to atrophy, World J 
Gastroenterol 12, 7463–66 (2006). 
248. Liu CC & Ahearn JM. Apoptosis of skeletal muscle cells and the pathogenesis of myositis: a perspective, Curr 
Rheumatol Rep 3, 325–33 (2001). 
249. Sandri M et al. Apoptosis of skeletal muscles during development and disease, IJBCB 31, 1373-90 (1999). 
250. Fujiwara M et al. Fas-mediated upregulation of vascular endothelial growth factor and monocyte 
chemoattractant protein-1 expression in cultured dermal fibroblasts: Role in the inflammatory response, J 
Dermatol 34, 99–109 (2007). 
Bibliography  
 10
0 
251. Date T et al. Differential effects of membrane and soluble Fas ligand on cardiomyocytes: role in 
ischemia/reperfusion injury, JMCC 35, 811–21 (2003). 
252. Bergmann O et al. Evidence for cardiomyocyte renewal in humans, Science 324, 98–102 (2009). 
253. Fieno DS et al. Infarct resorption, compensatory hypertrophy, and differing patterns of ventricular 
remodeling following myocardial infarctions of varying size, JACC 43, 2124–31 (2004). 
254. Mauro A et al. Satellite cell of skeletal muscle fibers, J Biophys Biochem Cytol 9, 493–5 (1961). 
255. Biressi S & Rando TA. Heterogeneity in the muscle satellite cell population, Sem Cell Develop Biol 21, 845–54 
(2010). 
256. Seale P et al. A New Look at the Origin, Function, and "Stem-Cell" Status of Muscle Satellite Cells, Dev Biol 
218, 115–24 (2000). 
257. Ferrari G et al. Muscle Regeneration by Bone Marrow-Derived Myogenic Progenitors, Science 279, 1528–30 
(1998). 
258. Okabe M et al. Green mice as a source of ubiquitous green cells, FEBS Letters 407, 313–19 (1997). 
259. Gödecke A et al. Disruption of myoglobin in mice induces multiple compensatory mechanisms, PNAS 96, 
10495–500 (1999). 
260. Huang L et al. Enhanced xanthine oxidoreductase expression and tissue nitrate reduction in germ free mice, 
Nitric Oxide 22, 191–5 (2010). 
261. Couffinhal T et al. Mouse Model of Angiogenesis, AJP 152, 1667–79 (1998). 
262. Lee CW et al. Temporal patterns of gene expression after acute hind limb ischemia in mice☆insights into the 
genomic program for collateral vessel development, JACC 43, 474–82 (2004). 
263. Wardell K et al. Laser Doppler Perfusion Imaging by Dynamic Light Scattering, IEEE Transactions Biomed 
Engin 40, 309–16 (1993). 
264. PeriScan System PIM II. Blood Perfusion Imager. 
265. Jiang J et al. Dual roles of tumor necrosis factor-  receptor-1 in a mouse model of hind limb ischemia, Vasc 
Med 14, 37–46 (2009). 
266. Dejam A et al. Erythrocytes are the major intravascular storage sites of nitrite in human blood, Blood 106, 
734–39 (2005). 
267. Pelletier MM et al. The measurement of blood and plasma nitrite by chemiluminescence: Pitfalls and 
solutions, FRBM 41, 541–8 (2006). 
268. Feelisch M et al. Concomitant S-, N-, and heme-nitros(yl)ation in biological tissues and fluids: implications for 
the fate of NO in vivo, FASEB 16, 1775–85 (2002). 
269. Grau M et al. Recent methodological advances in the analysis of nitrite in the human circulation: Nitrite as a 
biochemical parameter of the l-arginine/NO pathway, J Chromato B 851, 106–23 (2007). 
270. Rassaf T et al. Concomitant presence of N-nitroso and S-nitroso proteins in human plasma, FRBM 33, 1590–6 
(2002). 
271. MacArthur PH et al. Measurement of circulating nitrite and S-nitrosothiols by reductive chemiluminescence, J 
Chromato B 851, 93–105 (2007). 
272. Kurien BT et al. Mouse urine collection using clear plastic wrap, 83–86 (1999). 
273. Kurien BT et al. Experimental animal urine collection: a review, 333–61 (2004). 
274. Sgonc R et al. Simultaneous determination of cell surface antigens and apoptosis, Trends Genet 10, 41–42 
(1994). 
275. Pfaffl MW et al. Relative expression software tool (REST©) for group-wise comparison and statistical analysis 
of relative expression results in real-time PCR, Nucleic Acid Research (2002). 
276. Kehmeier ES, Kropp M et al. Serial measurements of whole blood nitrite in an intensive care setting, FRBM 
44, 1945–50 (2008). 
277. Kehmeier ES, Lepper W, Kropp M et al. TNF-α, myocardial perfusion and function in patients with ST-
Segment elevation myocardial infarction and primary percutaneous coronary intervention, Clin Res Cardiol 
101, 815-27 (2012). 
278. Motulsky HJ & Brown RE. Detecting outliers when fitting data with nonlinear regression - a new method 
based on robust nonlinear regression and the false discovery rate, BMC Bioinformatics 7, 123 (2006). 
279. National Institut of Health. Toxicology/Carcinogenesis Studies of Sodium Nitrite. 
280. Feldman RL et al. The surprising life of NITRIC OXIDE, Chem. Eng. News 71, 26–38 (1993). 
281. Petersson J et al. Gastroprotective and blood pressure lowering effects of dietary nitrate are abolished by an 
antiseptic mouthwash, FRBM 46, 1068–75 (2009). 
282. Kleinbongard P et al. Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans, 
FRBM 40, 295–302 (2006). 
283. Urbich C et al. EPC: Characterization and Role in Vascular Biology, Circ Res 95, 343–53 (2004). 
Bibliography  
 10
1 
284. Salter AB et al. Endothelial progenitor cell infusion induces hematopoietic stem cell reconstitution in vivo, 
Blood 113, 2104–07 (2009). 
285. Hehlgans T & Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor 
superfamily: players, rules and the games, Immunology 115, 1–20 (2005). 
286. Corpet DE et al. Red meat and colon cancer: Should we become vegetarians, or can we make meat safer?, 
Meat Science 89, 310–16 (2011). 
287. Green LC et al. Nitrate Synthesis in the Germfree and Conventional Rat, Science 212, 56–58 (1981). 
288. Wagner DA et al. Metabolic Fate of an Oral Dose of 15N-labeled Nitrate in Humans: Effect of Diet 
Supplementation with Ascorbic Acid, Cancer Research 43, 1921–5 (1983). 
289. Wagner DA et al. Mammalian nitrate biochemistry: metabolism and endogenous synthesis, IARC Sci Publ, 
247–53 (1984). 
290. Björne H et al. Intragastric generation of antimicrobial nitrogen oxides from saliva—Physiological and 
therapeutic considerations, FRBM 41, 1404–12 (2006). 
291. Kim HW et al. Essential Role of Extracellular SOD in Reparative Neovascularization Induced by Hind limb 
Ischemia, Circ Res 101, 409–19 (2007). 
292. Helisch A et al. Impact of Mouse Strain Differences in Innate Hind limb Collateral Vasculature, ATVB 26, 520–
6 (2005). 
293. Scholz D et al. Contribution of Arteriogenesis and Angiogenesis to Postocclusive Hind limb Perfusion in Mice, 
JMCC, 775–87 (2002). 
294. Limbourg A et al. Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb 
ischemia, Nat Protoc 4, 1737–48 (2009). 
295. Gabhann FM et al. Collateral Capillary Arterialization following Arteriolar Ligarion in Murine Skeletal Muscle, 
Microcirculation 17, 333–47 (2010). 
296. Yalcin B et al. Commercially Available Outbred Mice for Genome-Wide Association Studies, PLoS Genet 6, 
e1001085 (2010). 
297. Beck JA et al. Genealogies of mouse inbred strains, Nat Med (2000). 
298. Yang Z et al. Call for a reference model of chronic hind limb ischemia to investigate therapeutic angiogenesis, 
Vasc Pharmacol 51, 268–74 (2009). 
299. Germani A et al. Vascular Endothelial Growth Factor Modulates Skeletal Myoblast Function, AJP 163, 1417–
28 (2003). 
300. Di Santo S et al. Novel Cell-Free Strategy for Therapeutic Angiogenesis: In Vitro Generated Conditioned 
Medium Can Replace Progenitor Cell Transplantation, PLoS ONE 4, e5643 (2009). 
301. Arsic N et al. Vascular endothelial growth factor stimulates skeletal muscle regeneration in Vivo, Mol Ther 10, 
844–54 (2004). 
302. Borselli C et al. Regenerative Medicine Special Feature: Functional muscle regeneration with combined 
delivery of angiogenesis and myogenesis factors, PNAS 107, 3287–92 (2010). 
303. Fidzianska A et al. Apoptosis in Human Embryonic and Diseased Skeletal Muscle, BAM 6, 261–4 (1996). 
304. Adams V et al. Apoptosis in Skeletal Myocytes of Patients With Chronic Heart Failure Is Associated With 
Exercise Intolerance, JMCC 33, 559–64 (1999). 
305. Appell HJ et al. Satellite Cell Activation in Human Skeletal Muscle After Training: Evidence for Muscle Fiber 
Neoformation, Int J Sports Med 09, 297–99 (1988). 
306. Charge SBP et al. Cellular and Molecular Regulation of Muscle Regeneration, Physiol Rev 84, 209–38 (2004). 
307. Broek RW et al. Regulatory factors and cell populations involved in skeletal muscle regeneration, J Cel. 
Physiol, n/a (2010). 
308. Zammit PS et al. The Skeletal Muscle Satellite Cell: The Stem Cell That Came in From the Cold, J Histochem 
Cytochem 54, 1177–91 (2006). 
309. Schultz E et al. Satellite Cell Proliferative Compartments in Growing Skeletal Muscles, Dev Biol 175, 84–94 
(1996). 
310. Zammit PS et al. Muscle satellite cells adopt divergent fates: a mechanism for self-renewal?, JCB 166, 347–57 
(2004). 
311. Montarras D et al. Direct Isolation of Satellite Cells for Skeletal Muscle Regeneration, Science 309, 2064–7 
(2005). 
312. Collins CA et al. Stem Cell Function, Self-Renewal, and Behavioral Heterogeneity of Cells from the Adult 
Muscle Satellite Cell Niche, Cell 122, 289–301 (2005). 
313. Yaffe D et al. The Effect of Actinomycin D on Heart and Thigh Muscle Cells Grown in Vitro, Dev Biol 9, 347–66 
(1964). 
314. Rando TA et al. Primary Mouse Myoblast Purification, Characterization, and Transplantation for Cell-
mediated Gene Therapy, JCB 125, 1275–87 (1994). 
Bibliography  
 10
2 
315. Hazarika S et al. Myocyte Specific Overexpression of Myoglobin Impairs Angiogenesis After Hind-Limb 
Ischemia, ATVB 28, 2144–50 (2008). 
316. Yang Y et al. Myoglobin over-expression attenuates angiogenic response in hind limb ischemia in mice, Chin 
Med J 122, 1056–60 (2009). 
317. van Weel V et al. Vascular Endothelial Growth Factor Overexpression in Ischemic Skeletal Muscle Enhances 
Myoglobin Expression In Vivo, Circn Res 95, 58–66 (2004). 
318. Emanueli C et al. Prophylactic Gene Therapy With Human Tissue Kallikrein Ameliorates Limb Ischemia 
Recovery in Type 1 Diabetic Mice, Diabetes 53, 1096–1103 (2004). 
319. Ebrahimian TG et al. NADPH Oxidase-Derived Overproduction of Reactive Oxygen Species Impairs 
Postischemic Neovascularization in Mice with Type 1 Diabetes, AJP 169, 719–28 (2006). 
320. Goukassian DA et al. Tumor Necrosis Factor-  Receptor p75 Is Required in Ischemia-Induced 
Neovascularization, Circ 115, 752–62 (2007). 
321. Aranguren XL et al. MAPC Transplantation Confers a More Durable Benefit Than AC133+ Cell Transplantation 
in Severe Hind Limb Ischemia, Cell Transplant 20, 259–69 (2011). 
322. Grundmann S et al. A New Intra-Arterial DeliveryPlatform for Pro-Arteriogenic Compounds to Stimulate 
Collateral Artery Growth Via Transforming Growth Factor-β1 Release, JACC 50, 351–8 (2007). 
323. Rao X et al. Loss of methyl-CpG-binding domain protein 2 enhances endothelial angiogenesis and protects 
mice against hind-limb ischemic injury, Circn 123, 2964–74 (2011). 
324. Gianella A et al. Magnetic Resonance Imaging Of Human Endothelial Progenitors Reveals Opposite Effects On 
Vascular And Muscle Regeneration Into Ischemic Tissues, Cardiovasc Res 85, 503–13 (2010). 
325. Aicher A et al. Low-Energy Shock Wave for Enhancing Recruitment of Endothelial Progenitor Cells: A New 
Modality to Increase Efficacy of Cell Therapy in Chronic Hind Limb Ischemia, Circ 114, 2823–30 (2006). 
326. Westvik TS et al. Limb ischemia after iliac ligation in aged mice stimulates angiogenesis without 
arteriogenesis, J Vasc Surg 49, 464–73 (2009). 
327. Kuraitis D et al. A Stromal Cell-Derived Factor-1 Releasing Matrix Enhances The Progenitor Cell Response And 
Blood Vessel Growth In Ischaemic Skeletal Muscle, ECM 22, 109–23 (2011). 
328. Emanueli C et al. Local Delivery of Human Tissue Kallikrein Gene Accelerates Spontaneous Angiogenesis in 
Mouse Model of Hind limb Ischemia, Circn 103, 125–32 (2001). 
329. Rokutanda T et al. Passive Exercise Using Whole-Body Periodic Acceleration Enhances Blood Supply to 
Ischemic Hind limb, ATVB 31, 2872–80 (2011). 
330. Katayama A et al. Fenofibrate Enhances Neovascularization in a Murine Ischemic Hind limb Model, JCP 54, 
399–404 (2009). 
331. Kevil CG et al. Intercellular Adhesion Molecule-1 (ICAM-1) Regulates Endothelial Cell Motility through a Nitric 
Oxide-dependent Pathway, JBC 279, 19230–38 (2004). 
332. Duan et al J. Hypercholesterolemia Inhibits Angiogenesis in Response to Hind limb Ischemia : Nitric Oxide–
Dependent Mechanism, Circ 102, III-370-6 (2000). 
333. Thum T et al. Suppression of Endothelial Progenitor Cells in Human Coronary Artery Disease by the 
Endogenous Nitric Oxide Synthase Inhibitor Asymmetric Dimethylarginine, JACC 46, 1693–1701 (2005). 
334. Hamed S et al. Nitric Oxide: a Key Factor behind the Dysfunctionality of Endothelial Progenitor Cells in 
Diabetes Mellitus Type-2, Cardiovasc Res (2010). 
335. Gallagher KA et al. Diabetic impairments n NO-mediated endothelial progenitor cell mobilization and homing 
are reversed by hyperoxia and SDF-1a, JCI 117, 1249–59 (2007). 
336. Mikirova NA et al. Nutraceutical augmentation of circulating endothelial progenitor cells and hematopoietic 
stem cells in human subjects, J Transl Med 8, 34 (2010). 
337. Cho HJ et al. Role of host tissues for sustained humoral effects after endothelial progenitor cell 
transplantation into the ischemic heart, JEM 204, 3257–69 (2007). 
338. Miller-Kasprzak E & Jagodziński PP. Endothelial progenitor cells as a new agent contributing to vascular 
repair, Arch Immunol Ther Exp 55, 247–59 (2007). 
339. Muller WA et al. Leukocyte-Endothelial Cell Interactions in the Inflammatory Response, Lab Invest 82, 521–
33 (2002). 
340. Griffith OW et al. Nitric Oxide Synthases: Properties and Catalytic Mechanism, Annu. Rev. Physiol 57, 707–36 
(1995). 
341. Guzik TJ et al. Nitic oxide and superoxide in inflammation and immune regulation, J Physiol Pharmacol 54, 
469–87 (2003). 
342. Eskandari MK et al. LPS-induced muscularis macrophage nitric oxide suppresses rat jejunal circular muscle 
activity, Am J Physiol Gastrointest Liver Physiol 277, 478–86 (1999). 
343. Hsieh YL et al. Effects of Ultrasound and Diclofenac Phonophoresis on Inflammatory Pain Relief: Suppression 
of Inducible Nitric Oxide Synthase in Arthritic Rats, Physical Therapy 86, 39–49 (2006). 
Bibliography  
 10
3 
344. Salvemini D et al. Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw 
inflammation, BJP 118, 829–38 (1996). 
345. Albelda SM et al. Adhesion molecules and inflammatory injury, FASEB, 504–12 (1994). 
346. Wadhwa M & Thorpe R. Haematopoietic growth factors and their therapeutic use, Thromb Haemost 99, 863–
73 (2008). 
347. Deng Z et al. Effects of GM-CSF on the stem cells mobilization and plasma C-reactive protein levels in patients 
with acute myocardial infarction, Int J Cardiol 113, 92–96 (2006). 
348. Leung DW et al. Vascular Endothelial Growth Facotr is a secreted angiogenic mitogen (1989). 
349. Tischer E et al. Vascular Endothelial Growth Factor: a nwe member of the platelet-derived growth factor 
gene family, Biochem Biophys Res Comm 165, 1198-1206 (1989). 
350. Adams RH & Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis, Nat Rev Mol Cell Biol 8, 
464–78 (2007). 
351. Saharinen P et al. How do angiopoietins Tie with vascular endothelial growth factors?, Curr Op Hematol, 1 
(2010). 
352. Roy H et al. VEGF-D△N△C  mediated angiogenesis in skeletal muscles of diabetic WHHL rabbits, Eur JCI 40, 
422–32 (2010). 
353. Degenfeld G et al. Microenvironmental VEGF distribution is critical for stable and functional vessel growth in 
ischemia, FASEB 20, 2657–59 (2006). 
354. Lee SH et al. Early expression of Angiogenesis Factors in Acute Myocardial Ischemia and Infarction, NEJM 
342, 626–33 (2000). 
355. Wright DE et al. Hematopoietic Stem Cells Are Uniquely Selective in Their Migratory Response to 
Chemokines, JEM 195, 1145–54 (2002). 
356. Hattori K et al. Plasma elevation of stromal cell–derived factor-1 induces mobilization of mature mobilization 
of mature and immature hematopoietic progenitor and stem cells, Blood 97, 3354–60 (2001). 
357. Petit I et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4, 
Nat. Immunol 3, 687–94 (2002). 
358. Nagasawa T et al. Molecular cloning and structure of a pre-B-cell growth-stimulating factor, PNAS 91, 2305–9 
(1994). 
359. Bleul CC et al. A Highly Efficacious Lymphocyte Chemoattractant, Stromal Cell-derived Factor 1 (SDF-1), JEM 
184, 1101–9 (1996). 
360. Schober A et al. Chemokines in Vascular Dysfunction and Remodeling, ATVB 28, 1950–9 (2008). 
361. Pillarisetti K et al. Cloning and Relative Expression Analysis of Rat Stromal Cell Derived Factor-1 (SDF-1): SDF-1 
a mRNA is selectively Induced in Rat Model of Myocardial Infarction, Inflammation 25, 293–300 (2001). 
362. Levesque JP et al. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell 
mobilization induced by GCSF or cyclophosphamide, JCI 110, 187–96 (2003). 
363. Wang Y et al. Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth 
factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary 
intervention, Heart 92, 768–74 (2005). 
364. Moore MAS. Mobilization of Endothelial and Hematopoietic Stem and Progenitor Cells by Adenovector-
Mediated Elevation of Serum Levels of SDF-1, VEGF, and Angiopoietin-1. 
365. Ceradini DJ et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-
1, Nat Med 10, 858–64 (2004). 
366. Kopp HG et al. Contribution of endothelial progenitor and proangiogenic hematopoietic cells to 
vascularization of tumor and ischemic tissue, Curr Op Hematol 13, 175–81 (2006). 
367. Mogi M et al. Hypoxia Stimulates Release of the Soluble Form of Fas Ligand That Inhibits Endothelial Cell 
Apoptosis, Lab Invest 81, 177–84 (2001). 
368. Andrikoula M et al. Serum levels of sFas in patients with … [Immunol Invest. 2009] - PubMed - NCBI (2009). 
369. Ehrenschwender. The role of FasL and Fas in health and dise… [Adv Exp Med Biol. 2009] - PubMed - NCBI 
(2009). 
370. Henriques-Pons A et al. Is the Fas/Fas-L Pathway a Promising Target for Treating Inflammatory Heart 
Disease?, J Cardiovasc Pharmacol (2009). 
371. Dash P. Apoptosis. Available at http://www.sgul.ac.uk/depts/immunology/~dash/apoptosis/. 
372. Hotchkiss RS et al. Cell Death, NJEM 361, 1570–83 (2009). 
373. Greil R et al. Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, 
and therapeutic tools, JLB 74, 311–30 (2003). 
374. Locksley RM et al. The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology, Cell 104, 487–
501 (2001). 
375. Stonemann VEA et al. The Role of Fas/Fas-L in Vascular Cell Apoptosis, J Cardiovasc Pharmacol (2009). 
Bibliography  
 10
4 
376. Wajant H et al. The Fas Signaling Pathway: More Than a Paradigm, Science 296, 1635–6 (2002). 
377. Biancone BL et al. Development of inflammatory angiogenesis by local stimulation of Fas in vivo, JEM 186, 
147–52 (1997). 
378. Imtiyaz HZ et al. The Death Domain of FADD Is Essential for Embryogenesis, Lymphocyte Development, and 
Proliferation, JBC 284, 9917–26 (2009). 
379. Carlile GW et al. A non-apoptotic role for Fas/FasL in erythropoiesis, FEBS Letters 583, 848–54 (2009). 
380. Chen L et al. CD95 promotes tumour growth, Nature 465, 492–6 (2010). 
381. Wisniewski P et al. Non-apoptotic Fas signaling regulates invasiveness of glioma cells and modulates MMP-2 
activity via NFκB-TIMP-2 pathway, Cell Sig 22, 212–20 (2010). 
382. Zhang Y et al. Fas Signal Promotes Lung Cancer Growth by Recruiting Myeloid-Derived Suppressor Cells via 
Cancer Cell-Derived PGE2, J Immunol 182, 3801–8 (2009). 
383. Lambert C et al. Fas-Beyond Death: A regenerative role for Fas in the nervous system, Apoptosis 8, 551–62 
(2003). 
384. Yang J et al. Expression of antiapoptotic protein c-FLIP is upregulated in psoriasis epidermis, Eur J Dermatol 
19, 29–33 (2009). 
385. Yang J et al. Endothelial Cell Overexpression of Fas Ligand Attenuates Ischemia-Reperfusion Injury in the 
Heart, JCB 278, 15185–91 (2003). 
386. Pundt N et al. Susceptibility of rheumatoid arthritis synovial fibroblasts to FasL- and TRAIL-induced apoptosis 
is cell cycle-dependent, Arthritis Res Ther 11, R16 (2009). 
387. Kataoka T et al. The caspase-8 inhibitor FLIP promotes activation of NF-kB and Erk signaling pathways, Curr 
Biol 10, 640–8 (2000). 
388. Majka M et al. Numerous growth factors, cytokines, and chemokines are secreted by human CD34+ cells, 
myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an 
autocrine/paracrine manner, Blood 97, 3075–85 (2001). 
389. Stadnyk AW et al. When expression is not enough: The evolving thoughts on Fas/FasL and epithelial cell 
apoptosis, Inflamm Bowel Dis, NA (2009). 
390. Davies RM et al. The effect of topical application of chlorhexidine on the bacterial colonization of the teeth 
and gingiva, J Periodont Res 5, 96–101 (1970). 
391. Schiott CR et al. the effect of chlorhexidine moouthrinses on the human oral flora, J Peridontal Res 5, 84–89 
(1970). 
392. Papayannopoulou T et al. Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization, 
Blood 103, 1580–5 (2004). 
393. Schmidt A et al. Endothelial Precursor Cell Migration During Vasculogenesis, Circ Res 101, 125–36 (2007). 
394. Li H et al. Characterization of the Effects of Oxygen on Xanthine Oxidase-mediated Nitric Oxide Formation, 
JBC 279, 16939–46 (2004). 
395. Webb AJ et al. Mechanisms Underlying Erythrocyte and Endothelial Nitrite Reduction to Nitric Oxide in 
Hypoxia: Role for Xanthine Oxidoreductase and eNOS, Circ Res 103, 957–64 (2008). 
396. Heiss C et al. Vitaminsubstitution bei kardiovaskulären Erkrankungen aus der Sicht des Kardiologen (2003). 
397. Ignarro LJ et al. Nitric Oxide as a Signaling Molecule in the Vascular System: An Overview (1999). 
398. Heiss C et al. Plasma Nitroso Compounds Are Decreased in Patients With Endothelial Dysfunction, JACC 47, 
573–9 (2006). 
399. Mason RP et al. Nitric Oxide Mechanisms in the Pathogenesis of Global Risk, J Clin Hypertens 8, 31-38 (2006). 
400. Napoli C et al. Nitric oxide and atherosclerosis: An update, Nitric Oxide 15, 265–79 (2006). 
401. Liu VWT et al. Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthases gene 
disrupted mice, Cardiovasc Res 77, 19-29 (2008). 
402. Busse R et al. Nitric Oxide, Nitric Oxide Synthase, and Hypertensive vascular Disease, Curr Hypertens Rep 1, 
88–95 (1999). 
403. Kawashima S et al. Dysfunction of eNOS and Atherosclerosis, ATVB 24, 998–1005 (2004). 
404. Ignarro L & Napoli C. Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis, 
Curr Atheroscler Rep 6, 281–7 (2004). 
405. Mathew V et al. Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitritc oxide 
activity in experimental hypercholesterolemia, Circ, 1930–6 (1997). 
406. Lavi S et al. The Interaction Between Coronary Endothelial Dysfunction, Local Oxidative Stress, and 
Endogenous Nitric Oxide in Humans, Hypertension 51, 127–33 (2007). 
407. Lauer T et al. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but 
lacks intrinsic vasodilator action, PNAS 98, 12814–19 (2001). 
408. Goya K et al. Peroxisome Proliferator-Activated Receptor   Agonists Increase Nitric Oxide Synthase Expression 
in Vascular Endothelial Cells, ATVB 24, 658–63 (2004). 
Bibliography  
 10
5 
409. de Nigris F et al. Oxidation-sensitive mechanisms, vascular apop… [Trends Mol Med. 2003] - PubMed - NCBI, 
Trends Mol Med 9, 351–359 (2003). 
410. Petersen F et al. Neutrophil-Activating Peptides NAP-2 and IL-8 bind to the same sites on neutropholils but 
interact in different ways, J Immunol 152, 2467-78 (1994). 
411. Smith C et al. Increased Levels of Neutrophil-Activating Peptide-2 in Acute Coronary Syndromes, JACC 48, 
1591–9 (2006). 
412. von Hundelshausen P et al. Platelet-derived chemokines in vascular biology, Thromb Haemost 97, 704–13 
(2007). 
413. Puhakka M et al. Interleukin-6 and tumor necrosis factor alpha in relation to myocardial infarct size and 
collagen formation, J Cardiac Failure 9, 325–32 (2003). 
414. Rakhit RD et al. Tumour necrosis factor-alpha and interleukin-6 release during primary percutaneous 
coronary intervention for acute myocardial infarction is related to coronary collateral flow, Coron Artery Dis 
16, 147–52 (2005). 
415. Kurrelmeyer KM et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte against 
ischemic-induced apoptosis in a murine model of acute myocardial infarction, PNAS 97, 5456–61 (2000). 
416. Belosjorow S et al. TNF-a antibodies are as effective as ischemic preconditioning in reducing infarct size in 
rabbits, AJP Heart Circ Physiol, H927-30 (2003). 
417. Kempf K et al. Increased TNF-α and Decreased TGF-β Expression in Peripheral Blood Leukocytes after Acute 
Myocardial Infarction, Horm Metab Res 38, 346–51 (2006). 
418. Kosmala W et al. Plasma levels of TNF-α, IL-6, and IL-10 and their relationship with left ventricular diastolic 
function in patients with stable angina pectoris and preserved left ventricular systolic performance, Cor Art 
Dis 19, 375–82 (2008). 
419. Yao L et al. Acute myocardial infarction induced increases in plasma tumor necrosis factor-α and interleukin-
10 are associated with the activation of poly(ADP-ribose) polymerase of circulating mononuclear cell, Int J 
Cardiol 123, 366–8 (2008). 
420. Zernecke A & WEBER C. Inflammatory mediators in atherosclerotic vascular disease, Basic Res Cardiol 100, 
93–101 (2005). 
421. Schulz R & Heusch G. Tumor Necrosis Factor-  and Its Receptors 1 and 2: Yin and Yang in Myocardial 
Infarction?, Circ 119, 1355–7 (2009). 
422. Vandervelde S et al. Signaling factors in stem cell-mediated repair of infarcted myocardium, JMCC 39, 363–76 
(2005). 
423. Hynes B et al. Potent endothelial progenitor cell-conditioned media-related anti-apoptotic, cardiotrophic, 
and pro-angiogenic effects post-myocardial infarction are mediated by insulin-like growth factor-1, EHJ 
(2011). 
424. Yamaguchi JI et al. Stromal Cell-Derived Factor-1 Effects on Ex Vivo Expanded Endothelial Progenitor Cell 
Recruitment for Ischemic Neovascularization, Circ 107, 1322–8 (2003). 
425. Heusch G et al. Endogenous Nitric Oxide and Myocardial Adaptation to Ischemia, Circ Res 87, 146–52 (2000). 
426. Loscalzo J et al. NO Insufficiency, Platelet Activation, and Arterial Thrombosis, Circ Res 88, 756–62 (2001). 
427.  Quirici N et al. Differentiation and expansion of endothelial cells from human bone marrow CD1331 cells, BJH 
115, 186-94 (2001) 
428. Gupta A et al. Activated protein C ameliorates LPS-induced acute kidney injury and downregulates renal iNOS 
and angiotensin 2, Am J Physiol Renal Physiol 293, F245–54 (2007) 
429.  Budd RC et al. Death receptors couple to both cell proliferation and apoptosis, JCI 109, 437–42 (2002). 
430. Michael Nießen. Geweberegeneration nach Hinterlaufsischämie im Mausmodell: Analyse und 
Methodenetablierung. Dissertation. HHU Düsseldorf. In preparation 
431. Andreas Schicho. Diätetisches Nitrat verbessert die Regeneration im murinen Hinterlaufmodell über 
Modulation des mTOR-Signalweges. Dissertation. HHU Düsseldorf. In preparation 
Acknowledgment  
106 
 
Acknowledgment  
Firstly, I would like to express my gratitude to Prof. M. Kelm for giving me the possibility to work on my thesis 
in his clinic and laboratory. I would also particularly like to thank Prof. T. Rassaf for the supervision of this 
thesis. Furthermore, I would like to thank Prof. H. Wagner and Prof. J. Mey for their support which made a 
great difference to the thesis.  
My collaboration in the clinical studies would not be possible without Dr. E. Kehmeier. Thank you very much! 
Special thanks apply to all my colleagues of the cardiology laboratory. My work includes experiments which 
needed more than two hands and they helped me whenever it was needed. Additionally, constructive 
discussions were important for the success of my work. In the last year of this work I was forced to stop animal 
experiments because of getting a severe allergy against mice. My colleagues Dr. P. Lüdicke, Dr. C. Rammos, D. 
Semmler and A. Schicho helped me to finish my thesis, despite these circumstances by undertaking these tasks. 
Thank you all very much! 
I also would like to thank Msc D. Lou, M. Niessen, and A. Schicho. I supported them during their theses, but 
they also contributed to the success of my work supporting me in characterizing Endothel-Regenerating cells, 
isolation and characterization of satellite cells, measuring perfusion (LDPI), and histology. The docotoral theses 
of M. Niessen and A. Schicho are done in parallel to the current work and are designed and performed in close 
collaboration. Their establishment of LDPI analysis and examination of satellite cells gave important 
contribution to my work.  
I am very thankful N. Kaesler, M. Reeh, C. Drexhage and Dr. M. Cortese-Krott for not only for being great 
colleagues but also for their friendship.  
Besides professional support, this thesis would not have been completed without the huge support of my 
family and my friends. Although words cannot express what I feel. 
Thank you very much Mama, Andrea, Grandma and Grandpa for being there when I wanted to tell you about 
progress,  but especially for always listening during the difficult times – all the time! I love you! 
Thank you very much to Kerstin and Mareike for your patience. Waiting if I had no time, once again...having 
time for me, if I had the need to speak, so often... a thousand thanks! I hope that I could give you back even 
just a little bit of what you gave me! 
Unfortunately there is not enough room on this one page for me to mention all my great friends, who have 
been important to me during this eventful time. Many more names come to my mind and are in my heart while 
I am writing theses lines. I hope you all know that! 
Acknowledgment  
107 
 
Kind of contribution Method Extent of contribution Name 
Design of the work   Animal study  
Tienush Rassaf, Ulrike Hendgen-Cotta, Matthias 
Totzeck, Peter Lüdike, Martina Kropp 
    Clinical studies 
Tienush Rassaf, Malte Kelm, Wolfgang Lepper, Eva 
Kehmeier 
Data aquiring Care and Treatment of the animals 2007, feb - 2010, jan Martina Kropp 
    2010, jan-2010, sep 
Peter Lüdike, Christos Rammos, Andreas Schicho, 
Dominik Semmler 
  Microbiological evaluation of oral flora Sample preparation (figure 14) Martina Kropp 
    Culture and evaluation Animal Facility of the University Hospital Düsseldorf 
  Hind limb model surgery 2007, feb - 2010, jan Martina Kropp 
    2010, jan - 2010, sep Dominik Semmler 
  Bone-marrow transplantation 100% Martina Kropp 
  Laser-Doppler-Perfusion-Imaging (LDPI) 2007, feb - 2010, jan Martina Kropp 
    Contribution in establishment Michael Niessen 
    During surgery and finalization; 2010, jan - 2010, sep Andreas Schicho 
  Evaluation of Necrosis Score 2007, feb - 2010, jan Martina Kropp 
    2010, jan - 2010, sep Andreas Schicho 
  
NO2-/NO3- determination via High Pressure Liquid Chromatography 
combined with diazo coupling Sample preparation (figure 16-20) Martina Kropp 
    Measurement Simone Zander, Lisa Frommke 
  NO2-/NO3- determination via chemiluminescence Detection (CLD) 100% Martina Kropp 
  RXNO/RNNO determination via chemiluminescence Detection (CLD) Sample preparation (figure 20) Martina Kropp 
    Measurement (figure 20) Dominik Semmler, Matthias Totzeck 
  NO-Heme determination via chemiluminescence Detection (CLD) Sample preparation (figure 20) Martina Kropp 
    Measurement (figure 20) Matthias Totzeck 
  cGMP determination via EIA 100% Martina Kropp 
  Isolation of Endothel-Regenerating Cells 90% Martina Kropp 
    Figure 28 Dandan Lou 
  
Characterization of cultured Endothel-Regenerating Cells by 
immunfluorescence Design and supervision Martina Kropp 
    Figure 28 Dandan Lou 
  
Quantification and characterization of Endothel-Regenerating Cells by 
flowcytometry (FACS) 100% Martina Kropp 
  
Immunofluorescent determination of angiogenesis, neoangiogenesis, 
arteriogenesis, and iNOS expression     
  Cutting of the slides 20%, design and supervision Martina Kropp 
    80% Andreas Schicho 
  Staining 100% Martina Kropp 
Acknowledgment 
 108 
  Microscopy 100% Martina Kropp 
  
Viability analysis of Endothelial-Regenerating Cells by Tetrazolium Salt (WST-
8) Assay 100% Martina Kropp 
  Quantification of sFasL by Enzyme-linked-immunosorbent Assay (ELISA) 100% Martina Kropp 
  Isolation of Satellite Cells 50% Martina Kropp 
    50% Andreas Schicho 
  Culture of Satellite Cells 100% Martina Kropp 
  Characterization of Satellite Cells by culture and FACS 100% Martina Kropp 
  
Apoptosis analysis of Satellite Cells by Terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL) Design, establishment and supervision Martina Kropp 
  Determination of angiogenic and inflammatory cytokines by ELISA     
  Quantification of XOR activity by an enzymatic assay 100% Martina Kropp 
  XOR expression analysis by Real Time PCR Sample preparation (figure 45 A) Martina Kropp 
    Measurement and calculation of results (figure 45 A) Ulrike Hendgen-Cotta, Pia Stock 
  Clinical Chemistry   Central laboratory University Hospital Aachen 
Analysis and 
interpretation of data     
Tienush Rassaf, Ulrike Hendgen-Cotta, Matthias 
Totzeck, Peter Lüdike, Martina Kropp 
Statistical analysis     
Tienush Rassaf, Ulrike Hendgen-Cotta, Matthias 
Totzeck, Peter Lüdike, Martina Kropp 
Handling of funding and 
supervision     Tienush Rassaf 
Other Constructive  discussion of study design, results and data interpretation   
Tienush Rassaf, Ulrike Hendgen-Cotta, Peter Lüdike, 
Matthias Totzeck 
 
 
Curriculum vitae  
109 
 
Curriculum Vitae  
Personal Data 
Family name Kropp 
Forename  Martina  
Date of Birth  06.09.1976 
Place of birth Kiel 
Nationality   German 
Family status Single 
 
Career  
since 10 / 2012 University of Geneva, Department of Ophthalmology, University Hospital 
of Geneva (di.: Prof. Dr. F. Hafezi) 
Research assistant 
02/2012 – 09 / 2012 RWTH Aachen, Divison of Ophthalmology, University Hospital Aachen (dir.: 
Prof. Dr. P. Walter)  
  Research assistant 
07/2009 – 12/2011 HHU Düsseldorf, Division of Cardiology, Pulmonary Diseases and Vascular 
Medicine, University Hospital Düsseldorf (dir.: Prof. Dr. M. Kelm) 
Research assistant (Phd thesis) 
02/2007 - 06/2009     RWTH Aachen, Division of Cardiology, Pulmonary Diseases and Vascular 
Medicine, University Hospital Aachen (dir.: Prof. Dr. M. Kelm) 
Research assistant (Phd thesis) 
01/2007    RWTH Aachen, Division of Pathology (dir.: Prof. Dr. R. Knüchel-Clarke) 
   Practical cell culture course PD Dr. Sabine Neuß-Stein 
08/2006     RWTH Aachen, Institute for Biology II (dir.: Prof. Dr. H. Wagner) 
Diploma thesis in biology 
11/2000 - 05/2006 RWTH Aachen, Institute for Biology II (dir.: Prof. Dr. H. Wagner) 
Behavioural experiments with barn owls 
Supervision of the practical course „Tierphysiologisches Grundpraktikum“ 
Supervision of the practical course „Morphologie & Anatomie der Tiere“ 
Programming of „GUIs“ with „Igor“ 
10/1998 - 08/2006   RWTH Aachen 
Study of Biology 
 
Education  
 
1987 – 1996 Lauenburgische Gelehrtenschule Ratzeburg 
Graduation   Allgemeine Hochschulreife (equivalent to A-level) 
 
Teaching Experience 
since 2009 scientific supervision of Mr. Andreas Schicho (practical part completed) 
since 2008 scientific supervision of Mr. Michael Niessen (practical part completed) 
2008-2009 scientific supervision & examination of Mrs. M. sc. Dandan Lou (completed) 
2000-2006    supervision of several practical courses (see career) 
 
Advanced Education 
2010    Perimed Stockholm 
Practicum including theory & practical use of equipment for LDPI & LDPM 
2010    HHU Düsseldorf, Tierversuchsanstalt 
    Fachkundenachweis gemäß §9 des geltenden Tierschutzgesetzes 
2010    HHU Düsseldorf, Bildungszentrum 
Workshop „Projectmanagement for scientific research” 
10/2010-04/2012  HHU Düsseldorf, Büro der Gleichstellungsbeauftragten 
    Selma-Meyer-Wiss Mentoring program 
Publications 
 110 
Publications 
Ulrike B. Hendgen-Cotta, PhD, Peter Lüdike, MD, Matthias Totzeck, MD, Martina Kropp, MSc, Andreas Schicho, 
MS, Pia Stock, MSc, Christos Rammos, MD, Michael Niessen, MS, Christian Heiss, MD, Jon O. Lundberg, MD, 
PhD, Eddie Weitzberg, MD, PhD, Malte Kelm, MD, FESC, Tienush Rassaf, MD, FESC. Dietary Nitrate 
Supplementation Improves Revascularization in Chronic Ischemia. Circulation. 126(16). 1983-92 (2012)  
Eva S. Kehmeier, MD; Wolfgang Lepper, MD, Martina Kropp, MSc; Christian Heiss, MD; Ulrike Hendgen-Cotta, 
PhD,, Jan Balzer, MD; Mirja Neizel, MD; Christian Meyer, MD; Marc Merx, MD; Pablo E. Verde, PhD; Christian 
Ohmann, PhD; Gerd Heusch, MD; Malte Kelm, MD; Tienush Rassaf, MD. TNF-α, myocardial perfusion and 
function in patients with ST-Segment elevation myocardial infarction and primary percutaneous coronary 
intervention. Clin Res Cardiol. 101(10). 815-27 (2012) 
Kehmeier E. S., Kropp M., Kleinbongard P., Lauer T., Balzer J., Merx M. M., Heusch G., Kelm M., Lepper W., 
Rassaf T. Serial measurements of whole blood nitrite in an intensive care setting. Free Radical Biology & 
Medicine. 44(11). 1945-50 (2005) 
Eva S. Kehmeier, MD; Martina Kropp, MSc; Christian Heiss, MD; Ulrike Hendgen-Cotta, PhD,, Jan Balzer, MD; 
Mirja Neizel, MD; Pablo E. Verde, PhD; Christian Ohmann, PhD; Wolfgang Lepper, MD; Gerd Heusch, MD; Malte 
Kelm, MD; Tienush Rassaf, MD. TNF-α and Myocardial Perfusion and Function in Patients with ST-Segment 
Elevation Myocardial Infarction and Primary Percutaneous Coronary Intervention. 78. Jahrestagung der 
Deutschen Gesellschaft für Kardiologie, Mannheim (2012) 
M. Kropp, U. Hendgen-Cotta, A. Schicho, P. Lüdike, M. Totzeck, P. Stock, C. Heiss, M. Niessen, M. Kelm, T. 
Rassaf. Dietary nitrate mobilizes circulating angiogenic cells (Endothelial-regenerating cells) and exerts 
cytoprotective and angiogenic effects in the ischemic hind limb model in mice. 77th Annual Meeting of the 
German Cardiac Societ, Heart Failure and Regeneration, Mannheim (2011) 
Eva S. Kehmeier, Martina Kropp, Petra Kleinbongard, Thomas Lauer, Jan Balzer, Marc W. Merx, Gerd Heusch, 
Malte Kelm, Wolfgang Lepper, Tienush Rassaf. Serial Measurements of Whole Blood Nitrite in an Intensive Care 
Setting. Fifth International Conference of Biology, Chemistry and Therapeutic Applications of Nitric Oxide, 
Bregenz (2008) 
E. Kehmeier, M. Kropp, U. Hendgen-Cotta, M. Grau, P. Brouzos, P. Kleinbongard, T. Lauer, M. Merx, T. Rassaf, 
M. Kelm. Bestimmung von Nitrit im Vollblut bei kritisch kranken Patienten. 39. Gemeinsame Jahrestagung der 
Deutschen Gesellschaft für Internistische Intensivmedizin und Notfallmedizin (DGIIN) und der Österreichischen 
Gesellschaft für Allgemeine und Internistische Intensivmedizin (ÖGIAIM), Köln (2007) 
M. Kropp, D. T. T. Plachta, H. Wagner. A Comparison of the Soundlocalization of Freeflying Barn Owls under 
Open-Loop and Closed-Loop Conditions. Workshop “Neurobionics: Bonn-Köln-Aachen”, Aachen (2006)
Declaration 
111 
 
Declaration  
 
 
 
 
 
 
 
 
 
 
 
 
Hiermit versichere ich, Martina Kropp, dass ich die vorliegende Dissertation eigenhändig 
verfasst und ausschließlich die angegebenen Quellen und Hilfsmittel verwendet habe. 
 
 
 
 
 
 
 
 
 
Genf am 01.05.2013 
 
 
_________________________ 
Martina Kropp 
 
 
 
 
 
 
